Nucleic acid constructs comprising a cargo polynucleotide and an aptamer
Nucleic acid compositions with aptamers for nuclear localization and immune response avoidance enhance gene therapy efficacy by improving nuclear localization and reducing immune activation, addressing low transfection rates and immune response issues in existing methods.
Patent Information
- Application Number
- PCT/US2026/026961
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing gene therapy methods using ultrasound or sonoporation suffer from low transfection rates and insufficient gene expression due to poor nuclear localization of genetic cargos and activation of the cell's innate immune system, hindering clinical development and commercialization.
Nucleic acid compositions with aptamers at the 5' or 3' ends for nuclear localization and innate immune response avoidance, coupled with a cargo polynucleotide, enhance nuclear localization and reduce immune activation, using methods like annealing, ligating, and digesting in a single vessel to simplify manufacturing.
The nucleic acid compositions increase transgene expression by 1.5 to 4-fold and improve manufacturing efficiency by simplifying the process, making gene therapy more effective and durable.
Smart Images

Figure US2026026961_12112026_PF_FP_ABST
Abstract
Description
Docket No. 62668-747.601BIOLOGIC AGENTS AND METHODS OF USE AND METHODS AND COMPOSITIONS FOR A MANUFACTURER THEREOF CROSS-REFERENCE
[0001] This application claims the benefit of US Provisional Application Serial Number 63 / 801,763 filed on May 07, 2025, US Provisional Application Serial Number 63 / 801,765 filed on May 07, 2025, US Provisional Application Serial Number 63 / 801,744 filed on May 07, 2025, and US Provisional Application Serial Number 63 / 801,746 filed on May 07, 2025, each of which is incorporated by reference herein in its entirety.BACKGROUND
[0002] Gene therapy, in which a functional copy of a gene is transfected into a cell, has been proposed as a possible method of treating genetic diseases. One proposed method of delivering a gene therapy to a subject is delivery of therapeutic agents using ultrasound and microbubbles, also referred to as sonoporation. However, prior art methods of gene therapy using ultrasound or sonoporation suffer from significant shortcomings such as low transfection rates, and insufficient gene expression, which have prevented the clinical development and commercialization of these methodologies. There remains a need in the art for more effective gene therapy techniques that can transfect a gene to a cell in an organ or a tissue in a subject in a safe, effective, and durable manner.SUMMARY OF THE INVENTION
[0003] While sonoporation is extensively studied, little remains known regarding the underlying causes of poor efficiency of nucleic acid delivery using the technique. One potential barrier to efficient gene expression proposed herein includes poor nuclear localization of genetic cargos which are transfected to the cell, for example, due to the low tendency of genetic cargos to move through the cytosol and translocate across the nuclear envelope, or due to the clearance of double stranded DNA payloads in the cytosol by the cell’s innate immune system prior to nuclear localization. Disclosed and described herein are compositions and methods for overcoming such technical challenges which can increase nuclear localization of genetic payloads delivered to cells using sonoporation, and / or which can reduce the activation of the cell’s innate immune system and resulting clearance of the genetic cargo.
[0004] Aspects disclosed herein provide a nucleic acid composition comprising: a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, an aptamer comprising a nuclear localization element or an innate immune response avoidance moiety at either the 5’ end or the 3’ end, and a single stranded end not comprising an aptamer atDocket No. 62668-747.601the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end. In some embodiments, the aptamer comprises the nuclear localization element. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 50. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 46. In some embodiments, the nucleic acid composition increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the nuclear localization element. In some embodiments, the aptamer comprises the innate immune response avoidance moiety. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 53. In some embodiments, the nucleic acid composition increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the immune response avoidance moiety. In some embodiments, the aptamer is at the 5’ end and there is no aptamer at the 3’ end. In some embodiments, the aptamer is at the 3’ end and there is no aptamer at the 5’ end. In some embodiments, there is only one aptamer in the nucleic acid composition. In some embodiments, the single stranded end not comprising an aptamer comprises a sequence of any one of SEQ ID NOS: 254-281. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with an cargo polynucleotide positioned between the 5’ end and the 3’ end, a single aptamer having a sequence of SEQ ID NO: 50 at either the 5’ end or the 3’ end which is coupled to the cargo polynucleotide with an adaptor sequence of any one of SEQ ID NOS: 254, 256, or 258, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end having a sequence of any one of SEQ ID NOS: 254-281. In some embodiments, the adaptor sequence comprises a 5’ and a 3’ end, and the single aptamer having a sequence of SEQ ID NO: 50 is positioned between the 5’ and the 3’ end of the adaptor sequence. In some embodiments, the cargo polynucleotide comprises an expression cassette. In some embodiments, the expression cassette comprises a therapeutic transgene. In some embodiments, the therapeutic transgene comprises FVIII, FIX, DMD, COL4A5, PKD1, PKD2, or ATP7B. In some embodiments, the expression cassette comprises a promoter sequence. In some embodiments, the expression cassette is at least partially double stranded. In some embodiments, the promoter sequence is double stranded. In some embodiments, the aptamer is coupled to an adaptor sequence. In some embodiments, the adaptor sequence comprises a sequence of any one of SEQ ID NOS: 101-128, or 254-281.
[0005] Aspects disclosed herein provide a method of expressing a therapeutic transgene in a subject comprising administering to the subject the nucleic acid composition of any one of the preceding claims. Aspects disclosed herein provide a use of the nucleic acid composition of anyDocket No. 62668-747.601one of the preceding claims in a method of treating a genetic disorder in a subject in need thereof comprising administering to the subject the nucleic acid composition of any one of the preceding claims. In some embodiments, the method further includes administering to the subject a sonoactive agent. In some embodiments, the sonoactive agent comprises a microbubble. In some embodiments, the method further includes administering ultrasound energy to the subject. In some embodiments, applying ultrasonic energy to the cell of the subject comprises applying the ultrasound energy at a first mechanical index (MI) that is less than or equal to 0.4 (e.g., 0 < MI < 0.4). In some embodiments, the method further includes applying ultrasonic acoustic energy to the cell of the subject at a second MI that is greater than the first MI. In some embodiments, the first MI is about 0.07. In some embodiments, the second MI is at least 1.5. In some embodiments, the second MI is at least 2.0. In some embodiments, the second MI is at least 2.9. In some embodiments, applying ultrasonic energy to the cell at the second MI comprises applying the ultrasonic acoustic energy in a pulse. In some embodiments, the pulse is less than 2 s. In some embodiments, the pulse is up to 500 microseconds. In some embodiments, the pulse is 1 microsecond to 500 microseconds. In some embodiments, the pulse is about 100-300 microseconds. In some embodiments, the pulse is about 200 microseconds. In some embodiments, the ultrasound is applied at a frequence of about 0.5-20 MHz. In some embodiments, the subject is a mammalian subject. In some embodiments, the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector. In some embodiments, the ultrasound is directed toward a target cell. In some embodiments, the target cell is a liver cell. In some embodiments, the target cell is a hepatocyte. In some embodiments, the target cell is a LSEC. In some embodiments, the target cell is a kidney cell. In some embodiments, the target cell is a proximal tubular epithelial cell. In some embodiments, the target cell is a podocyte. In some embodiments, the target cell is a muscle cell. In some embodiments, the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy. In some embodiments, is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene wherein the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subject. In some embodiments, the method is a method for use of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy. In some embodiments, the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte. In someDocket No. 62668-747.601embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell. In some embodiments, the subject is a subject having a muscular dystrophy, the nucleic acid encodes dystrophin (DMD), and the target cell is a muscle cell, a cardiac cell, or a diagram cell. In some embodiments, the subject is a human subject.
[0006] Aspects disclosed herein provide a kit comprising the nucleic acid composition of any one of the preceding claims, and a sonoactive agent.
[0007] Aspects disclosed herein provide a nucleic acid composition comprising a cargo polynucleotide, means for increasing localization of the nucleic acid composition, and means for avoiding or reducing an innate immune response to the nucleic acid composition or a second means for increasing localization of the nucleic acid composition. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer comprising a nuclear localization element, and a second aptamer comprising an innate immune response avoidance moiety or a second nuclear localization element. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 46 at the 3’ end. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 53 at the 3’ end.
[0008] In some embodiments, the means for increasing localization of the nucleic acid composition comprises a first aptamer comprising a nuclear localization element. In some embodiments, the first aptamer comprises a nucleic acid sequence which binds a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 50. In some embodiments, the first aptamer comprises a nucleic acid sequence which binds a nucleolin protein. In some embodiments, the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 46. In some embodiments, the means for reducing an innate immune response to the nucleic acid composition comprises a second aptamer comprising an innate immune response avoidance moiety. In some embodiments, the innate immune response avoidance moiety comprises an antagonist inhibitor of TLR9 and TLR7. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 53. In some embodiments, the second means for increasing localization of the nucleic acid composition comprises a second aptamer comprising a secondDocket No. 62668-747.601nuclear localization element. In some embodiments, the second aptamer comprises a nucleic acid sequence which binds a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 50. In some embodiments, the second aptamer comprises a nucleic acid sequence which binds a nucleolin protein. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 46. In some embodiments, the first aptamer is located at the 3’ end. In some embodiments, the second aptamer is located at the 5’ end. In some embodiments, the first aptamer is located at the 5’ end. In some embodiments, the second aptamer is located at the 3’ end. In some embodiments, the cargo polynucleotide comprises an expression cassette. In some embodiments, the expression cassette comprises a therapeutic transgene. In some embodiments, the therapeutic transgene comprises FVIII, FIX, DMD, COL4A5, PKD1, PKD2, or ATP7B. In some embodiments, the expression cassette comprises a promoter sequence. In some embodiments, the expression cassette is at least partially double stranded. In some embodiments, the promoter sequence is double stranded. In some embodiments, the aptamer is coupled to an adaptor sequence. In some embodiments, the adaptor sequence comprises a sequence of any one of SEQ ID NOS: 101-128, or 254-281.
[0009] Aspects disclosed herein provide a method of expressing a therapeutic transgene in a subject comprising administering to the subject the nucleic acid composition of any one of the preceding claims. Aspects disclosed herein provide a use of the nucleic acid composition of any one of the preceding claims in a method of treating a genetic disorder in a subject in need thereof comprising administering to the subject the nucleic acid composition of any one of the preceding claims. In some embodiments, the method further includes administering to the subject a sonoactive agent. In some embodiments, the sonoactive agent comprises a microbubble. In some embodiments, the method further includes administering ultrasound energy to the subject. In some embodiments, applying ultrasonic energy to the cell of the subject comprises applying the ultrasound energy at a first mechanical index (MI) that is less than or equal to 0.4 (e.g., 0 < MI < 0.4). In some embodiments, the method further includes applying ultrasonic acoustic energy to the cell of the subject at a second MI that is greater than the first MI. In some embodiments, the first MI is about 0.07. In some embodiments, the second MI is at least 1.5. In some embodiments, the second MI is at least 2.0. In some embodiments, the second MI is at least 2.9. In some embodiments, applying ultrasonic energy to the cell at the second MI comprises applying the ultrasonic acoustic energy in a pulse. In some embodiments, the pulse is less than 2 s. In some embodiments, the pulse is up to 500 microseconds. In some embodiments, the pulse is 1 microsecond to 500 microseconds. In some embodiments, the pulse is about 100-Docket No. 62668-747.601300 microseconds. In some embodiments, the pulse is about 200 microseconds. In some embodiments, the ultrasound is applied at a frequence of about 0.5-20 MHz. In some embodiments, the subject is a mammalian subject. In some embodiments, the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector. In some embodiments, the ultrasound is directed toward a target cell. In some embodiments, the target cell is a liver cell. In some embodiments, the target cell is a hepatocyte. In some embodiments, the target cell is a LSEC. In some embodiments, the target cell is a kidney cell. In some embodiments, the target cell is a proximal tubular epithelial cell. In some embodiments, the target cell is a podocyte. In some embodiments, the target cell is a muscle cell. In some embodiments, the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy. In some embodiments, is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene wherein the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subject. In some embodiments, the method is a method for use of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy, wherein the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte. In some embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell. In some embodiments, the subject is a subject having a muscular dystrophy, the nucleic acid encodes dystrophin (DMD), and the target cell is a muscle cell, a cardiac cell, or a diagram cell. In some embodiments, the subject is a human subject.
[0010] Aspects disclosed herein provide a kit comprising the nucleic acid of any one of the preceding claims, and a sonoactive agent.
[0011] One proposal for increasing the efficacy of ultrasound or sonoporation based gene therapies is to utilize next-generation nucleic acid constructs which offer therapeutic benefits beyond the gain of function associated with successful transfection of a plasmid comprising an expression cassette. One such next-generation nucleic acid construct proposed herein for use in gene therapy are nucleic acid constructs comprising aptamers (a short, single-stranded nucleic acids that folds into a specific three-dimensional shape and bind a target antigen with high affinity and specificity), in which the aptamers provide an additional therapeutic benefit to the subject or transfection process beyond gain of function. Such next-generation nucleic acidDocketNo. 62668-747.601construct can provide benefits which can increase nuclear localization of genetic payloads delivered to cells and / or which can reduce the activation of the cell’s innate immune system and resulting clearance of the genetic cargo, among other possible benefits. However, the manufacture of such aptamer nucleic acid conjugated constructs remains a challenge, as such constructs comprise both a single-stranded aptamer region and a double-stranded expression cassette, which most plasmid focused biologic manufacturing processes are not equipped to accommodate. Disclosed herein are biologic manufacturing processes which provide for the manufacture of aptamer nucleic acid conjugated constructs, improve product yield, reduce manufacturing time, reduce the number of process steps, and otherwise simplify the manufacturing process, including, for example, by permitting a multistep manufacturing process to occur in a single vessel.
[0012] Aspects disclosed herein provide a method of producing an aptamer nucleic acid conjugated construct comprising a duplexed region and an aptamer, the method comprising: annealing a first end of a single stranded nucleic acid to a second end of the single stranded nucleic acid, the single stranded nucleic acid comprising the aptamer, to form an annealed fragment; ligating the annealed fragment to a linear duplexed nucleic acid fragment to form the aptamer nucleic acid conjugated construct, and digesting nucleic acid fragments; wherein, two or more of the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time. Aspects disclosed herein provide a method of producing a partially single stranded nucleic acid construct comprising a duplexed region and single stranded region, the method comprising: cleaving a nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 into a linear duplexed nucleic acid fragment comprising a nucleotide overhang; annealing a first end of a single stranded nucleic acid to a second end of the single stranded nucleic acid to form an annealed fragment; ligating the annealed fragment to the linear duplexed nucleic acid fragment to form the partially single stranded nucleic acid construct; and digesting nucleic acid fragments.
[0013] In some embodiments, the method further includes cleaving a nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 into a linear duplexed nucleic acid fragment comprising a nucleotide overhang, thereby forming the linear duplexed nucleic acid fragment. In some embodiments, the aptamer nucleic acid conjugated construct comprises the expression cassette, and cleaving the nucleic acid comprising the expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette toDocket No. 62668-747.601nucleotides outside of the expression cassette of at least 6: 1 increases a yield of the aptamer nucleic acid conjugated construct resulting from performance of the method by 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 58% w / w as compared to a process which uses a standard plasmid having more than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of less than 6:1. In some embodiments, the nucleic acid is circular. In some embodiments, the nucleic acid is linear. In some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides. In some embodiments, the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is at least 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. In some embodiments, the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is from 6: 1 up to 20:1. In some embodiments, the nucleic acid comprises an endonuclease recognition sequence. In some embodiments, the nucleic acid comprises a plurality of endonuclease recognition sequences. In some embodiments, the nucleic acid comprises a first endonuclease recognition sequence and a second endonuclease recognition sequence. In some embodiments, the first endonuclease recognition sequence is positioned on 5’ of the expression cassette on a sense strand, and the second endonuclease recognition sequence is positioned 3’ of the expression cassette on an anti-sense strand. In some embodiments, the nucleic acid comprises only the first recognition sequence and the second recognition sequence. In some embodiments, the endonuclease recognition sequence comprises a type IIS endonuclease recognition sequence. In some embodiments, the endonuclease recognition sequence is Bsal. In some embodiments, the expression cassette is at least 4000. 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 11000, 12000, 13000, 14000, 15000 or 16000 bp in length. In some embodiments, the single stranded region of the partially single stranded nucleic acid construct comprises an aptamer, the partially single stranded nucleic acid construct is an aptamer nucleic acid conjugated construct, and wherein, two or more of: the annealing, the digesting, or the ligating, occur in a same contiguous aqueous solution or occur at a same time. In some embodiments, the partially single stranded nucleic acid construct is an aptamer nucleic acid conjugated construct. In some embodiments, the construct comprises the single stranded region at an end of the duplexed region, the single stranded region closing the duplexed region. In some embodiments, the single stranded region forms a hairpin loop. In some embodiments, the hairpin loop comprises the aptamer. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind an antigen. In some embodiments, the aptamer comprises a nucleic acid sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides. In some embodiments, the aptamer comprises 25-75 nucleotides. In someDocket No. 62668-747.601embodiments, the aptamer comprises a nucleic acid sequence which forms a secondary structure. In some embodiments, one or more nucleotides in the nucleic acid sequence are paired to one or more other nucleotides in the nucleic acid sequence to form the secondary structure in the aptamer. In some embodiments, in the aptamer nucleic acid conjugated construct, the aptamer is properly folded in the secondary structure such that it is function in binding the antigen. In some embodiments, the single stranded nucleic acid comprises a first end comprising a first nucleic acid sequence and a second end comprising a second nucleic acid sequence, in which the second nucleic acid sequence is complementary to the first nucleic acid sequence. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end are each at least 10, 11, 12, 13, 14, or 15 nucleotides long. In some embodiments, the single stranded nucleic acid comprises an assembly sequence. In some embodiments, the assembly sequence comprises a nucleotide overhang. In some embodiments, the single stranded nucleic acid comprises a nucleotide overhang. In some embodiments, the nucleotide overhang is 5’ of the first nucleic acid sequence in the first end or 3’ of the second nucleic acid sequence in the second end. In some embodiments, the nucleotide overhang comprises a sequence configured for golden gate assembly. In some embodiments, the nucleotide overhang comprises a sequence which is complementary to a sticky end left by Bsal cleavage. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end each compromise non-palindromic sequences. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end each compromise non-palindromic sequences. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end do not comprise palindromic sequences. In some embodiments, the annealing further comprises annealing a first end of a second single stranded nucleic acid to a second end of the second single stranded nucleic acid, the second single stranded nucleic acid comprising a second aptamer to form a second annealed fragment. In some embodiments, the ligating the annealed fragment to the linear duplexed nucleic acid fragment further comprises ligating the second annealed fragment to a second end of the linear duplexed nucleic acid fragment. In some embodiments, the aptamer nucleic acid conjugated construct comprises different aptamers at each end of the construct, or comprises different aptamers at a 5’ end of the construct and a 3’ end of the construct. In some embodiments, the linear duplexed nucleic acid fragment comprises an assembly sequence. In some embodiments, the assembly sequence comprises the nucleotide overhang in the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence is positioned on a first end or a 5’ end of the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence in the in the linear duplexed nucleic acid fragment isDocket No. 62668-747.601complementary to the assembly sequence in the single stranded nucleic acid. In some embodiments, the linear duplexed nucleic acid fragment comprises a second assembly sequence. In some embodiments, the second assembly sequence comprises a nucleotide second overhang in the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence is positioned on a second end or a 3’ end of the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence in the in the linear duplexed nucleic acid fragment is complementary to the assembly sequence in the second single stranded nucleic acid. In some embodiments, all of the annealing, the digesting, and the ligating occur in a same contiguous aqueous solution or occur at a same time. In some embodiments, the annealing, the digesting, or the ligating are completed within 48 hours. The method of any one of the preceding claims, further comprising adding a buffer suitable for both digestion and ligation to the solution. In some embodiments, a salt concentration of the solution is at least 20, 25, 30, 35, 37.5, 40, 45, 50, 55, 60, 65, 70, or 75 mM. In some embodiments, a salt concentration of the solution is 20-75 mM. In some embodiments, a salt concentration of the solution is 20-60 mM 30-30 mM. In some embodiments, a salt concentration of the solution is 30-50 mM. In some embodiments, a salt concentration of the solution is at least 37.5 uM. In some embodiments, a salt concentration of the solution is about 37.5 uM. In some embodiments, the buffer suitable for both digestion and ligation comprises potassium acetate, tris-acetate, magnesium acetate, bovine serum albumin, and adenosine triphosphate. In some embodiments, the buffer comprises about 50 mM Potassium Acetate, 20 mM Tris- Acetate, 10 mM Magnesium Acetate, 100 pg / mL bovine serum albumin, and 1 mM adenosine triphosphate. In some embodiments, the ligating comprises adding a thermotol erant ligase to a solution comprising the annealed fragment. In some embodiments, the thermotolerant ligase is Hi-T4 ligase. In some embodiments, the thermotolerant ligase is concentrated in the solution to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to 4-12 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to 6-10 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to about 8 enzyme units / uL. In some embodiments, the ligating comprises incubating the solution at 37 C. In some embodiments, the solution is incubated for at least 4 hours. In some embodiments, the digesting comprises adding an exonuclease to the solution. In some embodiments, the digesting comprises adding a single exonuclease to the solution. In some embodiments, the exonuclease is Dral. In some embodiments, the digesting comprises incubating the solution for at least 2 hours at 37 C. In some embodiments, the method further includes purifying the aqueous solution comprising the aptamer nucleic acid conjugated construct in a single step purification. In some embodiments, the purifying comprises bindingDocket No. 62668-747.601the construct to a magnetic substrate and removing the aqueous solution. In some embodiments, the purifying comprises eluting the aptamer nucleic acid conjugated construct in a sterile aqueous solution. In some embodiments, the aptamer nucleic acid conjugated construct is DNA. In some embodiments, the single stranded nucleic acid is DNA. In some embodiments, the linear duplexed nucleic acid fragment is DNA. In some embodiments, the nucleic acid is DNA. In some embodiments, the nucleic acid is linear. In some embodiments, the linear nucleic acid is an amplification product comprising one or more copies of the expression cassette. In some embodiments, the amplification product is a product of rolling-circle amplification of a circular template. In some embodiments, the rolling-circle amplification is performed using a stranddisplacing DNA polymerase. In some embodiments, the strand-displacing DNA polymerase is 29 (phi29) DNA polymerase. In some embodiments, the rolling-circle amplification is multiply-primed rolling-circle amplification. In some embodiments, the multiply-primed rollingcircle amplification uses random primers. In some embodiments, the random primers are random hexamer primers. In some embodiments, the rolling-circle amplification is performed using one or more sequence-specific primers. In some embodiments, the rolling-circle amplification is performed isothermally. In some embodiments, the rolling-circle amplification is performed at a temperature of about 30 °C. In some embodiments, the circular template is provided in an amount of at most 1 pg, 100 ng, 10 ng, 1 ng, 100 pg, or 10 pg, and the amplification product comprises at least 1 pg, 10 pg, 100 pg, 1 mg, 5 mg, 10 mg, or 50 mg of nucleic acid. In some embodiments, the amplification product is a concatemeric nucleic acid comprising a plurality of tandem repeats of the expression cassette. In some embodiments, the concatemeric nucleic acid is double-stranded. In some embodiments, the concatemeric nucleic acid is hyperbranched. In some embodiments, the amplification product is processed prior to ligation to generate one or more linear duplexed nucleic acid fragments comprising the expression cassette. In some embodiments, the processing comprises contacting the amplification product with one or more endonucleases. In some embodiments, the one or more endonucleases comprise a type IIS endonuclease. In some embodiments, the type IIS endonuclease is Bsal. In some embodiments, the amplification product comprises a first endonuclease recognition sequence positioned 5' of the expression cassette on a sense strand and a second endonuclease recognition sequence positioned 3' of the expression cassette on an antisense strand. In some embodiments, contacting the amplification product with the one or more endonucleases excises the expression cassette without retention of either the first endonuclease recognition sequence or the second endonuclease recognition sequence on the linear duplexed nucleic acid fragment. In some embodiments, the processing comprises contacting the amplification product with a protelomerase to produce one or more closed-end linear duplexedDocket No. 62668-747.601nucleic acid fragments comprising the expression cassette. In some embodiments, the amplification product comprises one or more protelomerase recognition sites flanking the expression cassette. In some embodiments, the amplification product is used in the method without an intervening propagation, fermentation, or cloning step in a living host cell. In some embodiments, the circular template does not comprise an antibiotic-resistance marker. In some embodiments, the linear nucleic acid is substantially free of bacterial host-cell DNA. In some embodiments, the rolling-circle amplification, the processing of the amplification product, and the annealing, ligating, and digesting steps are performed in sequence in a single facility without an intervening bacterial fermentation step.BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Various features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0015] FIG. 1 A illustrates an embodiment of a nucleic acid delivery vector of the present disclosure;
[0016] FIG. IB illustrates an embodiment of a nucleic acid delivery vector of the present disclosure;
[0017] FIG. 2 illustrates the nuclear pore complex and import of cargo through the nuclear pore complex;
[0018] FIG. 3 illustrates a process in which embodiments of nucleic acid delivery vectors of the present disclosure are manufactured;
[0019] FIG. 4 illustrates a conformation of an aptamer of the present disclosure;
[0020] FIG. 5 illustrates a conformation of an aptamer of the present disclosure;
[0021] FIG. 6 illustrates a conformation of an aptamer of the present disclosure;
[0022] FIG. 7 illustrates the cGAS-STING pathway of the innate immune system for sensing and clearance of cytosolic DNA;
[0023] FIG. 8A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0024] FIG. 8B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;Docket No. 62668-747.601
[0025] FIG. 9A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0026] FIG. 9B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0027] FIG. 10A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0028] FIG. 10B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0029] FIG. 11 provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0030] FIG. 12A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0031] FIG. 12B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0032] FIG. 13 A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0033] FIG. 13B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0034] FIG. 14A provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;
[0035] FIG. 14B provides data illustrating in-vitro gene expression resulting from transfecting iPSC-Derived Hepatocytes with nucleic acid delivery vectors with aptamers of the present disclosure;Docket No. 62668-747.601
[0036] FIG. 15 illustrates an exemplary ultrasound transducer system having computer processors with a computer readable medium storing instructions for implementing the methods of the present disclosure;
[0037] FIG. 16 illustrates an embodiment of a nucleic acid manufacturing process of the present disclosure;
[0038] FIG. 17 illustrates an embodiment of a nucleic acid manufacturing process of the present disclosure;
[0039] FIG. 18 illustrates an embodiment of a nucleic acid manufacturing process of the present disclosure; and
[0040] FIG. 19 illustrates data showing increased gene expression in a study using an aptamer conjugated nucleic acid construct of the present disclosure.DETAILED DESCRIPTION OF THE INVENTION
[0041] While sonoporation is extensively studied, little remains known regarding the underlying causes of poor efficiency of nucleic acid delivery using the technique. One potential barrier to efficient gene expression proposed herein includes poor nuclear localization of genetic cargos which are transfected to the cell, for example, due to the low tendency of genetic cargos to move through the cytosol and translocate across the nuclear envelope, or due to the clearance of double stranded DNA payloads in the cytosol by the cell’s innate immune system prior to nuclear localization. Disclosed and described herein are compositions and methods for overcoming such technical challenges which can increase nuclear localization of genetic payloads delivered to cells using sonoporation, and / or which can reduce the activation of the cell’s innate immune system and resulting clearance of the genetic cargo.
[0042] Translocating a DNA payload across the nuclear envelope presents numerous technical challenges due to the complex architecture of the nuclear envelope, the characteristics of DNA molecules, and the mechanisms involved in nuclear transport, many of which have evolved in mammalian cells as defense mechanisms against injection by viral, bacterial, and fungal injections. The nuclear envelope is a double lipid bilayer structure that is formed from the outer nuclear membrane, which is generally continuous with the endoplasmic reticulum, and the inner nuclear membrane, which interacts with the nuclear lamina and chromatin DNA within the nucleus. Embedded within the nuclear envelope are nuclear pore complexes and nucleoporin proteins, which regulate molecular traffic between the cytoplasm and the nucleus. While small molecules can pass through nuclear pore complex via passive diffusion, larger macromolecules such as DNA generally require active transport mechanisms. DNA, including encapsulated DNA, is much larger than the cargo typically allowed by nuclear pore complex, and the largeDocket No. 62668-747.601size of unencapsulated DNA often impedes efficient translocation. DNA further carries a negative charge due to its phosphate backbone, which complicates its passage through the cellular environment and the nuclear pore complexes (NPCs), as nuclear import mechanisms are not optimized for such charged macromolecules. Nuclear import of large molecules generally requires nuclear localization signals that are recognized by transport proteins like importins, which facilitate their movement through nucleoporin complexes (FIG. 2). However, unencapsulated DNA administered through sonoporation, as is known within the art, lacks these nuclear localization signals, necessitating improvements to the art to facilitate transportation into the nucleus.
[0043] Described herein are methods and compositions which are adapted for increasing nuclear localization of genetic payloads in cell. Aspects disclosed herein provide a nucleic acid composition comprising: a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, an aptamer comprising a nuclear localization element or an innate immune response avoidance moiety at either the 5’ end or the 3’ end, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end. In some embodiments, the aptamer comprises the nuclear localization element. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 50. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 46. In some embodiments, the nucleic acid composition increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the nuclear localization element. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with an cargo polynucleotide positioned between the 5’ end and the 3’ end, a single aptamer having a sequence of SEQ ID NO: 50 at either the 5’ end or the 3’ end which is coupled to the cargo polynucleotide with an adaptor sequence of any one of SEQ ID NOS: 254, 256, or 258, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end having a sequence of any one of SEQ ID NOS: 254-281. In some embodiments, the adaptor sequence comprises a 5’ and a 3’ end, and the single aptamer having a sequence of SEQ ID NO: 50 is positioned between the 5’ and the 3’ end of the adaptor sequence.
[0044] Described herein are methods and compositions which are adapted for increasing nuclear localization of genetic payloads in cell, and which are adapted for evading the cell’s innate immune system for clearing exogenous genetic cargos. Aspects disclosed herein provide a nucleic acid composition comprising a cargo polynucleotide, means for increasing localization of the nucleic acid composition, and means for avoiding or reducing an innate immune responseDocket No. 62668-747.601to the nucleic acid composition or a second means for increasing localization of the nucleic acid composition. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer comprising a nuclear localization element, and a second aptamer comprising an innate immune response avoidance moiety or a second nuclear localization element. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 46 at the 3’ end. Aspects disclosed herein provide a nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 53 at the 3’ end. In some embodiments, the means for increasing localization of the nucleic acid composition comprises a first aptamer comprising a nuclear localization element. In some embodiments, the first aptamer comprises a nucleic acid sequence which binds a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 50. In some embodiments, the first aptamer comprises a nucleic acid sequence which binds a nucleolin protein. In some embodiments, the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 46. In some embodiments, the means for reducing an innate immune response to the nucleic acid composition comprises a second aptamer comprising an innate immune response avoidance moiety. In some embodiments, the innate immune response avoidance moiety comprises an antagonist inhibitor of TLR9 and TLR7. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 53. In some embodiments, the second means for increasing localization of the nucleic acid composition comprises a second aptamer comprising a second nuclear localization element. In some embodiments, the second aptamer comprises a nucleic acid sequence which binds a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 50. In some embodiments, the second aptamer comprises a nucleic acid sequence which binds a nucleolin protein. In some embodiments, the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 46. In some embodiments, the first aptamer is located at the 3’ end. In some embodiments, the second aptamer is located at the 5’ end. In some embodiments, the first aptamer is located at the 5’ end. In some embodiments, the second aptamer is located at the 3’ end.Docket No. 62668-747.601
[0045] In some cases, the nuclear localization element is configured to bind an importin protein which facilitates transport of the cargo polynucleotide comprising an expression cassette that comprises a therapeutic transgene into nucleus. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind importin. In some embodiments, the sequence configured to bind importin comprises a nucleic acid sequence of SEQ ID NO: 3-48, OR SEQ ID NO: 43-48, or SEQ ID NO: 48, 129, OR 130. In some embodiments, the aptamer comprises a sequence having at least at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, or at least 99% sequence identity to any one of SEQ ID NO: 3-54 or 78-85 OR SEQ ID NO: 43-48, or SEQ ID NO: 48, 129, OR 130. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind importin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0046] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind nucleolin. In some cases, the nuclear localization element is configured to bind a nucleolin protein primarily found in the dense fibrillar regions of the nucleus, which facilitates transport of the cargo polynucleotide comprising an expression cassette that comprises a therapeutic transgene into nucleus. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 3-47. In some embodiments, the aptamer comprises a sequence having at least at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, or at least 99% sequence identity to any one of SEQ ID NO: 3-54 or 78-85. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 43-47, OR SEQ ID NO: 135-148. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind nucleolin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0047] In some cases, the nuclear localization element is configured to bind a nuclear pore or a nucleoporin protein to facilitate transport of the cargo polynucleotide comprising an expression cassette that comprises a therapeutic transgene into nucleus. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments,Docket No. 62668-747.601the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358. In some embodiments, the nucleoporin protein comprises NUP 358. In some embodiments, the sequence configured to bind the nucleoporin protein comprises a nucleic acid sequence of any one of SEQ ID NO: 49-50. The aptamer encoded by SEQ ID NO: 50 is shown in conformational form in FIG. 5. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind a nucleoporin protein provides a beneficial technical effect of increasing nuclear localization of the nucleic acid and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene. In some embodiments, the method further includes administering ultrasonic acoustic energy to the target cell of the subject. In some embodiments, the method further includes administering a sonoactive agent to the subject. In some embodiments, the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, at least 1.45, at least 1.50, at least 1.55, at least 1.60, at least 1.65, at least 1.75, at least 1.80, at least 1.85, at least 1.90, at least 1.95, at least 2.0, at least 2.25. 2.5, at least 2.75. 3, at least 3.5, at least 4, at least 4.5, or 5 fold as compared to a nucleic acid lacking the nuclear localization element. In some embodiments, the nuclear localization element comprises a DNA aptamer, and the aptamer comprises a sequence configured to bind a nucleoporin protein; the cargo polynucleotide comprises an expression cassette encoding a therapeutic transgene; the cargo polynucleotide is covalently coupled to the aptamer; the nucleic acid is a closed linear DNA construct comprising covalently closed at both ends by hairpin loops comprising the aptamer. In some embodiments, the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 2.0 fold as compared to a nucleic acid lacking the nuclear localization element.
[0048] Aspects provided herein include sequences of nucleic acids and DNA aptamers which bind nucleoporin proteins, for example, NUP358. Aspects disclosed herein provide a nucleic acid comprising a sequence having at least 80% sequence identity to SEQ ID NO: 49 or 50. In some embodiments, the sequence of the nucleic acid has at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, or at least 99% sequence identity to SEQ ID NO: 49 or 50. In some embodiments, the sequence of the nucleic acid comprises the sequence of SEQ ID NO: 49 or 50. In some embodiments, the nucleic acid comprises an aptamer configured to bind a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358. In some embodiments, the nucleic acid is an aptamer configured to bind NUP358. In some embodiments, the nucleic acid is DNA and / or comprises a DNA aptamer. AspectsDocket No. 62668-747.601disclosed herein provide a nucleic acid for use in treating a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy. In some embodiments, the subject is a subject having Hemophilia A or FVIII deficiency, and the nucleic acid encodes FVIII. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV. In some embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1. IN some cases, a nucleic acid composition comprising a 5’ end and a 3’ end with an cargo polynucleotide positioned between the 5’ end and the 3’ end, a single aptamer having a sequence of SEQ ID NO: 50 at either the 5’ end or the 3’ end, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end having a sequence of any one of SEQ ID NOS: 254, 256, or 258, provides a beneficial technical effect of increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the nuclear localization element.
[0049] In addition to challenges associated with nuclear localization, the delivery of DNA to cells faces significant challenges due to the innate immune system’s ability to recognize and clear foreign genetic material. The innate immune system is the body’s first line of defense, and it has evolved to detect and eliminate potential threats, including exogenous DNA which biologically is delivered to the cell because of microbial infection. The innate immune system is equipped with pattern recognition receptors such as Toll-like receptors (TLRs) and cytosolic DNA sensors such as cyclic GMP-AMP synthase (cGAS), which detect foreign DNA. For example, sensing to cytosolic DNA can include binding of double stranded cytosolic DNA by cGAS, which can lead to a signaling cascade of an immune response including synthesis of a special asymmetric cyclic-dinucleotide, 2'3'-cGAMP, and activation of STING (endoplasmic reticulum (ER) membrane protein) for subsequent production of type I interferons and other immune-modulatory genes, as is illustrated in FIG. 11. In addition to type I IFN production, activation of the cGAS-STING pathway can also lead to the production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6), induction of cellular autophagy, activation of activation of caspase- 1 and subsequent processing and secretion of pro-inflammatory cytokines such as interleukin- 1 beta (IL-1 P) and interleukin- 18 (IL-18), and activation of apoptotic pathways. Other aspects of the innate immune system include TLR9 activation in endosomes which can recognize unmethylated CpG motifs in bacterial or synthetic DNA, triggering immune responses that activate inflammatory cytokines and interferons. Once exogenous cytosolic DNA is detected by any mechanism, the immune system launches a powerful inflammatory response, involving the production of type IDocket No. 62668-747.601interferons and other cytokines, working to activate immune cells such as natural killer (NK) cells, macrophages, and dendritic cells to clear the DNA and destroy transfected cells. In the context of a sonoporati on-based gene therapy, this can result in clearance of DNA delivered to a cell and resulting gene expression.
[0050] Described herein are methods and compositions which are adapted for evading the cell’s innate immune system for clearing exogenous genetic cargos. Aspects disclosed herein provide a nucleic acid composition comprising: a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, an aptamer comprising a nuclear localization element or an innate immune response avoidance moiety at either the 5’ end or the 3’ end, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end. In some embodiments, the aptamer comprises the innate immune response avoidance moiety. In some embodiments, the aptamer comprises a sequence of SEQ ID NO: 53. In some embodiments, the aptamer is at the 5’ end and there is no aptamer at the 3’ end. In some embodiments, the aptamer is at the 3’ end and there is no aptamer at the 5’ end. In some embodiments, there is only one aptamer in the nucleic acid composition. In some embodiments, the single stranded end not comprising an aptamer comprises a sequence of any one of SEQ ID NOS: 254-281. In some embodiments, the innate immune response avoidance moiety comprises an aptamer. In some embodiments, the innate immune response avoidance moiety comprises a DNA aptamer, and the aptamer comprises a sequence which is a cGAS or a TLR9 antagonist; the cargo polynucleotide comprises an expression cassette encoding a therapeutic transgene; the cargo polynucleotide is covalently coupled to the aptamer; the nucleic acid is a closed linear DNA construct comprising covalently closed at both ends by hairpin loops comprising the aptamer. In some embodiments, the innate immune response avoidance moiety increases expression of the cargo polynucleotide in the target cell by at least 2.0 fold as compared to a nucleic acid lacking the innate immune response avoidance moiety.
[0051] In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the innate immune response avoidance moiety comprises a cyclic GMP-AMP synthase (cGAS) antagonist. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind cGAS. In some embodiments, the nucleic acid sequence configured to bind a cGAS comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the cGAS comprises SEQ ID NO: 51 or 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind cGAS is a cGAS antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind cGAS competes with cGAS bindingDocket No. 62668-747.601by the exogenous DNA, and acts as a cGAS antagonist, prevents activation of cGAS by the exogenous DNA, and reduces or eliminates clearance of the nucleic acid from the cell. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind cGAS provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0052] In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the innate immune response avoidance moiety comprises an absent in melanoma 2 inflammasome (AIM2) antagonist. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind an AIM2. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises SEQ ID NO: 51 or 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind AIM2 is an AIM2 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind AIM2 competes for binding to the cytosolic DNA sensor AIM2, and acts as an AIM2 antagonist, prevents activation of AIM2 by the exogenous DNA, and reduces or eliminates clearance of the nucleic acid from the cell. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind AIM2 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0053] In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind TLR9. In some embodiments, the innate immune response avoidance moiety comprises a toll-like receptor 9 (TLR9) antagonist. In some embodiments, the sequence configured to bind TLR9 comprises a CpG motif. In some embodiments, the CpG motif comprises any one of SEQ ID NOS: 90-93. In some embodiments, the nucleic acid sequence configured to bind TLR9 comprises any one of SEQ ID NOS: 51-54. An exemplary aptamer encoded by SEQ ID NO: 53 configured to bind TLR9 is shown in FIG.7. As is shown in FIGS. 7-9, the aptamers may comprise a double stranded stem region 10 and a single stranded region 20 which has a conformational form in which the aptamer will bind the target antigen. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind TLR9 is a TLR9 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence is an antagonist of TLR9 and preventsDocket No. 62668-747.601TLR9-mediated activation of B-cells and macrophages which would work to clear the exogenous DNA, and reduces or eliminates clearance of the nucleic acid from the cell. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind TLR9 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0054] In some embodiments, the innate immune response avoidance moiety increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, at least 1.45, at least 1.50, at least 1.55, at least 1.60, at least 1.65, at least 1.75, at least 1.80, at least 1.85, at least 1.90, at least 1.95, at least 2.0, at least 2.25. 2.5, at least 2.75. 3, at least 3.5, at least 4, at least 4.5, or 5 fold as compared to a nucleic acid lacking the nuclear localization element. In some embodiments, the aptamer is a DNA aptamer. In some embodiments, the subject is a mammalian subject. In some embodiments, the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector. In some embodiments, the aptamer is a separate nucleic acid construct from the nucleic acid. In some embodiments, the hairpin loops comprise the aptamer. In some embodiments, the nucleic acid(s) are administered simultaneously with the sonoactive agent or microbubble. In some embodiments, the nucleic acid(s) and the sonoactive agent or microbubble are administered in a same intravenous infusion. In some embodiments, the nucleic acid(s) and the sonoactive agent or microbubble are administered in a same pharmaceutical composition.
[0055] Illustrated in FIG. 1 A is a nucleic acid delivery vector of the present disclosure which comprise a (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) one or more of: i) a nuclear localization element, ii) a immune response avoidance moiety; or iii) an aptamer. Referring to FIG. 1, the nucleic acid delivery vector can be a linear nucleic acid delivery vector 2000 with a closed end(s) 2030. The nucleic acid delivery vector can comprise an expression cassette 2035 encoding a therapeutic transgene in the double stranded portion 2020 of the vector in which the sense strand is complementarily paired to the antisense strand. The nucleic acid delivery vector can comprise a spacer sequence or an adaptor sequence 2015 preceding or following (e.g., 5’ or 3’) of the expression cassette 2035 before the closed end on a given strand (e.g., the sense strand). In some embodiments, the spacer sequence can be at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 15, at least 18, at least 21, at least 23, at least 27, or at least 30 nucleotides. In some cases, the spacer sequence provides a beneficial technical effect of reducing steric hindrance of the polynucleotide chain, permitting the proper base pairing of the aptamer 2005 to form its intended 3D conformation (see, e.g., FIGS. 4-6) to allow for theDocket No. 62668-747.601aptamer to bind its target antigen or moiety. In some cases, the nucleic acid delivery vector can be closed by an aptamer 2005. The aptamer may comprise a stem region 2010 which is formed from inverted terminal repeat sequences which are complementarily paired to another.
[0056] Illustrated in FIG. IB is a nucleic acid delivery vector of the present disclosure which comprise a (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) one or more of: i) a nuclear localization element, ii) a immune response avoidance moiety; or iii) an aptamer. Referring to FIG. IB, a nucleic acid delivery vector 3000 can be closed by an aptamer 2005 / 2040 at each end. In some cases, a second aptamer 2040 which comprises a different nucleic acid sequence and which is configured to bind a different moiety or antigen can be on the second end of the nucleic acid delivery vector 3000. In some embodiments the aptamer 2005 / 2040 at a first end is the nuclear localization element, and the aptamer 2005 / 2040 at the second end is the innate immune response avoidance moiety. In some embodiments the aptamers 2005 / 2040 at a first end and the second end are the same.
[0057] In some embodiments, the cargo polynucleotide comprises an expression cassette. In some embodiments, the expression cassette comprises a therapeutic transgene. In some embodiments, the therapeutic transgene comprises FVIII, FIX, DMD, COL4A5, PKD1, PKD2, or ATP7B. In some embodiments, the expression cassette comprises a promoter sequence. In some embodiments, the expression cassette is at least partially double stranded. In some embodiments, the promoter sequence is double stranded. In some embodiments, the aptamer is coupled to an adaptor sequence. In some embodiments, the adaptor sequence comprises a sequence of any one of SEQ ID NOS: 101-128, or 254-281.
[0058] In some embodiments, the cargo polynucleotide is covalently coupled to the aptamer, the nuclear localization element, or the innate immune response avoidance moiety. In some embodiments, the cargo polynucleotide is 5’ of the aptamer with reference to the sense strand, the nuclear localization element, or the innate immune response avoidance moiety. In some embodiments, the cargo polynucleotide is 3’ of the aptamer, the nuclear localization element, or the innate immune response avoidance moiety with reference to the sense strand.
[0059] In some embodiment, the aptamer is configured to promote an intracellular function. In some embodiments, the intracellular function comprises increased resistance to one or more intracellular nucleases. In some embodiments, the intracellular function comprises improved transcription of the cargo polynucleotide.
[0060] Aspects disclosed herein provide a method of expressing a therapeutic transgene in a subject comprising administering to the subject the nucleic acid composition of any one of the preceding claims. Aspects disclosed herein provide a use of the nucleic acid composition of any one of the preceding claims in a method of treating a genetic disorder in a subject in needDocket No. 62668-747.601thereof comprising administering to the subject the nucleic acid composition of any one of the preceding claims. In some embodiments, the method further includes administering to the subject a sonoactive agent. In some embodiments, the sonoactive agent comprises a microbubble. In some embodiments, the method further includes administering ultrasound energy to the subject. In some embodiments, applying ultrasonic energy to the cell of the subject comprises applying the ultrasound energy at a first mechanical index (MI) that is less than or equal to 0.4 (e.g., 0 < MI < 0.4). In some embodiments, the method further includes applying ultrasonic acoustic energy to the cell of the subject at a second MI that is greater than the first MI. In some embodiments, the first MI is about 0.07. In some embodiments, the second MI is at least 1.5. In some embodiments, the second MI is at least 2.0. In some embodiments, the second MI is at least 2.9. In some embodiments, applying ultrasonic energy to the cell at the second MI comprises applying the ultrasonic acoustic energy in a pulse. In some embodiments, the pulse is less than 2 s. In some embodiments, the pulse is up to 500 microseconds. In some embodiments, the pulse is 1 microsecond to 500 microseconds. In some embodiments, the pulse is about 100-300 microseconds. In some embodiments, the pulse is about 200 microseconds. In some embodiments, the ultrasound is applied at a frequence of about 0.5-20 MHz. In some embodiments, the subject is a mammalian subject. In some embodiments, the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector. In some embodiments, the ultrasound is directed toward a target cell. In some embodiments, the target cell is a liver cell. In some embodiments, the target cell is a hepatocyte. In some embodiments, the target cell is a LSEC. In some embodiments, the target cell is a kidney cell. In some embodiments, the target cell is a proximal tubular epithelial cell. In some embodiments, the target cell is a podocyte. In some embodiments, the target cell is a muscle cell. In some embodiments, the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy. In some embodiments, is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene wherein the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subject. In some embodiments, the method is a method for use of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy. In some embodiments, the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte. In some embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleicDocket No. 62668-747.601acid encodes polycystin-1, and the target cell is a kidney cell. In some embodiments, the subject is a subject having a muscular dystrophy, the nucleic acid encodes dystrophin (DMD), and the target cell is a muscle cell, a cardiac cell, or a diagram cell. In some embodiments, the subject is a human subject..
[0061] In some embodiments, the method further includes administering to the subject the sonoactive agent, the nucleic acid, and ultrasound acoustic energy at least a second time at least 24 hours after an initial administration of the sonoactive agent, the nucleic acid, and ultrasound acoustic energy.
[0062] Referring to FIG. 3, the nucleic acid delivery vectors of the present disclosure can be synthesized in an exemplary process beginning from double-stranded circular DNA. For example, a plasmid encoding an expression cassette of interest can be chemically synthesized, while single stranded DNA encoding the aptamer sequence of interest can be chemically synthesized, using methods known within the art. The plasmid DNA can be linearized with endonuclease digestion, e.g., BasI digestion, which can cut endonuclease recognition sites within the pDNA. The aptamer adaptors can by synthesized to comprise complementary sequences to the overhang sequences which are left by the endonuclease digestion, and the hybridized linear DNA molecule can be ligated using a ligase, for example, T4 ligase. After ligation, remaining backbone, aptamer sequences, and pDNA can be digested using additional endonucleases (e.g., Nhel, Pcil), and then treated with yet additional endonuclease to digest any remaining DNA which is not closed at each end (e.g., ExoIII). The remaining product can then be purified, concentrated, and stored or sequenced as necessary.
[0063] Aptamers of the present disclosure can be identified using a SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique, to identify high-affinity aptamers that specifically bind to a target antigen, for example, the Nup358 protein. The process can begin with the synthesis and immobilization of the target antigen on a solid support, such as NHS-activated Sepharose beads or high-binding plates, ensuring proper protein folding and functionality. A randomized nucleic acid library, composed of single-stranded DNA (ssDNA) or RNA, can be prepared with random nucleotide sequences of 20-80 bases, along with primerbinding sites for later amplification. To promote correct structural formation, the library can be denatured by heating to 95°C and then rapidly cooled. These nucleic acids may be then incubated with the immobilized target antigen in an appropriate buffer system that may include components like Tris-HCl, NaCl, KC1, and MgCL to maintain aptamer-protein interactions.
[0064] Following incubation, the unbound or weakly bound nucleic acids may be washed away using buffers of increasing ionic strength to improve the specificity of binding. The tightly bound aptamers may be eluted using either a high-salt buffer or a low-pH buffer, depending onDocket No. 62668-747.601the nature of the binding interaction. For RNA aptamers, mild heating may be used during elution to avoid degradation. The eluted aptamers may be then amplified through PCR (for ssDNA) or reverse transcription followed by PCR (for RNA), ensuring that the enriched sequences may be available for the next round of SELEX. The SELEX process can be carried out iteratively, typically over 8-12 rounds, with each cycle involving incubation with the target protein, washing, elution, and amplification. Over successive rounds, the washing stringency can be increased to enrich for aptamers with higher affinity and specificity for the target antigen. The progress of enrichment can be tracked using techniques such as fluorescence anisotropy, surface plasmon resonance (SPR), or electrophoretic mobility shift assays (EMSA), which measure the binding affinity of the selected aptamer pool.
[0065] To further refine specificity, a counter-SELEX step can be introduced. This involves exposing the nucleic acid library to irrelevant proteins or beads without the target antigen to eliminate non-specific binders. After the final SELEX round, the enriched pool of aptamers can be cloned into a suitable vector for sequencing, and bioinformatic analysis can be used to identify unique aptamer sequences. These sequences may be synthesized or transcribed for further characterization, including determining their dissociation constants (Kd) and binding specificity to NUP 358. High-affinity aptamers may be expected to exhibit minimal crossreactivity with other proteins. Throughout the SELEX process, various parameters such as washing stringency, immobilization techniques, and negative controls may be optimized to ensure high specificity and reduce non-specific binding.
[0066] Provided herein are methods for delivery or transfection of a nucleic acid to a cell, tissue, or organ of a subject in a targeted manner using sonoporation (e.g., a process comprising applying an ultrasonic acoustic energy to a cell, tissue, or organ, such as to provide increased porosity in the cell, tissue, or organ). Provided in certain embodiments herein are methods for delivering to a cell a nucleic acid comprising a cargo polynucleotide (e.g., an expression cassette comprising a transgene or therapeutic oligonucleotide) and an aptamer to a target cell using sonoporation. In certain embodiments the aptamer comprises a sequence configured to promote an intracellular function. In some cases, the intracellular function comprises increasing nuclear localization in the target cell, preventing degradation of the cargo polynucleotide from the one or more intracellular nucleases, or increasing transcription of the cargo polynucleotide. Provided in certain embodiments herein are methods for transfecting a nucleic acid into a target cell or tissue (e.g., of a subject) by applying an ultrasonic acoustic energy to a cell, tissue, or organ. In some cases, the applying the ultrasonic acoustic energy comprises applying a first ultrasonic acoustic energy to the cell, tissue, or organ, and applying a second ultrasonic acoustic energy to the cell, tissue, or organ. In specific embodiments herein are methods for transfecting a nucleicDocket No. 62668-747.601acid into a target cell or tissue by applying a first ultrasonic acoustic energy having a first mechanical index (MI) and applying a second ultrasonic acoustic energy having a second mechanical index (MI). The present disclosure provides methods for enhancing transfection of a nucleic acid into the target cell or tissue by applying alternating ultrasonic acoustic energy, the alternating acoustic energy alternating between a first mechanical index (MI) and a second MI. Application of ultrasonic acoustic energy can be repeated several times during sonoporation, and may increase the efficiency of nucleic acid transfection and / or delivery.
[0067] In some embodiments, a process provided herein provides sonoporation at two or more different ultrasonic acoustic energies (e.g., a first and second ultrasonic acoustic energy having a first and second MI, respectively). In certain embodiments, a process provided herein provides a process wherein an ultrasonic acoustic energy is continuously applied (e.g., ultrasonic acoustic energy transitions from the first ultrasonic acoustic energy to the second ultrasonic acoustic energy, without a period of no ultrasonic acoustic energy being applied). In certain embodiments, a transitory (e.g., third, fourth, etc.) ultrasonic acoustic energy is applied between application of the first and second ultrasonic acoustic energies.
[0068] In some embodiments, a sonoporation treatment (e.g., application of a first ultrasonic acoustic energy, a second ultrasonic acoustic energy, a single cycle of a first ultrasonic acoustic energy and a second ultrasonic acoustic energy, or series of cycles comprising a plurality of applications of a first ultrasonic acoustic energy and a plurality of applications of a second acoustic energy) can last for a few seconds (e.g., 1-100 seconds) or more, such as up to a few minutes (e.g., 1-3 minutes). In specific embodiments, a sonoporation treatment last for 1-30 seconds. In some specific embodiments, a sonoporation treatment lasts for 5-100 seconds. In certain embodiments, a sonoporation treatment lasts for at least 1 minute (e.g., 1-30 minutes).
[0069] In some embodiments, a first MI is a Low MI (e.g., less than 0.4). In certain embodiments, a second MI is a High MI (e.g., 0.4 or greater). In some embodiments, a first MI is a Low MI (e.g., less than 0.4) and a second MI is a High MI (e.g., 0.4 or greater). In some embodiments, a second MI is a Low MI (e.g., less than 0.4). In certain embodiments, a first MI is a High MI (e.g., 0.4 or greater). In specific embodiments, a second MI is a Low MI (e.g., less than 0.4) and a first MI is a High MI (e.g., 0.4 or greater).
[0070] In some embodiments, a Low MI is <0.3. In specific embodiments, a Low MI is <0.2. In more specific embodiments, a Low MI is <0.1. In still more specific embodiments, a Low MI is about 0.09. In still more specific embodiments, a Low MI is about 0.04. In still more specific embodiments, a Low MI is about 0.03.Docket No. 62668-747.601
[0071] In some embodiments, a second MI is a High MI (e.g., 0.4 or greater). In some embodiments, a High MI is >0.5. In specific embodiments, a High MI is 0.5 to 2.0 or is between 0.5 and 2.0. In more specific embodiments, a High MI is 0.5 to 1 or is between 0.5 and 2.0. In some embodiments, a High MI is 1.5. In some embodiments, a High MI is 1.8. In some embodiments, a High MI is 2.0. In some embodiments, a High MI is greater than 0.4. In some embodiments, a High MI is > 0.5. In specific embodiments, a High MI is 0.5 to 2.0 or is between 0.5 and 2.3. In more specific embodiments, a High MI is 0.5 to 1 or is between 0.5 and 2.0. In some embodiments, a High MI is > 0.5. In specific embodiments, a High MI is 0.5 to 2.3 or is between 0.5 and 2.3. In more specific embodiments, a High MI is 0.5 to 1 or is between 0.5 and 2.3. In some embodiments, a High MI is 1.5. In some embodiments, a High MI is 1.8. In some embodiments, a High MI is 2.0. In some embodiments, a High MI is >0.5. In specific embodiments, a High MI is 0.5 to 2.9 or is between 0.5 and 2.9. In more specific embodiments, a High MI is 0.5 to 1 or is between 0.5 and 2.9. In some embodiments, a High MI is >0.5. In specific embodiments, a High MI is 0.5 to 2.0 or is between 0.5 and 2.0. In more specific embodiments, a High MI is 0.5 to 1 or is between 0.5 and 2.9. In some embodiments, a High MI is 1.5.
[0072] In certain embodiments, any process provided herein (e.g., a sonoporation treatment) comprises administering of a continuous ultrasonic acoustic energy (which may have varying energy levels) that alternates (e.g., in identical, similar, or variable periods) between Low MI and High MI. In some embodiments, a (e.g., continuous, such as continuous but for administration of a second ultrasonic acoustic energy) Low MI (e.g., <0.1) (e.g., first) ultrasonic acoustic energy (also referred to herein as a Low MI) is administered to the subject with a set number pulses (e.g., of less than 30 seconds) of High MI (e.g., second) ultrasonic acoustic energy (also referred to herein as a High MI). In some embodiments, a process provided herein comprises administration of a plurality of pulses of High MI (e.g., second) ultrasonic acoustic energy, e.g., during an otherwise continuous administration of a Low MI (e.g., first) ultrasonic acoustic energy. In specific embodiments, the number of High MI pulses is about 4 or more, such as up to about 12, or an unlimited number of pulses. In specific embodiments the number of High MI pulses is 6-30. In still more specific embodiments, the number of High MI pulses is between 8, 9, 12, 15, or 18, or any number therebetween.
[0073] In specific embodiments, a pulse length is any suitable length, such as less than 30 seconds. In more specific embodiments, a pulse length is less than 15 seconds. In still more specific embodiments, a pulse length is less than 10 seconds. In yet more specific embodiments, a pulse length is less than 5 seconds. In more specific embodiments, a pulse length is less than 2 seconds. In still more specific embodiments, a pulse length is less than 1 second and / or may beDocket No. 62668-747.601greater than or equal to 1 microsecond. In some embodiments, a pulse length ranges from 100 to 300 microseconds. In some embodiments, a pulse length is up to about 200 microseconds. In some embodiments, a pulse length is up to about 500 microseconds. In some embodiments, a pulse length ranges from 1 to 500 microseconds.
[0074] In various embodiments, a High MI ultrasonic acoustic energy is provided first temporally (e.g., first in order). In other embodiments, a Low MI ultrasonic acoustic energy is provided second temporally (e.g., second in order).
[0075] In some embodiments, any process provided herein further comprises administering (e.g., systemically administering, such as via infusion) a nucleic acid (e.g., any nucleic acid provided herein) to a subject (e.g., to whom the ultrasonic acoustic energies are applied).
[0076] In some embodiments, any process provided herein further comprises administering (e.g., systemically administering, such as via infusion) a sonoactive structure (e.g., any sonoactive structure or microbubble described herein) to a subject (e.g., to whom the ultrasonic acoustic energies are applied).
[0077] In certain embodiments, provided herein is a method of delivering a nucleic acid in a target cell (e.g., of a tissue or organ) of a subject, the method comprising: administering to the subject a nucleic acid comprising the cargo polynucleotide; administering to the subject a plurality of sonoactive microstructures; and administering a sonoporation treatment.
[0078] In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to the target cell (e.g., of a tissue or organ of the subject) (e.g., the ultrasonic acoustic energy having a mechanical index (MI)). In some embodiments, applying an ultrasonic acoustic energy to the target cell comprises applying a first ultrasonic acoustic energy to the target cell and applying a second ultrasonic acoustic energy to the target cell. In some embodiments, the (e.g., first or second) ultrasonic acoustic energy has a first mechanical index (MI). In certain embodiments, (e.g., the other of the first or second) ultrasonic energy has a second mechanical index (MI). In some embodiments, the (e.g., first or second) MI is less than 0.4. In certain embodiments (e.g., the other of the first or second) MI is greater than 0.4 (e.g., and less than 2.3). In certain embodiments (e.g., the other of the first or second) MI is greater than 0.4 (e.g., and less than 2.9). In certain embodiments (e.g., the other of the first or second) MI is greater than 0.4 (e.g., and less than 2.0).
[0079] In specific embodiments, a first ultrasonic acoustic energy and a second ultrasonic acoustic energy are applied sequentially in a repeated manner.
[0080] In certain embodiments, the first (either High MI or Low MI) ultrasonic acoustic energy is applied before or after administration of any other agent, such as the nucleic acid and / or sonoactive structure. In some embodiments, the first ultrasonic acoustic energy is appliedDocket No. 62668-747.601after administration of the sonoactive structure to the subject. In certain embodiments, the first ultrasonic acoustic energy is applied after administration of the nucleic acid to the subject. In some embodiments, the first ultrasonic acoustic energy is applied after administration of both the nucleic acid and the sonoactive structure(s).
[0081] In some embodiments, the first ultrasonic acoustic energy is administered within 60 minutes of administration of the nucleic acid and / or sonoactive structure(s). In specific embodiments, the first ultrasonic acoustic energy is administered within 30 minutes of administration of the nucleic acid and / or sonoactive structure(s). In more specific embodiments, the first ultrasonic acoustic energy is administered within 5 minutes of administration of the nucleic acid and / or sonoactive structure(s). In still more specific embodiments, the first ultrasonic acoustic energy is administered within 2 minutes of administration of the nucleic acid and / or sonoactive structure(s). In still more specific embodiments, the first ultrasonic acoustic energy may be applied simultaneously with administration of the nucleic acid and / or sonoactive structure(s).
[0082] In specific embodiments, the first (e.g., High MI) ultrasonic acoustic energy is applied immediately upon administration (e.g., infusion) or a period of time after administration (e.g., infusion) of the sonoactive structure(s) and / or nucleic acid.
[0083] In some embodiments, either the first or second ultrasonic acoustic energy is an ultrasonic acoustic energy (e.g., Low MI) that when applied to a cell, tissue, or organ of a subject results in stable cavitation (or stable vibrational cavitation) of the sonoactive structure and / or a change in the average diameter of the sonoactive structure(s), for example, due to inherent resonance properties of the microbubbles.
[0084] In certain embodiments, the first or second ultrasonic acoustic energy is an ultrasonic acoustic energy (e.g., High MI) that when applied to a cell, tissue, or organ of a subject results in inertial cavitation or the collapse of the sonoactive structures and / or disruption of cell membrane and / or vascular endothelial integrity.
[0085] In certain embodiments, either the first or second ultrasonic acoustic energy is an ultrasonic acoustic energy (e.g., Low MI) that when applied to a cell, tissue, or organ of a subject results in stable cavitation (or stable vibrational cavitation) and / or a change in the average diameter of the sonoactive structure(s), and the other of the first or second ultrasonic acoustic energy is an ultrasonic acoustic energy (e.g., High MI) that when applied to a cell, tissue, or organ of a subject results in inertial cavitation or the collapse of the sonoactive structures and / or disruption of cell membrane and / or vascular endothelial integrity.
[0086] In some instances, disruption of cell membrane allows target cells to become permeable to circulating agents such as nucleic acids. In certain instances, such circulatingDocket No. 62668-747.601agents can then enter the target cells, tissues or organs, such as in a more rapid manner (e.g., relative to either Low MI or High MI ultrasonic acoustic energy application alone, or in the absence of ultrasonic acoustic energy application).
[0087] In some embodiments, the methods herein comprise alternating the ultrasonic acoustic energy applied between a first ultrasonic acoustic energy having a first MI and a second ultrasonic acoustic energy having a second MI. In some embodiments, applying alternating ultrasonic acoustic energy administered to a subject between a first MI and a second MI is performed repeatedly over a number of times, such as to enhance gene transfection into the target cells, tissue or organ (e.g., relative to a similar process wherein a first and second ultrasonic acoustic energy are not used and / or are not alternately applied and / or are not alternately applied repeatedly).
[0088] In some embodiments, the method comprises administering ultrasound energy transcutaneously to the subject in proximity to one or more target cells. In some embodiments, the one or more target cells are hepatic cells. In some embodiments, the one or more target cells are renal cells. In some embodiments, the one or more target cells are pancreatic cells. In some embodiments, the one or more target cells are cardiac cells. In some embodiments, the one or more target cells are myocytes. In some embodiments, the one or more target cells are neuronal cells. In some embodiments, the one or more target cells are brain cells. In some embodiments, the target cells are cancerous cells.
[0089] In some embodiments, the one or more target cells are comprised in a tissue. In some embodiments, the tissue is skeletal muscle tissue. In some embodiments, the tissue is smooth muscle tissue. In some embodiments, the tissue is connective tissue. In some embodiments, the tissue is lymphatic tissue. In some embodiments, the tissue is nervous tissue. In some embodiments, the tissue is diseased tissue, e.g., cancerous tissue, fibrotic tissue, or tissue otherwise in need of gene therapy.
[0090] In some embodiments, the target tissue is comprised in an organ. In some embodiments, the organ is the liver. In some embodiments, the organ is a kidney. In some embodiments, the organ is the pancreas. In some embodiments, the organ is the heart. In some embodiments, the organ is the brain. In some cases, the target cell comprises a hepatocyte, an LSEC, a podocyte, a cardiac cell, a cardiac myocyte, a pancreatic cell, a neural cell, or a muscle cell.
[0091] In some embodiments, the one or more target cells are comprised in a tumor. In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a liquid tumor.
[0092] In some embodiments, cells, tissue or organ are those of the liver. In some embodiments, cells, tissue or organ are those of the kidney.Docket No. 62668-747.601
[0093] In certain embodiments, a subject herein is a mammal. In some embodiments, the mammal is, by way of non-limiting example, a human, rat, mouse, monkey, and other nonhuman primates.
[0094] In certain embodiments, changing parameters of the ultrasound acoustic energy or MI can be performed to induce and / or enhance an expression of a transgene in a cell or an organ of a subject. In one aspect, provided herein are methods of transfection by alternating the ultrasonic acoustic energy using a first MI and a second MI. In some embodiments, the first MI that results in stable vibrational cavitation is applied prior to the second MI, which results in inertial cavitation. In some embodiments, the ultrasonic acoustic energy using the first MI and the second MI are reapplied for a number of times to increase transfection efficiency at the target cell. In some embodiments, during the application of sonoporation, the ultrasonic acoustic energy is applied at the first MI continuously except for when the ultrasonic acoustic energy is applied at the second MI. For example, applying an ultrasonic acoustic energy to the target cell at the first MI then applying an ultrasonic acoustic energy to the target cell at the second MI are repeated between 4 to 18 times. In some embodiments, applying an ultrasonic acoustic energy to the target cell at the first MI then applying an ultrasonic acoustic energy to the target cell at the second MI are repeated an unlimited number of times. In one aspect, during this time, the ultrasonic acoustic energy of the first MI is applied continuously except for when the ultrasonic acoustic energy of the second MI is applied.
[0095] In some embodiments, the first MI ranges from about 0.05 to about 0.4. In some embodiments, the first MI ranges from about 0.1 to about 0.4. In some embodiments, the first MI ranges from about 0.15 to about 0.4. In some embodiments, the first MI ranges from about 0.2 to about 0.4. In some embodiments, the first MI ranges from about 0.25 to about 0.4. In some embodiments, the first MI ranges from about 0.3 to about 0.4. In some embodiments, the first MI ranges from about 0.05 to about 0.3. In some embodiments, the first MI ranges from about 0.1 to about 0.3. In some embodiments, the first MI ranges from about 0.15 to about 0.3. In some embodiments, the first MI ranges from about 0.2 to about 0.3. In some embodiments, the first MI ranges from about 0.25 to about 0.3. In some embodiments, the first MI is about 0.05. In some embodiments, the first MI is about 0.07. In some embodiments, the first MI is about 0.09. In some embodiments, the first MI is about 0.11.
[0096] In some embodiments, the second MI is greater than the first MI. In some embodiments, the second MI ranges from about 0.5 to about 2.3. In some embodiments, the second MI ranges from about 1.0 to about 1.8. In some embodiments, the second MI ranges from about 1.0 to about 2.0. In some embodiments, the second MI ranges from about 1.0 to about 2.9.Docket No. 62668-747.601
[0097] In some embodiments, the second MI is at least about 1. In some embodiments, the second MI is at least about 1.5. In some embodiments, the second MI is at least about 2.0. In some embodiments, the second MI is at least about 2.5. In some embodiments, the second MI is at least about 2.9. In some embodiments, the second MI is at least about 3.0. In some embodiments, the second MI is at least about 3.5.
[0098] In some embodiments, the applying the ultrasound acoustic energy comprises applying the ultrasound acoustic energy at the first MI or the second MI with an ultrasound probe applying the ultrasonic acoustic energy is in constant contact with the surface of the subject’s skin at the location of application (e.g., abdomen, chest wall, skull, etc.). In some embodiments, an ultrasound transducer (see, e.g., FIG. 15) that applies the ultrasonic acoustic energy to the target cell is continuously in contact with tissue of the subject and is continuously either (1) applying the ultrasound acoustic energy to the subject or (2) receiving reflected ultrasound energy from the subject. In certain embodiments, a transitory (e.g., third, fourth, etc.) ultrasonic acoustic energy is applied between application of the first and second ultrasonic acoustic energies. In certain embodiments, applying the ultrasound acoustic energy comprises applying the ultrasonic acoustic energy without regard to an EKG gating signal regulating the application of the ultrasound acoustic energy. In certain embodiments, applying the ultrasound acoustic energy comprises applying the ultrasonic acoustic energy without turning off power to the ultrasound transducer off. In some embodiments, applying the ultrasound acoustic energy comprises an ultrasound transducer sending ultrasound acoustic energy or receiving reflected ultrasound acoustic energy at least 95% of a period of time in which an ultrasound transducer continuously is contacting the subject.
[0099] In some instances, the ultrasonic acoustic energy of the second MI is applied using a pulse. In some instances, a pulse comprises applying the ultrasonic acoustic energy in a short pulse (e.g., microsecond length pulse). In some cases, the high MI is applied with the pulse, results in induces inertial cavitation and destruction of the sonoactive microstructure, resulting in the disruption of cell membrane and vascular endothelial integrity, transducing the cargo polynucleotide to the cell. In some instances, the pulse is applied with a duration of from about 1 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 1 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 1 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 1 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 1 ps to about 1000 ps. In some instances, the pulse is applied with a duration of from about 1 ps to about 500 ps. In some instances, the pulse is applied with a duration of from about 1 ps to about 300 ps. In some instances, the pulse is applied with a duration of from about 1 ps to about 200 ps. In someDocket No. 62668-747.601instances, the pulse is applied with a duration of from about 1 ps to about 100 ps. In some instances, the pulse is applied with a duration of from about 1 ps to about 50 ps. In some instances, the pulse is applied with a duration of from about 100 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 100 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 100 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 100 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 100 ps to about 1000 ps. In some instances, the pulse is applied with a duration of from about 100 ps to about 500 ps. In some instances, the pulse is applied with a duration of from about 100 ps to about 300 ps. In some instances, the pulse is applied with a duration of from about 100 ps to about 200 ps. In some instances, the pulse is applied with a duration of from about 200 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 200 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 200 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 200 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 200 ps to about 1000 ps. In some instances, the pulse is applied with a duration of from about 200 ps to about 500 ps. In some instances, the pulse is applied with a duration of from about 200 ps to about 300 ps. In some instances, the pulse is applied with a duration of from about 300 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 300 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 300 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 300 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 300 ps to about 1000 ps. In some instances, the pulse is applied with a duration of from about 300 ps to about 500 ps. In some instances, the pulse is applied with a duration of from about 500 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 500 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 500 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 500 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 500 ps to about 1000 ps. In some instances, the pulse is applied with a duration of from about 1000 ps to about 2 s. In some instances, the pulse is applied with a duration of from about 1000 ps to about 1 s. In some instances, the pulse is applied with a duration of from about 1000 ps to about 0.5 s. In some instances, the pulse is applied with a duration of from about 1000 ps to about 5000 ps. In some instances, the pulse is applied with a duration of from about 200 ps.
[0100] In some cases, alternating the ultrasonic acoustic energy between the first MI and the second MI for a number of times also allows reperfusion of the sonoactive microstructures andDocket No. 62668-747.601the nucleic acids to the target cell, tissue, or organ, following disruption of the sonoactive microstructures within or proximal to the target cell, tissue, or organ.
[0101] In some embodiments, applying ultrasonic acoustic energy at the first MI or the low MI induces stable vibration cavitation of the sonoactive microstructures. In some embodiments, applying ultrasonic acoustic energy at the first MI or the low MI does not induce substantial disruption of the sonoactive microstructures. In some embodiments, applying ultrasonic acoustic energy at the first MI or the low MI does not induce substantial disruption of the sonoactive microstructures in a vasculature space and an extravascular space, or induces stable vibration cavitation of the sonoactive microstructures in a vasculature space and an extravascular space.
[0102] In some embodiments, applying ultrasonic acoustic energy at the first MI or the low MI induces formation of an intercellular gap or an interendothelial gap or endocytosis. In some embodiments, the intercellular gap or the interendothelial gap ranges from about 10 nm to about 10 um. In some embodiments, the stable vibration cavitation of the sonoactive microstructures moves the nucleic acid from an intravenous space into an interstitial space or into the cytoplasm.
[0103] In some embodiments, applying ultrasonic acoustic energy in at the second MI or the high MI induces inertial cavitation of the sonoactive microstructures to disrupt the sonoactive microstructures. In some embodiments, applying ultrasonic acoustic energy at the second MI or the high MI induces inertial cavitation of the sonoactive microstructures to disrupt the sonoactive microstructures in a vasculature space and an extravascular space. In some embodiments, the extravascular spaces comprise an interstitial space, a subcutaneous space, intramuscular or a lymphatic space. In some embodiments, the extravascular spaces comprise an extravascular tissue. In some embodiments, the extravascular tissue comprises an interstitial space, a cytoplasmic space, a subcutaneous, a lymph tissues, muscular or combinations thereof.
[0104] In some embodiments, applying the ultrasonic acoustic energy at the second MI or the high MI induces formation of a pore in a membrane of the cell. In some embodiments, the formation of a pore in a membrane of the cell ranges from about 10 nm to about 10 um.
[0105] In some embodiments, administration of the sonoactive microstructures and nucleic acids occurs simultaneously in that the sonoactive microstructures are mixed with a solution comprising the nucleic acids prior to delivery to the subject. Such mixtures can comprise of 50% v / v of the sonoactive microstructures (e.g., Optison) and 50% v / v of a solution comprising a nucleic acid. Such mixtures can comprise varying percentages 5-90% v / v of the sonoactive microstructures.
[0106] In some embodiments, the nucleic acid comprises a miniplasmid backbone in the closed linear DNA construct construct. As used herein, the term “miniplasmid (mpDNA) backbone” refers to nucleic acids that are smaller in size (i.e., contain fewer base pairs (bp)) thanDocket No. 62668-747.601conventional plasmids or pDNA in non-coding and non-regulatory portions of the vector. In some embodiments, the miniplasmid backbone comprises a backbone smaller than 1 kb. In some embodiments, the miniplasmid backbone is smaller than 1000 bp excluding an expression cassette. In some embodiments, the miniplasmid backbone comprises a backbone smaller than 0.5 kb. In some embodiments, the miniplasmid backbone comprises are smaller than 500 bp excluding an expression cassette. In some embodiments, the miniplasmid backbone comprises not comprise a bacterial origin of replication. As used herein, the term “Nanoplasmid ™” (e.g., Nanopasmid sourced from Aldevron, Fargo, South Dakota.) refers to a small mpDNA construct that has a plasmid backbone that is less than 500 bp and does not contain an antibiotic resistance gene.
[0107] The miniplasmid backbone comprises can be utilized to deliver an expression cassette, a transgene, or a nonendogenous gene to cells in target cell-types, tissues or organs. In some embodiments, the miniplasmid backbone comprises less than 1000 base pairs excluding an expression cassette. In some embodiments, the miniplasmid backbone comprises less than 500 base pairs excluding an expression cassette. In some embodiments, the miniplasmid backbone does not comprise antibiotic resistant genes. In some embodiments, the miniplasmid backbone does not comprise a bacterial genome. In some embodiments, miniplasmid backbone enhances the expression of the nonendogenous gene or a therapeutic transgene when used in conjunction with the claimed methods and ultrasound acoustic profiles. In some embodiments, the cargo polynucleotide comprises an expression cassette. In some embodiments, the expression cassette comprises a transgene. In some embodiments, the cargo polynucleotide comprises a transgene (endogenous or non-endogenous). In some embodiments, the transgene comprises a therapeutic transgene. In some embodiments, inducing expression of the cargo polynucleotide comprises inducing expression of the therapeutic transgene. In some embodiments, the transgene comprises a detectible marker. In some embodiments, the transgene comprises luciferase. In some embodiments, inducing expression of the cargo polynucleotide comprises inducing expression of luciferase.
[0108] In some embodiments, a cargo polynucleotide comprises a regulatory element such as a promoter, (e.g., APOE-ATT). In some embodiments, a total amount (e.g., dose) of the nucleic acid (e.g., DNA) administered to a subject for purposes of sonoporation can range from 100 micrograms to 200 mg.
[0109] In some embodiments, the cargo polynucleotide is covalently coupled to the aptamer. In some embodiments, the cargo polynucleotide is 5’ of the aptamer. In some embodiments, the cargo polynucleotide is 3 ’ of the aptamer.Docket No. 62668-747.601
[0110] In some embodiments, the therapeutic payload is a nonendogenous gene. In some embodiments, the cargo polynucleotide is configured to perform gene augmentation, gene replacement, gene editing, gene knockdown, or gene knockout.[OHl] In some embodiments, the nucleic acid comprises one or more regulatory elements, such as a promoter, enhancer, ribosome binding site, or transcription termination signal. In some embodiments, the nucleic acid comprises a constitutively active promoter. In some embodiments, the nucleic acid comprises an organ specific promoter. In some embodiments, the nucleic acid comprises a tissue specific promoter. In some embodiments, the nucleic acid comprises a cell specific promoter. Examples of promoters contemplated herein include, but are not limited to, e.g., CMV promoter, UbC promoter, CAG promoter, EF-la promoter, ApoE promoter, ApoE-AATl promoter, 3XSERP promoter, or P3-hybrid promoter. In some embodiments, the nucleic acid comprises a promoter sequence comprising CAG. In some embodiments, the nucleic acid comprises a promoter sequence comprising ApoE. In some embodiments, the nucleic acid comprises a promoter sequence comprising SERP. In some embodiments, the nucleic acid comprises a promoter sequence comprising P3.
[0112] In some embodiments, the nucleic acid is a linear DNA construct. In some embodiments, a linear DNA construct is a DNA molecule which is not a circular double stranded construct. In some embodiments, the nucleic acid is a closed linear DNA construct. In some embodiments, a linear DNA construct is formed from a circular DNA that has been linearized using a restriction enzyme or a CRISPR nuclease to create a double stranded break prior to closing the linearized ends with an aptamer. In some embodiments, the nucleic acid is a closed linear DNA construct comprising a stem region comprising a double stranded DNA sequence covalently closed at both ends by hairpin loops. In some embodiments, the hairpin loops are single-stranded. In some embodiments, the hairpin loops form a stem region of the aptamer.
[0113] In some embodiments, the nucleic acid is a closed linear DNA construct comprising at least two modified nucleotides. In some embodiments, the nucleic acid is a closed linear DNA construct comprising at least three modified nucleotides. In some embodiments, the nucleic acid is a closed linear DNA construct comprising at least four modified nucleotides. In some embodiments, the nucleic acid is a closed linear DNA construct comprising at least five modified nucleotides. In some embodiments, the at least two modified nucleotides are located in one single-stranded end loop of the closed linear DNA construct. In some embodiments, the at least two modified nucleotides are located in both single-stranded end loops of the closed linear DNA construct. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops. In some embodiments, the at least three modified nucleotides areDocket No. 62668-747.601located in both single-stranded end loops of the closed linear DNA construct. In some embodiments, the at least four modified nucleotides are located in one single-stranded end loop of the closed linear DNA construct. In some embodiments, the at least four modified nucleotides are located in both single-stranded end loops of the closed linear DNA construct. In some embodiments, the at least five modified nucleotides are located in one single-stranded end loop of the closed linear DNA construct. In some embodiments, the at least five modified nucleotides are located in both single-stranded end loops of the closed linear DNA construct. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops. In some embodiments, at least two modified nucleotides are located in one of the single stranded end loops. In some embodiments, at least three modified nucleotides are located in one of the single stranded end loops. In some embodiments, at least four modified nucleotides are located in one of the single stranded end loops. In some embodiments, at least five modified nucleotides are located in one of the single stranded end loops. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least two modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least three modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least four modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least five modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops and at least one modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops and at least two modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops and at least three modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least one modified nucleotide is located in one of the single stranded end loops and at least four modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least two modified nucleotides are located in one of the single stranded end loops and at least one modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least two modified nucleotides are located in one of the single stranded end loops and at least two modified nucleotides are located in one of the single stranded end loops forming the stem region of theDocket No. 62668-747.601aptamer. In some embodiments, at least two modified nucleotides are located in one of the single stranded end loops and at least three modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least three modified nucleotides are located in one of the single stranded end loops and at least two modified nucleotides are located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least three modified nucleotides are located in one of the single stranded end loops and at least one modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, at least four modified nucleotides are located in one of the single stranded end loops and at least one modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer.
[0114] In some embodiments, at least two modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer. In some embodiments, at least three modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer. In some embodiments, at least four modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer. In some embodiments, at least five modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer.
[0115] In some embodiments, the aptamer comprises a sequence configured to increase nuclear localization of the cargo polynucleotide. In some embodiments, the aptamer comprises a sequence configured to bind nucleolin. In some embodiments, the aptamer comprises a sequence having at least at least 81, at least 82, at least 83, at least 84, at least 85, at least 86, at least 87, at least 88, at least 89, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, or at least 99% sequence identity to any one of SEQ ID NO: 3-54 or 78-85. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NO: 3-54, 129-130, or 135-148. In some embodiments, the aptamer comprises a sequence configured to bind importin. In some embodiments, the aptamer comprises the sequence of SEQ ID NO: 48, 129, OR 130. In some embodiments, the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NO: 49-50. In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the extra-nuclear DNA comprises DNA located in cytosol in the cell. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NO: 51-54.
[0116] In some embodiments, nucleic acid comprising the cargo polynucleotide described herein may be administered with an aptamer. In some cases, the aptamer is a separate nucleicDocket No. 62668-747.601acid construct from the nucleic acid. In some embodiments, the nucleic acid may be coformulated with an aptamer. In some embodiments, the nucleic acid may be co-formulated with an aptamer by using a polymer, and / or a polymeric nanoparticle.
[0117] In some embodiments, at least two modified nucleotides are independently selected form the group consisting of 2-amino- deoxyadenosine, 5-methyl-deoxycytidine, thiophosphate nucleotide, inosine nucleotide, locked nucleic acid (LNA) nucleotide, L-DNA nucleotide, 8-oxo-deoxyadenosine nucleotide, and 5-Fluoro-deoxyuracil nucleotide. In some embodiment, at least two modified nucleotides are 2-amino- deoxy ad enosine. In some embodiment, at least two modified nucleotides are 5-methyl-deoxycytidine. In some embodiment, at least two modified nucleotides are thiophosphate nucleotide. In some embodiment, at least two modified nucleotides are inosine nucleotide. In some embodiment, at least two modified nucleotides are locked nucleic acid (LNA) nucleotide. In some embodiment, at least two modified nucleotides are L-DNA nucleotide. In some embodiment, at least two modified nucleotides are 8-oxo-deoxyadenosine nucleotide. In some embodiment, at least two modified nucleotides are 5-Fluoro-deoxyuracil nucleotide.
[0118] In some embodiments, the closed linear DNA construct comprises from about 3 to about 20 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 1 modified nucleotide. In some embodiments, the closed linear DNA construct comprises about 2 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 3 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 4 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 5 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 6 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 7 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 8 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 9 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 10 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 11 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 12 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 13 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 14 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 15 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 16 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 17 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 18 modifiedDocket No. 62668-747.601nucleotides. In some embodiments, the closed linear DNA construct comprises about 19 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 20 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 21 modified nucleotides. In some embodiments, the closed linear DNA construct comprises about 22 modified nucleotides.
[0119] In some embodiments, the closed linear DNA construct comprises at least two LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least three LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least four LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least five LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least two thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least three thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least four thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least five thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least two restriction sites flanking the expression cassette. In some embodiments, the closed linear DNA construct comprises at least three restriction sites flanking the expression cassette. In some embodiments, the closed linear DNA construct comprises at least four restriction sites flanking the expression cassette. In some embodiments, the closed linear DNA construct comprises at least five restriction sites flanking the expression cassette. In some embodiment, the closed linear DNA construct comprises a primase recognition site. In some embodiments, the closed linear DNA construct comprises two primase recognition sites. In some embodiments, the closed linear DNA construct comprises three primase recognition sites. In some embodiments, the closed linear DNA construct comprises an inverted terminal repeats (ITR). In some embodiments, the closed linear DNA construct comprises two ITRs. In some embodiments, the closed linear DNA construct comprises three ITRs.
[0120] In some embodiments, inducing expression of the cargo polynucleotide comprises inducing production of RNA encoded by the payload. In some embodiments, inducing expression of the cargo polynucleotide comprises inducing production of protein encoded by the payload.
[0121] Aspects disclosed herein provide an isolated nucleic acid encoding any one of SEQ ID NO: 1-253.
[0122] Mammalian somatic cells generally exhibit innate immune DNA sensing to cytosolic DNA, providing a pathological immune response cytosolic DNA. The present of an innate immune response to cytosolic DNA provides several benefits to cells such as defense againstDocket No. 62668-747.601various pathogens, for example, viruses, in addition to detection and response to cellular damage or aberrant cellular processes. For example, cytosolic DNA sensing allows for: detection of pathogens when viral, bacterial, or parasitic DNA genomes are released into the cytosol during the pathogen replication cycle, allowing for an inflammatory immune response to occur; detection of cellular damage resulting in DNA fragmentation, for example, during apoptosis or necrosis; and maintenance of genome integrity, by detection and response to aberrant DNA which may be associated with development of cancer. However, when delivering DNA to cells as part of a gene therapy treatment, an immune response from the host cell is not ideal, and may reduce the delivery of the nucleic acid payload to the cell, and resulting gene expression.
[0123] Mechanisms of innate immune DNA sensing to cytosolic DNA can include binding of double stranded cytosolic DNA by cyclic GMP-AMP synthase (cGAS), leading to a signaling cascade driving a further immune response including synthesis of a special asymmetric cyclic-dinucleotide, 2'3'-cGAMP, and activation of STING (endoplasmic reticulum (ER) membrane protein) for subsequent production of type I interferons and other immune-modulatory genes, as is illustrated in FIG. 7. In addition to type I IFN production, activation of the cGAS-STING pathway can also lead to the production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6), induction of cellular autophagy, activation of activation of caspase- 1 and subsequent processing and secretion of pro-inflammatory cytokines such as interleukin- 1 beta (IL- 1 (3) and interleukin- 18 (IL- 18), and activation of apoptotic pathways. The design of nucleic acid delivery vectors which can successfully avoid mechanisms of innate immune DNA sensing and resulting immune responses has the potential to improve the delivery of nucleic acids to target cells in gene therapy treatments, resulting transgene expression, and subject outcomes with reduced inflammatory responses. In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the extra-nuclear DNA comprises DNA located in cytosol in the cell. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NO: 51-54.
[0124] In some embodiments, the payload comprises or encodes a therapeutic RNA. In some embodiments, the therapeutic RNA is an mRNA. In some embodiments, the therapeutic RNA is an RNA interference (RNAi) agent, e.g., a double-stranded RNA, a single-stranded RNA, a micro RNA (miRNA), a short interfering RNA (siRNA), short hairpin RNA (shRNA), or a triplex-forming oligonucleotide. In some embodiments, the therapeutic RNA is a catalytically active RNA molecule (ribozyme). In some embodiments, the therapeutic RNA is a transfer RNA (tRNA). In some embodiments, the therapeutic RNA comprises one or more chemical modifications (e.g., one or more modified nucleobases, nucleosides, or nucleotides). In someDocket No. 62668-747.601embodiments, the nucleic acid is configured to perform gene augmentation, gene replacement, base editing, base knockdown, gene editing gene knockdown, or gene knockout. In some embodiments, delivering the cargo polynucleotide to the target cell of the subject increases or decreases expression of a gene in the target cell.
[0125] In some embodiments, the payload comprises or encodes one or more components of a gene editing system. In some embodiments, the payload comprises a nuclease or engineered nuclease suitable for gene editing. In some embodiments, the nuclease is delivered as a polypeptide. In some embodiments, the nuclease is delivered as a nucleic acid encoding the nuclease. In some embodiments, the gene editing system is a CRISPR / Cas system. In some embodiments, the payload comprises a gRNA or a nucleic acid molecule encoding a gRNA (e.g., a plasmid encoding the gRNA). In some embodiments, the payload comprises a Cas protein or homologs or variants thereof, or a nucleic acid molecule encoding the Cas protein or homologs or variants thereof. In some embodiments, the payload comprises a TALEN or a nucleic acid molecule encoding the TALEN. In some embodiments, the payload comprises a zinc-finger nuclease (ZFN) or a nucleic acid encoding the ZFN. In some embodiments, the nuclease is an engineered nuclease. In some embodiments, the engineered nuclease is catalytically inactive. In some embodiments, the engineered nuclease is a fusion protein comprising the engineered nuclease a regulatory protein or an enzyme, or a functional domain thereof (e.g., a nuclease fused to a transcriptional regulatory domain or a nuclease fused to a deaminase) In some embodiments, the payload may further comprise a template DNA molecule suitable for knock-in to the subject’s genome via non-homologous end joining (NHEJ) or homology directed repair (HDR). In some embodiments, the payload may comprise payload may further comprise a template DNA molecule which is a transposase, an ARCUS, a TPRT enzyme, or a CAS transposases, or a nucleic acid which encodes a transposase, an ARCUS, a TPRT enzyme, or a CAS transposases.
[0126] In some embodiments, the payload comprises a nucleic acid that exceeds the size limitation of conventional gene therapy vectors. In some embodiments, the payload exceeds the size limitation of an adeno-associated viral vector (AAV). In some embodiments, the payload is greater than about 4.7 kb. In some embodiments, the payload is greater than about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11, about 11.5, about 12, about 12.5, or about 13 kb.
[0127] Aptamers are short sequences of artificial DNA, or RNA sequences that bind to one or more target molecules. In some embodiments, the aptamer comprises a sequence configured to promote an intracellular function. In some embodiments, the intracellular function comprises nuclear localization. In some embodiments, the intracellular function comprises increasingDocket No. 62668-747.601nuclear localization in the target cell. In some embodiments, the intracellular function comprises increased resistance to one or more intracellular nucleases. In some embodiments, the intracellular function comprises preventing degradation of the cargo polynucleotide by preventing degradation of the cargo polynucleotide from the one or more intracellular nucleases. In some embodiments, the intracellular function comprises improved transcription of the cargo polynucleotide. In some embodiments, the intracellular function comprises increasing transcription of the cargo polynucleotide. In some embodiments, the aptamer comprises a sequence configured to increase nuclear localization of the cargo polynucleotide. In some embodiments, the aptamer comprises a sequence configured to bind nucleolin. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NOS: 1-47. In some embodiments, the aptamer comprises a sequence configured to bind importin. In some embodiments, the aptamer comprises the sequence of SEQ ID NO: 48, 129, OR 130. In some embodiments, the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the aptamer comprises a sequence of any one of SEQ ID NOS: 48-49.
[0128] Sonoactive agents (also referred to as sonoactive microstructures acoustic microspheres or “microbubbles”) contemplated herein include, but are not limited to, those used as ultrasonic imaging contrast agents. In some embodiments, the sonoactive agent comprises a phospholipid stabilized microstructure. In some embodiments, the phospholipid stabilized microstructure comprises a high molecular wight gas core, or a perflutran core. Examples of sonoactive agents include, but are not limited to, OPTISON (GE Healthcare), Sonazoid (GE Healthcare), or DEFINITY and Definity RT (Lantheus Medical Imaging, Inc). In some embodiments, the sonoactive agents are LUMASON (Bracco) (sulfur hexafluoride lipid-type A microspheres). In some embodiments, the sonoactive agents are SonoVue (sulfur hexafluoride microbubbles). In some embodiments, the sonoactive agents comprise a protein stabilized microstructure. In some embodiments, the sonoactive agents are Optison microbubbles.
[0129] The sonoactive agent can be administered prior to, after, or simultaneous (e.g., coadministered) with the administration of the nucleic acid (or cargo polynucleotide). In some embodiments, the nucleic acid and the sonoactive agent are coadministered. In some embodiments, the administering of the nucleic acid and the sonoactive agent occurs serially, concurrently, sequentially, or continuously. In some embodiments, the administering of the nucleic acid and the sonoactive agent occurs serially. In some embodiments, the administering of the nucleic acid and the sonoactive agent occurs concurrently. In some embodiments, the administering of the nucleic acid and the sonoactive agent occurs sequentially. In some embodiments, the administering of the nucleic acid and the sonoactive agent occurscontinuously.Docket No. 62668-747.601
[0130] In some embodiments, the nucleic acid is administered at a dosage of about 0.5 mg / kg to about 500 mg / kg. In some embodiments, about 2xlOA13 to about 3xl0A13 copies of the nucleic acid are administered to the subject.
[0131] In some embodiments, the sonoactive microstructures are administered at a dosage of about 1-50 mL, for example 1 mL of Optison. The sonoactive microstructures may be administered at a concentration of about 5M to about 8M microstructures per mL. In some embodiments, the sonoactive microstructures are administered at a concentration of about 5x 10A8 to about 1.2x 10A9 microstructures / mL, for example lx 10A9 of Definity RT. In some embodiments, the sonoactive microstructures are administered at a concentration of about 0.1 to about 0.8 mg / kg. In some embodiments, the sonoactive microstructures are administered at a concentration of about 0.1 to about 1.0 mL / kg. In some embodiments, the sonoactive microstructures are administered at a concentration of about 10A9 microstructures / mL. In some embodiments, the sonoactive microstructures are administered at a concentration of about 5x 10A8 to about 8x 10A8 microstructures / mL.
[0132] In some embodiments, the nucleic acid and the sonoactive microstructures are mixed prior to being coadministered. In some instances, the sonoactive microstructures are mixed with the nucleic acids before administering to the subject. In some instances, the sonoactive microstructures are mixed with the nucleic acids along with additional buffers or agents such as saline or other biocompatible solutions with varying electrostatic charges and surface chemistries and ligands before administering to the subject. For example, Optison sonoactive microstructures can be mixed with a miniplasmid construct, e.g., a Nanoplasmid, comprising a promoter coupled to a transgene, e.g., APOE-Fluc, and saline, and administered together.
[0133] In some embodiments, the administering of the nucleic acid and the sonoactive agent is by intravenous administration or subcutaneous or intramuscular or intra-arterial or inter-osseus or direct organ puncture.
[0134] In some embodiments, after administering of the nucleic acid and sonoactive agent, the ultrasound acoustic energy is applied at the target cell, tissue, or organ.
[0135] Once the nucleic acids are inside the target cell, expression of the cargo polynucleotide is induced. In some embodiments, the cargo polynucleotide comprises luciferase.
[0136] In some embodiments, inducing expression of the cargo polynucleotide comprises inducing expression within about 3 to about 12 hours of administering the payload. In some embodiments, inducing expression of the cargo polynucleotide comprises inducing expressing within about 3 hours of administration. In some embodiments, inducing expression of the cargo polynucleotide comprises inducing expressing within about 6 hours of administration. In someDocket No. 62668-747.601embodiments, inducing expression of the cargo polynucleotide comprises inducing expression within about 12 hours of administration.
[0137] Undesirable effects on living cells or tissues can occur due to ultrasound applications. In some embodiments, the present disclosure provides methods for improvement of gene transfection and not result in substantial DNA or cell damage in the target cells, tissues, or organs, using sonoporation by alternating ultrasonic acoustic energy between the first MI and the second MI. In some embodiments, the method does not result in substantial cellular damage to the target cell. In some embodiments, the method results in less than 1%, 5%, or 10% of target cells undergoing apoptosis.
[0138] A sonoporation treatment using the methods described herein can be used to induce expression of a cargo polynucleotide in a cell in a liver or a cell in a kidney.
[0139] A sonoporation treatment using the methods described herein can be used to treat a subject in need for gene therapy or protein replacement treatment. In another aspect, the present disclosure provides methods of treating a subject having a liver condition. In some embodiments, the liver condition treated is: Wilson's Disease, Cholestasis progressive familial intrahepatic, Von Willebrand disease, Hemophilia A, Hemophilia B, Factor 5 deficiency, Alpha-Mannosidosis, Gaucher's (glucocerebrosidase deficiency, glucocerebrosidosis), Niemann Pick Disease A / B, Carbamoylphosphate Synthetase I Deficiency, Glycogen Storage Disease Type III, Cystinosis, Al AT deficiency, Citrullinemia Type I & II.
[0140] In some embodiments, the present disclosure provides methods of treating a subject having a liver condition with a therapeutic transgene. In some embodiments, the therapeutic transgene encodes one or more of: ATP7B; ABCB11; ABCB4; ATP8B1; TJP2; VWF ; FVIII ; FIX ; F5; MAN2B1; GBA; SMPD1; CPS1; GDE / AGL; CTNS; SERPINA1; ASS1, and / or SLC25A13.
[0141] In some embodiments, the present disclosure provides methods of treating a subject having a liver condition with a therapeutic transgene. In some embodiments, the liver condition is Wilson’s Disease, and the therapeutic transgene encodes ATP7B. In some embodiments, the liver condition is Cholestasis, progressive familial intrahepatic (PFIC1-4) and the therapeutic transgene encodes one or more of ABCB11, ABCB4, ATP8B1 and / or TJP2. In some embodiments, the liver condition is Von Willebrand Disease and the therapeutic transgene encodes VWF. In some embodiments, the liver condition is Hemophilia A, and the therapeutic transgene encodes FVIII. In some embodiments, the liver condition is Hemophilia B, and the therapeutic transgene encodes FIX. In some embodiments, the liver condition is Factor V Deficiency, and the therapeutic transgene encodes F5. In some embodiments, the liver condition is Alpha-Mannosidosis, and the therapeutic transgene encodes MAN2B1. In some embodiments,Docket No. 62668-747.601the liver condition is Gaucher's (glucocerebrosidase deficiency, glucocerebrosidosis), and the therapeutic transgene encodes GBA . In some embodiments, the liver condition is Niemann Pick Disease A / B, and the therapeutic transgene encodes SMPD1. In some embodiments, the liver condition is Carbamoylphosphate Synthetase I Deficiency, and the therapeutic transgene encodes CPS1. In some embodiments, the liver condition is Glycogen Storage Disease Type III, and the therapeutic transgene encodes GDE / AGL. In some embodiments, the liver condition is Cystinosis, and the therapeutic transgene encodes CTNS. In some embodiments, the liver condition is Al AT deficiency, and the therapeutic transgene encodes SERPINA1. In some embodiments, the liver condition is Citrullinemia Type I & II, and the therapeutic transgene encodes one or more of ASS1 and / or SLC25A13. In some embodiments, the methods comprise administering to the subject a nucleic acid comprising the cargo polynucleotide (e.g., a therapeutic transgene); administering to the subject a plurality of sonoactive microstructures; and administering a sonoporation treatment. In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a liver at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the liver at a second MI that is greater than 0.4 and less than 2.0; In some embodiments, the method comprises repeating application of the low MI and the high MI a number of times. In some embodiments, the method comprises delivering the cargo polynucleotide and the plurality of sonoactive microstructures systemically (e.g., by intravenous administration). In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a liver at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the liver at a second MI that is greater than 0.4 and less than 2.3; In some embodiments, the method comprises repeating application of the low MI and the high MI a number of times. In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a liver at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the liver at a second MI that is greater than 0.4 and less than 2.9. In some embodiments, the method comprises repeating application of the low MI and the high MI a number of times. In some embodiments, the method comprises delivering the cargo polynucleotide and the plurality of sonoactive microstructures systemically (e.g., by intravenous administration).
[0142] In some embodiments, provided herein is a method of treating a subject having Hemophilia A comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.0 (e.g., 0.4 < MI < 2.0). In some embodiments, providedDocket No. 62668-747.601herein is a method of treating a subject having Hemophilia A comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.3 (e.g., 0.4 < MI < 2.3). In some embodiments, provided herein is a method of treating a subject having Hemophilia A comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.9 (e.g., 0.4 < MI < 2.9). In some embodiments, the therapeutic transgene is operably linked to a liver specific promoter. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding Factor VIII. In some embodiments, the nucleic acid and the plurality of sonoactive microstructures are administered systemically (e.g., by intravenous administration).
[0143] In some embodiments, provided herein is a method of treating a subject having Wilson’s Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.0 (e.g., 0.4 < MI < 2.0). In some embodiments, provided herein is a method of treating a subject having Wilson’s Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.3 (e.g., 0.4 < MI < 2.3). In some embodiments, provided herein is a method of treating a subject having Wilson’s Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.9 (e.g., 0.4 < MI < 2.9). In some embodiments, the therapeutic transgene is operably linked to a liver specific promoter. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding ATP7B. InDocket No. 62668-747.601some embodiments, the nucleic acid and the plurality of sonoactive microstructures are administered systemically (e.g., by intravenous administration).
[0144] In one aspect, using the methods described herein, the present disclosure provides methods of treating a subject having a kidney condition. In some embodiments, the kidney condition treated is: Alport Syndrome, or Autosomal Dominant Polycystic Kidney Disease.
[0145] In some embodiments, the present disclosure provides methods of treating a subject having a kidney condition with a therapeutic transgene. In some embodiments, the therapeutic transgene encodes one or more of COL4A3, COL4A4, COL4A5, PKD1 and / or PKD2.
[0146] In some embodiments, the present disclosure provides methods of treating a subject having a kidney condition with a therapeutic transgene. In some embodiments, the kidney condition is Alport Syndrome, and the therapeutic transgene encodes one or more of COL4A3, COL4A4, and / or COL4A5. In some embodiments, the kidney condition is Autosomal Dominant Polycystic Kidney Disease, and the therapeutic transgene encodes one or more of PKD1 and / or PKD2. In some embodiments, the methods comprise administering to the subject a nucleic acid comprising the cargo polynucleotide; administering to the subject a plurality of sonoactive microstructures; and administering a sonoporation treatment. In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a kidney at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the kidney at a second MI that is greater than 0.4 and less than 2.0. In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a kidney at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the kidney at a second MI that is greater than 0.4 and less than 2.3. In some embodiments, the method comprises repeating application of the low MI and the high MI a number of times. In some embodiments, the sonoporation treatment comprises applying an ultrasonic acoustic energy to a kidney at a first mechanical index (MI) that is less than 0.4; applying an ultrasonic acoustic energy to the kidney at a second MI that is greater than 0.4 and less than 2.9. In some embodiments, the method comprises delivering the cargo polynucleotide and the plurality of sonoactive microstructures systemically (e.g., by intravenous administration).
[0147] In some embodiments, provided herein is a method of treating a subject having Alport Syndrome comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.0 (e.g., 0.4 < MI < 2.0). In some embodiments, provided herein is a method of treating a subject having Alport Syndrome comprisingDocket No. 62668-747.601administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.3 (e.g., 0.4 < MI < 2.3). In some embodiments, provided herein is a method of treating a subject having Alport Syndrome comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.9 (e.g., 0.4 < MI < 2.9). In some embodiments, the therapeutic transgene is operably linked to a kidney specific promoter. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding COL4A3. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding COL4A4. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding COL4A5. In some embodiments, the nucleic acid and the plurality of sonoactive microstructures are administered systemically (e.g., by intravenous administration).
[0148] In some embodiments, provided herein is a method of treating a subject having Autosomal Polycystic Kidney Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.0 (e.g., 0.4 < MI < 2.0). In some embodiments, provided herein is a method of treating a subject having Autosomal Polycystic Kidney Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.3 (e.g., 0.4 < MI < 2.3). In some embodiments, provided herein is a method of treating a subject having Autosomal Polycystic Kidney Disease comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.9 (e.g., 0.4 < MI < 2.9). In some embodiments, the therapeutic transgene is operably linked to a kidney specific promoter. In some embodiments, the therapeutic transgeneDocket No. 62668-747.601comprises a nucleic acid sequence encoding PKD1. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding PKD2. In some embodiments, the nucleic acid and the plurality of sonoactive microstructures are administered systemically (e.g., by intravenous administration).
[0149] In some embodiments, provided herein is a method of treating a subject having a muscular dystrophy comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.0 (e.g., 0.4 < MI < 2.0). In some embodiments, provided herein is a method of treating a subject having muscular dystrophy comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.3 (e.g., 0.4 < MI < 2.3). In some embodiments, provided herein is a method of treating a subject having muscular dystrophy comprising administering to the subject a nucleic acid comprising a therapeutic transgene; administering to the subject a plurality of sonoactive microstructures; applying an ultrasonic acoustic energy to the target cell at a first mechanical index (MI) that is up to 0.4 (e.g., 0 < MI < 0.4); and applying an ultrasonic acoustic energy to the target cell at a second MI that is greater than 0.4 and up to 2.9 (e.g., 0.4 < MI < 2.9). In some embodiments, the therapeutic transgene is operably linked to a kidney specific promoter. In some embodiments, the therapeutic transgene comprises a nucleic acid sequence encoding dystrophin (DMD). In some embodiments, the nucleic acid and the plurality of sonoactive microstructures are administered systemically (e.g., by intravenous administration).
[0150] Aspects disclosed herein provide a pharmaceutical composition comprising: a microbubble; and a nucleic acid composition as disclosed herein comprising (1) a cargo polynucleotide comprising an expression cassette that comprises a therapeutic transgene and (2) an aptamer, wherein the aptamer comprises a sequence configured to increase nuclear localization. Aspects disclosed herein provide a pharmaceutical composition comprising: a sonoactive agent; a nucleic acid comprising (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) one or both of: (i) a nuclear localization element, and / or (ii) an innate immune response avoidance moiety.
[0151] Aspects disclosed herein provide a pharmaceutical composition comprising an isolated nucleic acid composition as disclosed herein comprising a cargo polynucleotide and aDocket No. 62668-747.601nuclear localization element, wherein the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.25 fold as compared to a nucleic acid lacking the nuclear localization element. Aspects disclosed herein provide a pharmaceutical composition comprising an isolated nucleic acid comprising a cargo polynucleotide and an innate immune response avoidance moiety, wherein the innate immune response avoidance moiety increases expression of the cargo polynucleotide in the target cell by at least 1.25 fold as compared to a nucleic acid lacking the nuclear localization element. Aspects disclosed herein provide a pharmaceutical composition comprising: a sonoactive agent; and nucleic acids comprising (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) one or both of: (i) a nuclear localization element, and / or (ii) an innate immune response avoidance moiety.
[0152] In some embodiments, the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, at least 1.45, at least 1.50, atleast 1.55, atleast 1.60, atleast 1.65, at least 1.75, at least 1.80, atleast 1.85, atleast 1.90, at least 1.95, atleast 2.0, atleast 2.25. 2.5, at least 2.75. 3, at least 3.5, at least 4, at least 4.5, at least or 5 fold as compared to a nucleic acid lacking the nuclear localization element. In some embodiments, the immune response avoidance moiety increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, at least 1.45, at least 1.50, at least 1.55, atleast 1.60, at least 1.65, atleast 1.75, atleast 1.80, at least 1.85, at least 1.90, at least 1.95, atleast 2.0, at least 2.25. 2.5, at least 2.75. 3, at least 3.5, atleast 4, at least 4.5, at least or 5 fold as compared to a nucleic acid lacking the immune response avoidance moiety. In some embodiments, the isolated nucleic acid further comprises an innate immune response avoidance moiety. In some embodiments, the isolated nucleic acid further comprises an innate immune response avoidance moiety. In some embodiments, the nucleic acid is up to 40 nucleotides in length. In some embodiments, the nucleic acid is an isolated nucleic acid. In some embodiments, the target cell is a liver cell. In some embodiments, the target cell is a hepatocyte. In some embodiments, the target cell is a LSEC. In some embodiments, the target cell is a kidney cell. In some embodiments, the target cell is a proximal tubular epithelial cell. In some embodiments, the target cell is a podocyte. In some embodiments, the target cell is a muscle cell. In some embodiments, the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy. In some embodiments, the method is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene. In some embodiments, the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subject. In some embodiments, the method is a method for useDocket No. 62668-747.601of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy. In some embodiments, the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte. In some embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell. In some embodiments, the subject is a human subject.
[0153] In some embodiments, one or both of: (i) the nuclear localization element, or (ii) the innate immune response avoidance moiety, comprise an aptamer. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind nucleolin. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 3-47. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 43-47, OR SEQ ID NO: 135-148. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind nucleolin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0154] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind importin. In some embodiments, the sequence configured to bind importin comprises a nucleic acid sequence of SEQ ID NO: 48, OR SEQ ID NO: 129-130. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind importin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0155] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358. In some embodiments, the nucleoporin protein comprises NUP 358. In some embodiments, the sequence configured to bind the nucleoporin protein comprises a nucleic acid sequence of any one of SEQ ID NOS: 49-50. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind a nucleoporin protein provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.Docket No. 62668-747.601
[0156] In some embodiments, the innate immune response avoidance moiety comprises a cyclic GMP-AMP synthase (cGAS) antagonist, absent in melanoma 2 inflammasome (AIM2) antagonist, or toll -like receptor 9 (TLR9) antagonist.
[0157] In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the extra-nuclear DNA comprises DNA located in cytosol in the cell. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind cGAS.
[0158] In some embodiments, the nucleic acid sequence configured to bind a cGAS comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the cGAS comprises any SEQ ID NO: 51 or 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind cGAS is a cGAS antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind cGAS provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0159] In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind an AIM2 inflammasome. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises SEQ ID NO: 51 or 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind AIM2 is an AIM2 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind AIM2 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0160] In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind TLR9. In some embodiments, the sequence configured to bind TLR9 comprises a CpG motif. In some embodiments, the CpG motif comprises any one of SEQ ID NO: 90-93. In some embodiments, the sequence configured to bind TLR9 comprises any one of SEQ ID NO: 51-54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind TLR9 is a TLR9 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind TLR9 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0161] In another aspect, the present disclosure provides a kit to perform the methods described herein. In some embodiments, the kit comprises: (a) a first container comprisingDocket No. 62668-747.601microbubbles for sonoporation; and (b) a second container comprising nucleic acids comprising a cargo polynucleotide encoding a transgene and an aptamer; and (c) instructions for administration of ultrasound acoustic energy. In some embodiments, the kit comprises: (a) a first container comprising sonoactive agents; and (b) a second container comprising nucleic acids comprising a cargo polynucleotide encoding a transgene and an aptamer; and (c) instructions for administration of ultrasound acoustic energy.
[0162] Aspects disclosed herein provide a kit comprising the nucleic acid of any one of the preceding claims, and a sonoactive agent. Aspects disclosed herein provide a kit comprising: nucleic acid composition as disclosed herein comprising (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) one or both of: (i) a nuclear localization element, and / or (ii) an innate immune response avoidance moiety; and a sonoactive agent. In some embodiments, the kit further includes instructions for applying ultrasound acoustic energy to a subject, wherein the ultrasound acoustic energy is configured to deliver the nucleic acids to the cell. In some embodiments, the ultrasound acoustic energy is configured to deliver the nucleic acids to the cell. In some embodiments, the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, atleast 1.45, atleast 1.50, atleast 1.55, at least 1.60, at least 1.65, atleast 1.75, atleast 1.80, atleast 1.85, atleast 1.90, atleast 1.95, at least 2.0, at least 2.25. 2.5, at least 2.75. 3, at least 3.5, atleast 4, atleast 4.5, atleast or 5 fold as compared to a nucleic acid lacking the nuclear localization element. In some embodiments, the immune response avoidance moiety increases expression of the cargo polynucleotide in the target cell by at least 1.35, at least 1.40, at least 1.45, atleast 1.50, atleast 1.55, at least 1.60, atleast 1.65, at least 1.75, at least 1.80, atleast 1.85, atleast 1.90, atleast 1.95, at least 2.0, atleast 2.25. 2.5, at least 2.75. 3, at least 3.5, at least 4, at least 4.5, at least or 5 fold as compared to a nucleic acid lacking the immune response avoidance moiety.
[0163] In some embodiments, one or both of: (i) the nuclear localization element, or (ii) the innate immune response avoidance moiety, comprise an aptamer. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind nucleolin. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 3-47, OR SEQ ID NO: 135-148. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind nucleolin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0164] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind importin. In some embodiments, the sequence configured to bindDocket No. 62668-747.601importin comprises a nucleic acid sequence of SEQ ID NO: 48, 129, or 130. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358. In some embodiments, the nucleoporin protein comprises NUP 358. In some embodiments, the sequence configured to bind the nucleoporin protein comprises a nucleic acid sequence of any one of SEQ ID NO: 49-50. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind the nucleoporin protein provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0165] In some embodiments, the innate immune response avoidance moiety comprises a cyclic GMP-AMP synthase (cGAS), absent in melanoma 2 inflammasome (AIM2), or toll-like receptor 9 (TLR9) antagonist. In some embodiments, the aptamer comprises a sequence configured to reduce an innate immune response to extra-nuclear DNA in a cell. In some embodiments, the extra-nuclear DNA comprises DNA located in cytosol in the cell. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind cGAS. In some embodiments, the nucleic acid sequence configured to bind a cGAS comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the cGAS comprises any one of SEQ ID NO: 51, 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind cGAS is a cGAS antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind cGAS provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0166] In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind an AIM2. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises a telomeric motif. In some embodiments, the telomeric motif comprises SEQ ID NO: 89. In some embodiments, the nucleic acid sequence configured to bind the AIM2 comprises any one of SEQ ID NO: 51, or 54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind AIM2 is an AIM2 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind AIM2 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.Docket No. 62668-747.601
[0167] In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind TLR9. In some embodiments, the sequence configured to bind TLR9 comprises a CpG motif. In some embodiments, the CpG motif comprises any one of SEQ ID NO: 90-93. In some embodiments, the sequence configured to bind TLR9 comprises any one of SEQ ID NO: 51-54. In some embodiments, the aptamer comprising the nucleic acid sequence configured to bind TLR9 is a TLR9 antagonist. In some cases, the innate immune response avoidance moiety or the aptamer comprising the sequence configured to bind TLR9 provides a beneficial technical effect of reducing clearance of the nucleic acid by the cell and increasing gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0168] In some embodiments, the sonoactive agent comprises a microbubble. In some embodiments, the sonoactive agent comprises a protein-stabilized shell. In some embodiments, the sonoactive agent comprises a lipid stabilized shell. In some embodiments, the cargo polynucleotide is covalently coupled to one or both of: (i) a nuclear localization element, and / or (ii) an innate immune response avoidance moiety. In some embodiments, the nucleic acid comprising the cargo polynucleotide is a linear DNA construct. In some embodiments, the nucleic acid comprising the cargo polynucleotide is a closed linear DNA constructclosed linear DNA construct. In some embodiments, the nucleic acid comprising the cargo polynucleotide is a closed linear DNA construct comprising at least 2 modified nucleotides. In some embodiments, the nucleic acid comprising the cargo polynucleotide is a closed linear DNA construct comprising a stem region comprising a double stranded DNA sequence covalently closed at both ends by hairpin loops. In some embodiments, the hairpin loops are single-stranded. In some embodiments, the hairpin loops comprise any one of SEQ ID NO: 55-62, 101-128, or 205-252. In some embodiments, a first hairpin loop of the hairpin loops comprise any one of SEQ ID NO: 55-62, 101-128, or 205-252, and wherein a second hairpin loop of the hairpin loops comprise a different sequence than the first hairpin loop of any one of SEQ ID NO: 55-62, 101-128, or 205-252. In some embodiments, the hairpin loops form a stem region of the aptamer. In some embodiments, the at least two modified nucleotides are located in one or both single-stranded end loops of the closed linear DNA construct; at least one modified nucleotide is located in one of the single stranded end loops and at least another modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, the at least two modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer. In some embodiments, the at least two modified nucleotides are independently selected form the group consisting of 2-amino- deoxyadenosine, 5-methyl-deoxycytidine, thiophosphate nucleotide, inosine nucleotide, locked nucleic acid (LNA) nucleotide, L-DNA nucleotide, 8-oxo-deoxyadenosine nucleotide, and 5-Fluoro-deoxyuracilDocket No. 62668-747.601nucleotide. In some embodiments, the closed linear DNA construct comprises from 3 to 20 modified nucleotides, for example, 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or 20 modified nucleotides. In some embodiments, the closed linear DNA construct comprises at least two LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least two thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least two restriction sites flanking the expression cassette. In some embodiments, the closed linear DNA construct comprises a primase recognition site. In some embodiments, the closed linear DNA construct comprises an inverted terminal repeat(s) (ITR) sequence.
[0169] Aspects disclosed herein provide an isolated nucleic acid composition as disclosed herein comprising: a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene configured for expression in a target cell of a subject, and a nuclear localization element configured to increase expression of the cargo polynucleotide in the target cell. In some embodiments, the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.25 fold as compared to a nucleic acid lacking the nuclear localization element. In some embodiments, the nuclear localization element comprises an aptamer. In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind nucleolin. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 3-47. In some embodiments, the sequence configured to bind nucleolin comprises a nucleic acid sequence of any one of SEQ ID NO: 43-47, OR SEQ ID NO: 135-148. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind nucleolin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene. In some embodiments, the target cell is a liver cell. In some embodiments, the target cell is a hepatocyte. In some embodiments, the target cell is a LSEC. In some embodiments, the target cell is a kidney cell. In some embodiments, the target cell is a proximal tubular epithelial cell. In some embodiments, the target cell is a podocyte. In some embodiments, the target cell is a muscle cell. In some embodiments, the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy. In some embodiments, the method is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene. In some embodiments, the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subject. In some embodiments, the method is a method for use of the nucleicDocket No. 62668-747.601acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy. In some embodiments, the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell. In some embodiments, the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte. In some embodiments, the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell. In some embodiments, the subject is a human subject.
[0170] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind importin. In some embodiments, the sequence configured to bind importin comprises a nucleic acid sequence of SEQ ID NO: 48, 129, or 130. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind importin provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0171] In some embodiments, the nuclear localization element or the aptamer comprises a sequence configured to bind a nucleoporin protein. In some embodiments, the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex. In some embodiments, the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358. In some embodiments, the nucleoporin protein comprises NUP 358. In some embodiments, the sequence configured to bind the nucleoporin protein comprises a nucleic acid sequence of any one of SEQ ID NO: 49-50. In some cases, the nuclear localization element or the aptamer comprising the sequence configured to bind a nucleoporin protein provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene.
[0172] In some embodiments, the cargo polynucleotide is covalently coupled to the nuclear localization element. In some cases, the cargo polynucleotide being covalently coupled to the nuclear localization element provides a beneficial technical effect of increasing nuclear localization and resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene. In some embodiments, the isolated nucleic acid comprising the cargo polynucleotide is a linear DNA construct. In some embodiments, the isolated nucleic acid comprising the cargo polynucleotide is a closed linear DNA construct. In some embodiments, the isolated nucleic acid comprising the cargo polynucleotide is a closed linear DNA construct comprising at least 2 modified nucleotides. In some embodiments, the isolated nucleic acid comprising the cargo polynucleotide is a closed linear DNA construct comprising a stem region comprising a double stranded DNA sequence covalently closed at both ends by hairpin loops. In some embodiments,Docket No. 62668-747.601the hairpin loops are single-stranded. In some embodiments, the hairpin loops form a stem region of the aptamer. In some embodiments, the at least two modified nucleotides are located in one or both single-stranded end loops of the closed linear DNA construct; at least one modified nucleotide is located in one of the single stranded end loops and at least another modified nucleotide is located in one of the single stranded end loops forming the stem region of the aptamer. In some embodiments, the at least two modified nucleotides are in one or both single stranded end loops forming the stem region of the aptamer. In some embodiments, the at least two modified nucleotides are independently selected form the group consisting of 2-amino-deoxyadenosine, 5-methyl-deoxycytidine, thiophosphate nucleotide, inosine nucleotide, locked nucleic acid (LNA) nucleotide, L-DNA nucleotide, 8-oxo-deoxyadenosine nucleotide, and 5-Fluoro-deoxyuracil nucleotide. In some embodiments, the closed linear DNA construct comprises from 3 to 20 modified nucleotides, for example, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19 or 20 modified nucleotides. In some embodiments, the closed linear DNA construct comprises at least two LNA nucleotides. In some embodiments, the closed linear DNA construct comprises at least two thiophosphate nucleotides. In some embodiments, the closed linear DNA construct comprises at least two restriction sites flanking the expression cassette. In some embodiments, the closed linear DNA construct comprises a primase recognition site. In some embodiments, the closed linear DNA construct comprises an inverted terminal repeat(s) (ITR) sequence(s). In some embodiments, the ITR sequence(s) are located in the stem region of the aptamer. In some embodiments, the second aptamer comprises a different nucleic acid sequence than the nuclear localization element which comprises the aptamer. In some embodiments, the isolated nucleic acid comprises a spacer sequence preceding or following (e.g., 5’ or 3’) of the expression cassette before the hairpin loop(s). In some embodiments, the spacer sequence is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 23, 27, or 30 nucleotides. In some cases, the spacer sequence provides a beneficial technical effect of allowing for proper aptamer secondary conformation forms (see, e.g., FIGS. 5-7) and improves resulting gene expression of the cargo polynucleotide encoding a therapeutic transgene In some embodiments, the aptamer(s) are comprised within the hairpin loop(s). In some embodiments, the aptamer(s) are at least partially single stranded. In some embodiments, the aptamer(s) comprise any one of SEQ ID NO: 3-54, 129-130, or 135-148. In some embodiments, the isolated nucleic acid comprises a spacer sequences preceding and following (e.g., 5’ or 3’) of the expression cassette before the hairpin loop(s). In some embodiments, the isolated nucleic acid is configured to form an episome in a nucleus of the cell. In some embodiments, the therapeutic transgene configured for expression in the target cell is an exogenous transgene to the subject. In some embodiments, the exogenous transgene provides a gain of function to the subject by expression of theDocket No. 62668-747.601therapeutic transgene. In some embodiments, the expression cassette is at least 4.5, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, or at least 15 kb long. In some embodiments, the isolated nucleic acid is at least 4.5, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least or 15 kb long. In some embodiments, the therapeutic transgene encodes FVIII, FIX, alpha5(IV) chain of collagen IV, alpha4(IV) chain of collagen IV, alpha3(IV) chain of collagen IV, protein polycystin-1 (PCI), or polycystin-2 protein (PC2). In some embodiments, the therapeutic transgene is FVIII, FIX, COL4A3, COL4A5, COL4A4, PKD1, or PKD2.
[0173] In some embodiments, the nucleic acids comprises an expression cassette. As used herein, an expression cassette comprises a coding nucleic acid sequences, e.g., an expression cassette encoding a transgene. In some cases, an expression cassette can comprise a regulatory element such as a promoter, enhancer, ribosome binding site, or transcription termination signal.
[0174] In some embodiments, the first container and second container are configured to induce the expression of the transgene in the target cell of the subject within 20 hours after the transfection.
[0175] In some embodiments, the method further includes inducing expression of the cargo polynucleotide and maintaining expression of a protein encoded by the cargo polynucleotide for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least or 7 days following administration of the microbubble and the nucleic acid, and application of the ultrasonic acoustic energy. In some embodiments, the method further includes inducing expression of the cargo polynucleotide and maintaining expression of a protein encoded by the cargo polynucleotide for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least or 7 days following administration of the microbubble and the nucleic acid, and application of the ultrasonic acoustic energy.
[0176] In some embodiments, the method further includes increasing expression of the cargo polynucleotide by increasing the dosage of the cargo polynucleotide administered to the subject. In some embodiments, the method further includes increasing expression of the cargo polynucleotide by increasing the dosage of the nucleic acid administered to the subject in a linear manner.
[0177] In some embodiments, the kit further comprises instructions for software and hardware directions for the safe and effective operation of an ultrasound machine sufficient to disrupt the sonoactive microstructures or sonoactive agents to generate the sonoporation processes which include but are not limited to the following: disrupting the microstructures, inducing inertial and stable cavitation, promoting endocytosis and inter-endothelial gap formation, microstreaming at cell surfaces, thereby increasing transfection of a cargoDocket No. 62668-747.601polynucleotide to a cell. In some embodiments, the instructions described methods for improvement of gene transfection using sonoporation by applying alternating ultrasonic acoustic energy between a first MI then a second MI. In some embodiments, the kit further comprises instructions for administration of the first container and the second container.
[0178] One proposal for increasing the efficacy of ultrasound or sonoporation based gene therapies is to utilize next-generation nucleic acid constructs which offer therapeutic benefits beyond the gain of function associated with successful transfection of a plasmid comprising an expression cassette. One such next-generation nucleic acid construct proposed herein for use in gene therapy are nucleic acid constructs comprising aptamers (a short, single-stranded nucleic acids that folds into a specific three-dimensional shape and bind a target antigen with high affinity and specificity), in which the aptamers provide an additional therapeutic benefit to the subject or transfection process beyond gain of function. Such next-generation nucleic acid construct can provide benefits which can increase nuclear localization of genetic payloads delivered to cells and / or which can reduce the activation of the cell’s innate immune system and resulting clearance of the genetic cargo, among other possible benefits. However, the manufacture of such aptamer nucleic acid conjugated constructs remains a challenge, as such constructs comprise both a single-stranded aptamer region and a double-stranded expression cassette, which most plasmid focused biologic manufacturing processes are not equipped to accommodate. Disclosed herein are biologic manufacturing processes which provide for the manufacture of aptamer nucleic acid conjugated constructs, improve product yield, reduce manufacturing time, reduce the number of process steps, and otherwise simplify the manufacturing process. FIG. 16, FIG. 17, and FIG. 18 each illustrate an embodiment of a nucleic acid manufacturing process of the present disclosure.
[0179] One challenge associated with the manufacture of nucleic acid constructs comprising both a single-stranded aptamer region and a double-stranded expression cassette is ensuring proper folding of the aptamer’s secondary structure such that it maintains its intended antigen binding activity. Aptamers rely on precise secondary and tertiary structures to bind their targets with high affinity and specificity. During synthesis and purification, the aptamer region can be prone to misfolding or partial duplex formation if aspects of manufacturing process are not carefully controlled. In addition, when an aptamer is attached to a double-stranded expression cassette, partial or unintended hybridization between the single-stranded aptamer and one strand of the double stranded cassette or other nucleic acids in the solution can occur, especially if there is any sequence complementarity or if the constructs are subjected to conditions promoting partial denaturation, potentially leading to ligation at unintended locations and a final construct with unintended sequences or activity. As the size of the double stranded expression cassetteDocket No. 62668-747.601increases (e.g., 5000+ 10000+, or 15000+ base pairs), the potential for negative aptamer to nucleic acid reactions rises, and further limits manufacturing options.
[0180] The manufacture of nucleic acid constructs comprising both a single-stranded aptamer region and a double-stranded expression cassette presents a number of challenges that are not adequately addressed by conventional plasmid-based biologic manufacturing processes. Several of these challenges, and the manner in which the methods disclosed herein address them, are summarized in the description that follows.
[0181] In some cases, the aptamer nucleic acid conjugated constructs disclosed herein comprise a duplexed expression cassette region (necessary for transcription and translation in a target cell) together with a single-stranded aptamer region (necessary for adoption of a folded secondary or tertiary structure that enables the aptamer to bind its target antigen). Conventional plasmid manufacturing processes — which produce uniformly double-stranded circular DNA — are not designed to accommodate, preserve, or quality-control products that contain both singlestranded and double-stranded structural elements within a single molecule.
[0182] In some cases, the therapeutic activity of an aptamer depends on the proper folding of the single-stranded nucleic acid into a defined three-dimensional shape. Manufacturing operations that subject the construct to harsh thermal, denaturing, or chemical conditions, or that introduce extended periods at temperatures above the aptamer's melting temperature, risk denaturing the aptamer and producing a product with diminished or absent target-binding activity. Methods that minimize the number of process steps, the duration of each step, and the cumulative thermal load on the aptamer are accordingly preferred.
[0183] In some cases, a traditional cassette-and-aptamer assembly process can involve at least three separately conducted enzymatic reactions (digestion, annealing, and ligation), each typically followed by an intervening purification or buffer-exchange step. Each handling step contributes a finite product loss, and the cumulative effect of multi-step workflows is a substantial reduction in overall yield, an increase in starting-material requirement, and an increase in process time, cost, and risk of contamination.
[0184] In some cases, the restriction endonucleases conventionally used to release a linear duplexed expression cassette (e.g., type IIS endonucleases such as Bsal) operate efficiently at moderate temperatures (e.g., about 37 °C) in particular buffer compositions, while the DNA ligases conventionally used to join linear duplexes to single-stranded or hairpin oligonucleotides (e.g., T4 DNA ligase) operate efficiently at lower temperatures (e.g., about 16 °C) in different buffer compositions. This incompatibility has historically required that digestion and ligation be carried out sequentially in separate vessels with intervening heat-inactivation, purification, or buffer-exchange steps.Docket No. 62668-747.601
[0185] In some cases, in some applications, an aptamer nucleic acid conjugated construct of therapeutic interest comprises more than one aptamer, for example, a different aptamer at each end of the construct, providing two distinct binding specificities (e.g., one aptamer for target-cell binding and a second aptamer for nuclear localization, immune modulation, or a second targeting specificity). The manufacture of such multi-aptamer constructs requires that each aptamer be ligated to a defined end of the linear duplexed expression cassette in a defined orientation, without cross-reactivity between the aptamer-bearing oligonucleotides themselves and without ligation of an aptamer to the wrong end of the cassette. Symmetric or palindromic ligation chemistries cannot enforce the required orientation, and an assembly reaction that combines two aptamer-bearing oligonucleotides with a doubly-cleaved expression cassette under non-discriminating conditions will produce a population of incorrectly assembled and orientationally scrambled products.
[0186] In some cases, conventional cloning plasmids include several thousand nucleotides of backbone sequence (e.g., bacterial origin of replication, antibiotic-resistance marker, multiplecloning site, ancillary regulatory elements) outside the expression cassette of interest. After release of the linear duplexed expression cassette by restriction digestion, this backbone sequence is waste material that must be removed and disposed of, and represents a corresponding inefficiency in the use of starting material.
[0187] In some cases, the circular plasmids that conventionally serve as the source of the linear duplexed expression cassette are produced by amplification in a bacterial host and are accompanied by bacterial endotoxin, host-cell protein, host-cell DNA, and antibiotic-resistance marker sequences associated with the bacterial culture. These bacterially derived impurities require dedicated downstream purification operations to remove and contribute to the overall complexity, cost, and regulatory burden of nucleic acid manufacturing.
[0188] The methods disclosed herein address each of the foregoing challenges through one or more of the inventive features described in the embodiments that follow.
[0189]
[0190] Aspects disclosed herein provide a method of producing an aptamer nucleic acid conjugated construct comprising a duplexed region and an aptamer, the method comprising: annealing a first end of a single stranded nucleic acid to a second end of the single stranded nucleic acid, the single stranded nucleic acid comprising the aptamer, to form an annealed fragment; ligating the annealed fragment to a linear duplexed nucleic acid fragment to form the aptamer nucleic acid conjugated construct, and digesting nucleic acid fragments; wherein, two or more of: the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time.Docket No. 62668-747.601
[0191] Aspects disclosed herein provide a method of producing a partially single stranded nucleic acid construct comprising a duplexed region and single stranded region, the method comprising: cleaving a nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 into a linear duplexed nucleic acid fragment comprising a nucleotide overhang; annealing a first end of a single stranded nucleic acid to a second end of the single stranded nucleic acid to form an annealed fragment; ligating the annealed fragment to the linear duplexed nucleic acid fragment to form the partially single stranded nucleic acid construct; and digesting nucleic acid fragments. In some embodiments, the nucleic acid is circular. In some embodiments, the nucleic acid is linear. In some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.
[0192] In some embodiments, the method further includes cleaving a nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 into a linear duplexed nucleic acid fragment comprising a nucleotide overhang, thereby forming the linear duplexed nucleic acid fragment. In some embodiments, the aptamer nucleic acid conjugated construct comprises the expression cassette, and cleaving the nucleic acid comprising the expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 increases a yield of the aptamer nucleic acid conjugated construct resulting from performance of the method by 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 58% w / w as compared to a process which uses a standard plasmid having more than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of less than 6:1. In some cases, utilizing the nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6:1 increases the percentage of nucleotides in the nucleic acid (e.g., source plasmid) which is usable (for example, supplies an increased number of usable DNA molecules per unit of mass) in the conversion of the source plasmid into the aptamer nucleic acid conjugated construct or the partially single stranded nucleic acid construct. In some cases, utilizing the nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 increases the percentage of nucleotides in the nucleic acid (e.g., source plasmid) which isDocket No. 62668-747.601converted into the aptamer nucleic acid conjugated construct or the partially single stranded nucleic acid construct. In some embodiments, the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is at least 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. In some embodiments, the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is from 6: 1 up to 20:1. In some cases, utilizing the nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression provides a beneficial technical effect of improving process yield. In some cases, utilizing the nucleic acid comprising an expression cassette and less than 750 nucleotides outside of the expression provides a beneficial technical effect of improving process yield by 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 58% w / w as compared to a process which uses a standard plasmid having more than 750 nucleotides outside of the expression cassette. In some embodiments, the nucleic acid is circular. In some embodiments, the nucleic acid is linear. In some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.
[0193] In some embodiments, the nucleic acid comprises an endonuclease recognition sequence. In some embodiments, the nucleic acid comprises a plurality of endonuclease recognition sequences. In some embodiments, the nucleic acid comprises a first endonuclease recognition sequence and a second endonuclease recognition sequence. In some embodiments, the first endonuclease recognition sequence is positioned on 5’ of the expression cassette on a sense strand, and the second endonuclease recognition sequence is positioned 3’ of the expression cassette on an anti-sense strand. In some embodiments, the nucleic acid comprises only the first recognition sequence and the second recognition sequence. In some embodiments, the endonuclease recognition sequence comprises a type IIS endonuclease recognition sequence. In some embodiments, the endonuclease recognition sequence is Bsal. In some embodiments, the expression cassette is at least 4000. 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 11000, 12000, 13000, 14000, 15000 or 16000 bp in length. In some cases, the positioning of the first endonuclease recognition sequence and the second endonuclease recognition sequence provides a beneficial technical effect of allows for extraction of the expression cassette from the source plasmid without any remaining endonuclease recognition sequences remaining in the linearized expression cassette, thereby preventing subsequent cleaving of the hairpin adaptors following ligation, providing a beneficial technical effect of allowing all process reactions to occur in a same contiguous aqueous solution or occur at a same time, simplifying the process manufacturing and reducing manufacturing time. In some embodiments, the nucleic acid is circular. In some embodiments, the nucleic acid is linear. InDocket No. 62668-747.601some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.
[0194] In some embodiments, the single stranded region of the partially single stranded nucleic acid construct comprises an aptamer, the partially single stranded nucleic acid construct is an aptamer nucleic acid conjugated construct, and wherein, two or more of: the annealing, the digesting, or the ligating, occur in a same contiguous aqueous solution or occur at a same time. In some embodiments, the partially single stranded nucleic acid construct is an aptamer nucleic acid conjugated construct. In some embodiments, the construct comprises the single stranded region at an end of the duplexed region, the single stranded region closing the duplexed region. In some embodiments, the single stranded region forms a hairpin loop. In some embodiments, the hairpin loop comprises the aptamer. In some embodiments, the aptamer comprises a nucleic acid sequence configured to bind an antigen. In some embodiments, the aptamer comprises a nucleic acid sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides. In some embodiments, the aptamer comprises 25-75 nucleotides. In some embodiments, the aptamer comprises a nucleic acid sequence which forms a secondary structure. In some embodiments, one or more nucleotides in the nucleic acid sequence are paired to one or more other nucleotides in the nucleic acid sequence to form the secondary structure in the aptamer. In some embodiments, in the aptamer nucleic acid conjugated construct, the aptamer is properly folded in the secondary structure such that it is function in binding the antigen. In some embodiments, the single stranded nucleic acid comprises a first end comprising a first nucleic acid sequence and a second end comprising a second nucleic acid sequence, in which the second nucleic acid sequence is complementary to the first nucleic acid sequence. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end are each at least 10, 11, 12, 13, 14, or 15 nucleotides long. In some cases, the annealing of the single stranded nucleic acid to form the annealed fragment occurs prior to the cleaving the nucleic acid comprising the expression cassette when the process occurs in a same contiguous aqueous solution or occur at a same time. In some cases, the first and the second ends of the single stranded nucleic acid being complementary to one another provides a beneficial technical effect of permitting or promoting proper aptamer folding such that the annealed fragment comprises the aptamer in its secondary structure with active antigen binding activity. In some cases, the first and the second ends of the single stranded nucleic acid being complementary to one another provides a beneficial technical effect of permitting or promoting the manufacture of the aptamer nucleic acid conjugated construct in its secondary structure with active antigen binding activity. In some embodiments, the nucleic acid is circular.Docket No. 62668-747.601In some embodiments, the nucleic acid is linear. In some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.
[0195] In some embodiments, the single stranded nucleic acid comprises a modified nucleotide. In some embodiments, the aptamer comprises a modified nucleotide. In some embodiments, the single stranded nucleic acid comprises at least two modified nucleotides. In some embodiments, the aptamer comprises at least two modified nucleotides. In some embodiments, the modified nucleotide comprises a locked nucleic acid nucleotide. In some embodiments, at least two modified nucleotides are independently selected form the group consisting of 2-amino- deoxyadenosine, 5-methyl-deoxycytidine, thiophosphate nucleotide, inosine nucleotide, locked nucleic acid (LNA) nucleotide, L-DNA nucleotide, 8-oxo-deoxyadenosine nucleotide, and 5-Fluoro-deoxyuracil nucleotide. In some embodiment, at least two modified nucleotides are 2-amino- deoxy ad enosine. In some embodiment, at least two modified nucleotides are 5-methyl-deoxycytidine. In some embodiment, at least two modified nucleotides are thiophosphate nucleotide. In some embodiment, at least two modified nucleotides are inosine nucleotide. In some embodiment, at least two modified nucleotides are locked nucleic acid (LNA) nucleotide. In some embodiment, at least two modified nucleotides are L-DNA nucleotide. In some embodiment, at least two modified nucleotides are 8-oxo-deoxyadenosine nucleotide. In some embodiment, at least two modified nucleotides are 5-Fluoro-deoxyuracil nucleotide.
[0196] In some embodiments, the single stranded nucleic acid comprises an assembly sequence. In some embodiments, the assembly sequence comprises a nucleotide overhang. In some embodiments, the single stranded nucleic acid comprises a nucleotide overhang. In some embodiments, the nucleotide overhang is 5’ of the first nucleic acid sequence in the first end or 3’ of the second nucleic acid sequence in the second end. In some embodiments, the nucleotide overhang comprises a sequence configured for golden gate assembly. In some embodiments, the nucleotide overhang comprises a sequence which is complementary to a sticky end left by Bsal cleavage. In some case, the single stranded nucleic acid comprising a nucleotide overhang provides a beneficial technical effect of allowing an enzymatic ligation process. In some case, the single stranded nucleic acid comprising a nucleotide overhang provides a beneficial technical effect of reducing manufacturing time.
[0197] In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end each compromise non-palindromic sequences. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end each compromise non-palindromic sequences. In some embodiments, the first nucleic acid sequence in the first end and second nucleic acid sequence in the second end do notDocket No. 62668-747.601comprise palindromic sequences. In some embodiments, all of the annealing, the digesting, and the ligating occur in a same contiguous aqueous solution or occur at a same time. In some embodiments, the annealing, the digesting, or the ligating are completed within 48 hours. In some cases, the first end and second nucleic acid sequence in the second end each compromising non-palindromic sequences provides a beneficial technical effect of preventing annealing and ligation of the hairpin structures to other hairpin structures (e.g., annealed fragments) in the vessel. In some cases, the first end and second nucleic acid sequence in the second end each compromising non-palindromic sequences provides a beneficial technical effect of preventing annealing and ligation of the annealed fragments to one another in the vessel (as opposed to annealing and ligating to the linear duplexed nucleic acid fragment), thereby allowing two or more of: the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time.
[0198] The method of any one of the preceding claims, further comprising adding a buffer suitable for both digestion and ligation to the solution. In some embodiments, a salt concentration of the solution is at least 20, 25, 30, 35, 37.5, 40, 45, 50, 55, 60, 65, 70, or 75 mM. In some embodiments, a salt concentration of the solution is 20-75 mM. In some embodiments, a salt concentration of the solution is 20-60 mM 30-30 mM. In some embodiments, a salt concentration of the solution is 30-50 mM. In some embodiments, a salt concentration of the solution is at least 37.5 uM. In some embodiments, a salt concentration of the solution is about 37.5 uM. In some embodiments, the buffer suitable for both digestion and ligation comprises potassium acetate, tris-acetate, magnesium acetate, bovine serum albumin, and adenosine triphosphate. In some embodiments, the buffer comprises about 50 mM Potassium Acetate, 20 mM Tris-Acetate, 10 mM Magnesium Acetate, 100 pg / mL bovine serum albumin, and 1 mM adenosine triphosphate. In some embodiments, the ligating comprises adding a thermotolerant ligase to a solution comprising the annealed fragment. In some embodiments, the thermotolerant ligase is Hi-T4 ligase. In some embodiments, the thermotolerant ligase is concentrated in the solution to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to 4-12 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to 6-10 enzyme units / uL. In some embodiments, the thermotolerant ligase is concentrated in the solution to about 8 enzyme units / uL. In some embodiments, the ligating comprises incubating the solution at 37 C. In some embodiments, the solution is incubated for at least 4 hours. In some cases, the thermotolerant ligase is active at the salt concentrations disclosed herein, and provides a beneficial technical effect of thereby allowing two or more of: the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time withoutDocket No. 62668-747.601requiring dilution of the solution or purification. In some cases, the thermotolerant ligase at the concentrations disclosed herein is active at the salt concentrations disclosed herein, and provides a beneficial technical effect of thereby allowing two or more of: the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time without requiring dilution of the solution or purification.
[0199] In some embodiments, the digesting comprises adding an exonuclease to the solution. In some embodiments, the digesting comprises adding a single exonuclease to the solution. In some embodiments, the exonuclease is Dral. In some embodiments, the digesting comprises incubating the solution for at least 2 hours at 37 C. In some cases, utilizing a nucleic acid comprising an expression cassette having less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1 as a source plasmid for the expression cassette significantly reduces the time required for the digesting (for example, by the exonuclease), and provides a beneficial technical effect of reducing the overall manufacturing time. In some cases, utilizing a nucleic acid comprising an expression cassette having less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6:1 as a source plasmid for the expression cassette allows for all or substantially all nucleic acid fragments (e.g., un-ligated fragments) to be digested with the exonuclease, and provides a beneficial technical effect of reducing or eliminating a purification step.
[0200] In some embodiments, the annealing further comprises annealing a first end of a second single stranded nucleic acid to a second end of the second single stranded nucleic acid, the second single stranded nucleic acid comprising a second aptamer to form a second annealed fragment. In some embodiments, the ligating the annealed fragment to the linear duplexed nucleic acid fragment further comprises ligating the second annealed fragment to a second end of the linear duplexed nucleic acid fragment. In some embodiments, the aptamer nucleic acid conjugated construct comprises different aptamers at each end of the construct, or comprises different aptamers at a 5’ end of the construct and a 3’ end of the construct. In some embodiments, the linear duplexed nucleic acid fragment comprises an assembly sequence. In some embodiments, the assembly sequence comprises the nucleotide overhang in the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence is positioned on a first end or a 5’ end of the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence in the in the linear duplexed nucleic acid fragment is complementary to the assembly sequence in the single stranded nucleic acid. In some embodiments, the linear duplexed nucleic acid fragment comprises a second assembly sequence. In some embodiments,Docket No. 62668-747.601the second assembly sequence comprises a nucleotide second overhang in the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence is positioned on a second end or a 3’ end of the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence in the in the linear duplexed nucleic acid fragment is complementary to the assembly sequence in the second single stranded nucleic acid.
[0201] In some embodiments, the method further includes purifying the aqueous solution comprising the aptamer nucleic acid conjugated construct in a single step purification. In some embodiments, the purifying comprises binding the construct to a magnetic substrate and removing the aqueous solution. In some embodiments, the purifying comprises eluting the aptamer nucleic acid conjugated construct in a sterile aqueous solution. In some embodiments, the aptamer nucleic acid conjugated construct is DNA. In some embodiments, the single stranded nucleic acid is DNA. In some embodiments, the linear duplexed nucleic acid fragment is DNA. In some embodiments, the nucleic acid is DNA. In some embodiments, the nucleic acid is circular. In some embodiments, the nucleic acid is linear. In some embodiments, the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.
[0202] One embodiment of an exemplary process for production of an aptamer nucleic acid conjugated construct is illustrated in FIG. 17. In FIG. 17, it shown that on Day 1, the source plasmid is provided and is digested with Bsal restriction enzyme to linearize the plasmid with nucleotide overhangs, and is incubated overnight at 37 C. The restriction enzyme is then heat inactivated by heating to 75 C, and the linearized plasmid is purified with magnetic bead purification before elution into a subsequent solution. Next, on Day 2 in a separate vessel, the single stranded nucleic acid comprising the aptamer, a first end comprising a first nucleic acid sequence flanked by an overhang sequence, and a second end a second nucleic acid sequence in which the second nucleic acid sequence is complementary to the first nucleic acid sequence, is heated to 95 C for 10 minutes such that the first and the second ends anneal to one another and form a hairpin structure (e.g., an annealed fragment). In the hairpin structure, the aptamer is able to properly fold into its secondary conformation in which it its antigen binding activity is active, while being attached to a partially duplex region defined by the annealed first and second ends, the first end having a small overhang for golden gate assembly. Next, the hairpin structures (e.g., an annealed fragments) and the linearized plasmid (e.g., linearized duplexed nucleic acid fragment) comprising the expression cassette of interest are mixed in a vessel with T4 ligase and are ligated by incubating overnight at 16 C, followed by heat inactivation of the ligase at 75C. Following this, on Day 3, nucleic acid fragments (e.g., un-ligated fragments) are digested with an exonuclease (e.g., ExoIII), followed by heat inactivation by heating to 75C. The remaining nucleic acids are them purified using magnetic bead purification. Next, a second digestion with aDocket No. 62668-747.601second exonuclease (e.g., Dral) is performed to further remove the remaining DNA byproducts, a final round of magnetic bead purification is performed, and the integrity of the final product confirmed by NGS.
[0203] Another embodiment of an exemplary process for production of an aptamer nucleic acid conjugated construct is illustrated in FIG. 18. In FIG. 18, on Day 1, the single stranded nucleic acid comprising the aptamer, a first end comprising a first nucleic acid sequence flanked by an overhang sequence, and a second end a second nucleic acid sequence in which the second nucleic acid sequence is complementary to the first nucleic acid sequence, is heated to 95 C for 10 minutes such that the first and the second ends anneal to one another and form a hairpin structure (e.g., an annealed fragment). In the hairpin structure, the aptamer is able to properly fold into its secondary conformation in which it its antigen binding activity is active, while being attached to a partially duplex region defined by the annealed first and second ends, the first end having a small overhang for golden gate assembly. The solution in the vessel is then cooled to 37 C. In parallel, also on Day 1, in the same vessel, Bsal restriction enzyme and a source plasmid comprising an expression cassette and less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6:1, an expression cassette, a first endonuclease recognition sequence which is positioned on 5’ of the expression cassette on a sense strand, and a second endonuclease recognition sequence is positioned 3’ of the expression cassette on the anti-sense strand, are added to the vessel. The source plasmid is digested with Bsal restriction enzyme to linearize the plasmid with nucleotide overhangs, and is incubated overnight at 37 C. The digestion with Bsal excises the expression cassette with no remainder of the endonuclease recognition sequence left attached to the expression cassette. In parallel, also on Day 1, in the same vessel, and at the same time, a thermotolerant ligase is added to the vessel to allow for ligation of the hairpin structures (e.g., annealed fragments) to the linearized plasmid (e.g., linearized duplexed nucleic acid fragment) comprising the expression cassette of interest by incubating overnight at 37 C, during which time the digestion and the ligation are occurring at a same time or at least partially simultaneously. Next, on Day 2, nucleic acid fragments (e.g., unligated fragments) are removed from the solution by addition of an exonuclease (e.g., ExoIII) to the solution, which is incubated for 4 hours at 37C. The aptamer nucleic acid conjugated construct is then separated from the solution by magnetic bead purification, and the fidelity of the final product verified by NGS. In some embodiments, an aptamer conjugated nucleic acid construct with an aptamer only on one end as illustrated in FIG. 1 A or with different aptamer at each end as shown in one interpretation of FIG. IB can be produced by utilizing a source miniplasmid which comprises a first assembly sequence (e.g., a sticky end) positioned adjacentDocket No. 62668-747.601to the to the first endonuclease recognition sequence, and a second assembly sequence (e.g., a sticky end) positioned adjacent to the to the second endonuclease recognition sequence, the first and the second assembly sequences being different. In such an embodiment, ligation of ligation of different aptamers on each end, or an aptamer on one end and a single stranded end without an aptamer on another end, can by accomplished by using assembly sequences (e.g., sticky ends) on each end of the expression cassette which comprise distinct sequences. The first and second assembly sequences (e.g., sticky ends) on each end of the expression cassette comprise distinct sequences which are complementary to the overhangs on the first single stranded nucleic acid hairpin structure comprising the first aptamer, and the second single stranded nucleic acid hairpin structure comprising the second aptamer (or the single stranded end without an aptamer), respectively.
[0204] Illustrated in FIGS. 1 A-1B are nucleic acid delivery vectors of the present disclosure which comprise a (1) a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene and (2) an aptamer. Referring to FIG. 1 A, the nucleic acid delivery vector can be a linear nucleic acid delivery vector 2000 with a closed end(s) 2030. The nucleic acid delivery vector can comprise an expression cassette 2035 encoding a therapeutic transgene in the double stranded portion 2020 of the vector in which the sense strand is complementarily paired to the antisense strand. The nucleic acid delivery vector can comprise a spacer sequence 2015 preceding or following (e.g., 5’ or 3’) of the expression cassette 2035 before the closed end on a given strand (e.g., the sense strand). In some embodiments, the spacer sequence can be at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 23, 27, or 30 nucleotides. In some cases, the spacer sequence provides a beneficial technical effect of reducing steric hindrance of the polynucleotide chain, permitting the proper base pairing of the aptamer 2005 to form its intended 3D conformation (see, e.g., FIG. 4, FIG. 5, and FIG. 6) to allow for the aptamer to bind its target antigen or moiety. In some cases, the nucleic acid delivery vector can be closed by an aptamer 2005. The aptamer may comprise a stem region 2010 which is formed from inverted terminal repeat sequences which are complementarily paired to another. Referring to FIG. IB, an alternative nucleic acid delivery vector 3000 can be closed by an aptamer 2005 / 2040 at each end. In some cases, a second aptamer 2040 which comprises a different nucleic acid sequence and which is configured to bind a different moiety or antigen can be on the second end of the nucleic acid delivery vector 3000.
[0205] In some embodiments, the methods disclosed herein address the challenges of cumulative yield loss across multi-step workflows, preservation of aptamer secondary structure, and overall process complexity by performing two or more of the annealing, digesting, and ligating steps in a same contiguous aqueous solution, or at a same time, or both. In someDocket No. 62668-747.601embodiments, all three of the annealing, digesting, and ligating steps are performed in a same contiguous aqueous solution.
[0206] In some embodiments, the single-vessel embodiment is enabled by selection of buffer and enzyme conditions compatible with concurrent operation of the digesting reaction and the ligating reaction. In some embodiments, the digesting and ligating are performed in a single buffer suitable for both reactions. In some embodiments, the buffer suitable for both digestion and ligation comprises potassium acetate, tris-acetate, magnesium acetate, bovine serum albumin, and adenosine triphosphate; in particular embodiments, the buffer comprises about 50 mM potassium acetate, about 20 mM tris-acetate, about 10 mM magnesium acetate, about 100 pg / mL bovine serum albumin, and about 1 mM adenosine triphosphate. The buffer composition is selected to support activity of both the restriction endonuclease (e.g., a type IIS endonuclease such as Bsal) and the DNA ligase under shared conditions. In some embodiments, the salt concentration of the solution is between 20 and 75 mM, between 20 and 60 mM, between 30 and 50 mM, at least 37.5 mM, or about 37.5 mM, selected to balance the activity requirements of the two enzymes.
[0207] In some embodiments, the ligating step employs a thermotolerant ligase (e.g., Hi-T4 DNA ligase) that retains ligation activity at a temperature compatible with the digesting step (e.g., about 37 °C), thereby allowing digestion and ligation to proceed simultaneously at a single temperature without intervening heat-inactivation or buffer-exchange operations. In some embodiments, the thermotolerant ligase is concentrated in the solution at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 enzyme units per pL, at a concentration of 4-12 enzyme units per pL, at a concentration of 6-10 enzyme units per pL, or at about 8 enzyme units per pL, in order to drive efficient ligation under the shared reaction conditions. In some embodiments, the ligating comprises incubating the solution at about 37 °C for at least 4 hours.
[0208] The reduction in the number of vessels, transfers, intervening purifications, heatinactivation steps, and buffer exchanges achieved by the single-vessel embodiment reduces cumulative product loss across the workflow, reduces the cumulative thermal exposure of the folded aptamer (and accordingly preserves aptamer secondary structure and target-binding activity), reduces the total process time, and reduces the number of operations during which the partially assembled product can be lost, contaminated, or damaged. In some embodiments, the single-vessel embodiment of the methods reduces process time by at least 25%, at least 33%, or at least 50% compared to an otherwise equivalent multi-vessel embodiment, and increases overall product yield by at least 25%, at least 50%, or more compared to an otherwise equivalent multi-vessel embodiment.Docket No. 62668-747.601
[0209] In some embodiments, the methods disclosed herein address the challenge of excess plasmid backbone sequence as manufacturing waste by employing as the source of the linear duplexed expression cassette a circular nucleic acid (e.g., a source plasmid or source miniplasmid) that comprises the expression cassette and less than 750 nucleotides outside of the expression cassette, or that exhibits a sequence-length ratio of expression cassette to noncassette nucleotides of at least 6:1. In some embodiments, the sequence-length ratio is at least 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. By minimizing the length of non-cassette sequence carried into the manufacturing process, the methods disclosed herein increase the proportion of source nucleic acid that contributes to the final product, reduce the absolute mass of waste backbone generated per unit of product, reduce the burden of downstream purification operations required to remove backbone fragments, and increase the effective yield of construct relative to the input mass of source plasmid (e.g., by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 58% w / w compared to a process using a standard plasmid having greater than 750 nucleotides outside the expression cassette).
[0210] In some embodiments, the methods disclosed herein address the challenge of producing aptamer nucleic acid conjugated constructs comprising more than one aptamer (e.g., a different aptamer at each end of the construct, or a different aptamer at a 5' end and a 3' end of the construct) in a defined orientation by employing an asymmetric, unidirectional assembly design in which the linear duplexed nucleic acid fragment carries a first assembly sequence at a first end and a second assembly sequence, distinct from and not interchangeable with the first, at a second end.
[0211] In such embodiments, the annealing further comprises annealing a first end of a second single stranded nucleic acid comprising a second aptamer to a second end of the second single stranded nucleic acid to form a second annealed fragment. In such embodiments, the ligating the annealed fragment to the linear duplexed nucleic acid fragment further comprises ligating the second annealed fragment to a second end of the linear duplexed nucleic acid fragment, such that the resulting aptamer nucleic acid conjugated construct comprises a first aptamer at one end of the construct (e.g., a 5' end) and a second aptamer, different from the first aptamer, at the other end of the construct (e.g., a 3' end).
[0212] In some embodiments, the linear duplexed nucleic acid fragment comprises an assembly sequence. In some embodiments, the assembly sequence comprises the nucleotide overhang in the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence is positioned on a first end or a 5' end of the linear duplexed nucleic acid fragment. In some embodiments, the assembly sequence in the linear duplexed nucleic acid fragment isDocket No. 62668-747.601complementary to an additional assembly sequence in the single stranded nucleic acid comprising the first aptamer. In some embodiments, the linear duplexed nucleic acid fragment further comprises a second assembly sequence. In some embodiments, the second assembly sequence comprises a second nucleotide overhang in the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence is positioned on a second end or a 3' end of the linear duplexed nucleic acid fragment. In some embodiments, the second assembly sequence in the linear duplexed nucleic acid fragment is complementary to a second additional assembly sequence in the second single stranded nucleic acid comprising the second aptamer.
[0213] In some embodiments, the first assembly sequence and the second assembly sequence are not complementary to one another, are non-palindromic, and are non-self-complementary, such that the first assembly sequence cannot anneal to the second assembly sequence, the first assembly sequence cannot anneal to itself, and the second assembly sequence cannot anneal to itself. In some embodiments, the first additional assembly sequence in the single stranded nucleic acid comprising the first aptamer is complementary only to the first assembly sequence and not to the second assembly sequence, and the second additional assembly sequence in the second single stranded nucleic acid comprising the second aptamer is complementary only to the second assembly sequence and not to the first assembly sequence.
[0214] The asymmetric, unidirectional assembly design — in which the two ends of the linear duplexed nucleic acid fragment carry distinct, non-interchangeable assembly sequences, each complementary only to its intended partner aptamer-bearing single stranded nucleic acid — enforces ligation of the first aptamer to the first end and the second aptamer to the second end of the linear duplexed nucleic acid fragment, in a single defined orientation. Cross-reactive products (e.g., ligation of the first aptamer to the second end, ligation of the second aptamer to the first end, ligation of two copies of the same aptamer to opposite ends of the same cassette, ligation of two cassettes to one another, and ligation in reversed orientation) are accordingly suppressed, and the assembly reaction proceeds in a unidirectional, orientation-correct manner. The asymmetric, unidirectional assembly design further enables both aptamer-ligation events to be carried out concurrently in a same contiguous aqueous solution (e.g., together with the digesting and annealing steps in the single-vessel embodiment described above) without crossreactivity between the two aptamer-bearing single stranded nucleic acids, and accordingly cooperates with the single-vessel embodiment to produce a defined dual-aptamer construct in a single forward reaction.
[0215] In some embodiments, the construct produced by the methods disclosed herein comprises a different aptamer at each end of the construct, or comprises a different aptamer at a 5' end of the construct and a 3' end of the construct. In some embodiments, the constructDocket No. 62668-747.601produced by the methods disclosed herein comprises a bispecific functionality (e.g., one aptamer providing target-cell binding specificity and a second aptamer providing nuclear localization, immune modulation, intracellular targeting, or a second target-cell binding specificity).
[0216] In some embodiments, the methods disclosed herein further address the challenge of bacterially derived impurities (e.g., bacterial endotoxin, bacterial host-cell protein, bacterial host-cell DNA, and antibiotic-resistance marker sequences) accompanying conventional fermentation-derived plasmid source material by providing the linear duplexed nucleic acid fragment as an amplification product of a circular template, rather than as a digestion product of a circular plasmid that is itself produced by bacterial fermentation. In such embodiments, a circular template comprising an expression cassette is provided as input to a rolling-circle amplification (RCA) reaction. The circular template is contacted with a strand-displacing DNA polymerase, such as 029 (phi29) DNA polymerase, in the presence of one or more primers and deoxynucleoside triphosphates (dNTPs), under isothermal conditions, for example at a temperature of about 30 °C. The strand-displacing polymerase initiates synthesis at the primer and continues processively around the circular template, displacing the previously synthesized strand to generate an amplification product comprising one or more tandem copies of the unit sequence of the circular template, including one or more copies of the expression cassette.
[0217] In some embodiments, the rolling-circle amplification is multiply-primed rollingcircle amplification, in which a plurality of primers (e.g., random hexamer primers) anneal to the circular template at a plurality of positions and to the displaced strands at additional positions, generating a hyperbranched, double-stranded concatemeric nucleic acid comprising the unit sequence in tandem head-to-tail copies. In some embodiments, the rolling-circle amplification is performed using one or more sequence-specific primers in place of, or in addition to, random primers. The choice of primer (random or sequence-specific), the primer concentration, the polymerase concentration, the deoxynucleoside triphosphate concentration, the buffer composition, the temperature, and the duration of the reaction can be selected by a person of ordinary skill in the art using parameters available in the art for rolling-circle amplification (e.g., as described in Dean et al., Genome Research 11 : 1095-1099 (2001); Lizardi et al., Nature Genetics 19:225-232 (1998); andReagin et al., Journal of Biomolecular Techniques 14:143-148 (2003), each incorporated herein by reference). In some embodiments, the circular template is provided in an amount of at most 1 pg, 100 ng, 10 ng, 1 ng, 100 pg, or 10 pg, and the amplification product comprises at least 1 pg, 10 pg, 100 pg, 1 mg, 5 mg, 10 mg, or 50 mg of nucleic acid, providing a high amplification ratio without bacterial fermentation of the circular template.Docket No. 62668-747.601
[0218] In some embodiments, the amplification product is processed to generate the linear duplexed nucleic acid fragment that is used in the subsequent annealing, ligating, and digesting steps of the methods disclosed herein. In one such embodiment, the amplification product is contacted with one or more endonucleases that cleave the concatemeric amplification product at recognition sequences positioned within the unit sequence to release one or more linear duplexed nucleic acid fragments comprising the expression cassette. In some embodiments, the one or more endonucleases comprise a type IIS endonuclease (e.g., Bsal). In some embodiments, the unit sequence of the amplification product comprises a first endonuclease recognition sequence positioned 5' of the expression cassette on a sense strand and a second endonuclease recognition sequence positioned 3' of the expression cassette on an anti-sense strand, such that contacting the amplification product with the one or more endonucleases excises the expression cassette as the linear duplexed nucleic acid fragment without retention of either the first endonuclease recognition sequence or the second endonuclease recognition sequence on the released fragment.
[0219] In another embodiment, the amplification product is contacted with a protelomerase that recognizes one or more protelomerase recognition sites engineered into the unit sequence of the circular template (and thus present in the amplification product) flanking the expression cassette. The protelomerase cleaves and joins strands of the amplification product at the protelomerase recognition sites, generating one or more closed-end linear duplexed nucleic acid fragments comprising the expression cassette. The closed-end linear duplexed nucleic acid fragment can be used in the subsequent annealing, ligating, and digesting steps as the linear duplexed nucleic acid fragment, optionally after additional processing (e.g., additional endonuclease cleavage or other suitable means) to expose nucleotide overhangs compatible with assembly to the annealed fragment.
[0220] In some embodiments, the amplification product is used in the methods disclosed herein without an intervening propagation, fermentation, or cloning step in a living host cell. In some embodiments, the rolling-circle amplification is performed without exposure of any reagent or product to a living bacterial cell, such that the linear duplexed nucleic acid fragment provided to the subsequent steps of the method is substantially free of bacterial host-cell DNA. In some embodiments, the circular template used as input to the rolling-circle amplification reaction does not comprise an antibiotic-resistance marker. In some embodiments, the rollingcircle amplification, the processing of the amplification product, and the subsequent annealing, ligating, and digesting steps of the methods disclosed herein are performed in sequence in a single facility without an intervening bacterial fermentation step.Docket No. 62668-747.601Exemplary Embodiments
[0221] Among the exemplary embodiments are:1. A nucleic acid composition comprising a cargo polynucleotide, means for increasing localization of the nucleic acid composition, and means for avoiding or reducing an innate immune response to the nucleic acid composition or a second means for increasing localization of the nucleic acid composition.2. A nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer comprising a nuclear localization element, and a second aptamer comprising an innate immune response avoidance moiety or a second nuclear localization element.3. The nucleic acid composition of embodiment 1, wherein the means for increasing localization of the nucleic acid composition comprises a first aptamer comprising a nuclear localization element.4. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer comprises a nucleic acid sequence which binds a nucleoporin protein.5. The nucleic acid composition of any one of the preceding embodiments, wherein the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex.6. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 50.7. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer comprises a nucleic acid sequence which binds a nucleolin protein.8. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer comprises a nucleic acid sequence of SEQ ID NO: 46.9. The nucleic acid composition of embodiment 1, wherein the means for reducing an innate immune response to the nucleic acid composition comprises a second aptamer comprising an innate immune response avoidance moiety.10. The nucleic acid composition of any one of the preceding embodiments, wherein the innate immune response avoidance moiety comprises an antagonist inhibitor of TLR9 and TLR7.11. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 53.12. The nucleic acid composition of any one of the preceding embodiments, wherein the second means for increasing localization of the nucleic acid composition comprises a second aptamer comprising a second nuclear localization element.Docket No. 62668-747.60113. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer comprises a nucleic acid sequence which binds a nucleoporin protein.14. The nucleic acid composition of any one of the preceding embodiments, wherein the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex.15. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 50.16. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer comprises a nucleic acid sequence which binds a nucleolin protein.17. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer comprises a nucleic acid sequence of SEQ ID NO: 46.18. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer is located at the 3’ end.19. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer is located at the 5’ end.20. The nucleic acid composition of any one of the preceding embodiments, wherein the first aptamer is located at the 5’ end.21. The nucleic acid composition of any one of the preceding embodiments, wherein the second aptamer is located at the 3’ end.22. A nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 46 at the 3’ end.23. A nucleic acid composition comprising a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, a first aptamer having a sequence of SEQ ID NO: 50 at the 5’ end, and a second aptamer having a sequence of SEQ ID NO: 53 at the 3’ end.24. The nucleic acid composition of any one of the preceding embodiments, wherein the cargo polynucleotide comprises an expression cassette.25. The nucleic acid composition of any one of the preceding embodiments, wherein the expression cassette comprises a therapeutic transgene.26. The nucleic acid composition of any one of the preceding embodiments, wherein the therapeutic transgene comprises FVIII, FIX, DMD, COL4A5, PKD1, PKD2, or ATP7B.27. The nucleic acid composition of any one of the preceding embodiments, wherein the expression cassette comprises a promoter sequence.Docket No. 62668-747.60128. The nucleic acid composition of any one of the preceding embodiments, wherein the expression cassette is at least partially double stranded.29. The nucleic acid composition of any one of the preceding embodiments, wherein the promoter sequence is double stranded.30. The nucleic acid composition of any one of the preceding embodiments, wherein the aptamer is coupled to an adaptor sequence.31. The nucleic acid composition of any one of the preceding embodiments, wherein the adaptor sequence comprises a sequence of any one of SEQ ID NOS: 101-128, or 254-281.32. A method of expressing a therapeutic transgene in a subject comprising administering to the subject the nucleic acid composition of any one of the preceding embodiments.33. Use of the nucleic acid composition of any one of the preceding embodiments in a method of treating a genetic disorder in a subject in need thereof comprising administering to the subject the nucleic acid composition of any one of the preceding embodiments.34. The method of any one of the preceding embodiments, further comprising administering to the subject a sonoactive agent.35. The method of any one of the preceding embodiments, wherein the sonoactive agent comprises a microbubble.36. The method of any one of the preceding embodiments, further comprising administering ultrasound energy to the subject.37. The method of any one of the preceding embodiments, wherein applying ultrasonic energy to the cell of the subject comprises applying the ultrasound energy at a first mechanical index (MI) that is less than or equal to 0.4 (e.g., 0 < MI < 0.4).38. The method of any one of the preceding embodiments, further comprising applying ultrasonic acoustic energy to the cell of the subject at a second MI that is greater than the first MI.39. The method of any one of the preceding embodiments, wherein the first MI is about 0.07.40. The method of any one of the preceding embodiments, wherein the second MI is at least 1.5.41. The method of any one of the preceding embodiments, wherein the second MI is at least 2.0.42. The method of any one of the preceding embodiments, wherein the second MI is at least 2.9.43. The method of any one of the preceding embodiments, wherein applying ultrasonic energy to the cell at the second MI comprises applying the ultrasonic acoustic energy in a pulse.44. The method of any one of the preceding embodiments, wherein the pulse is less than 2 s.45. The method of any one of the preceding embodiments, wherein the pulse is up to 500microseconds.Docket No. 62668-747.60146. The method of any one of the preceding embodiments, wherein the pulse is 1 microsecond to 500 microseconds.47. The method of any one of the preceding embodiments, wherein the pulse is about 100-300 microseconds.48. The method of any one of the preceding embodiments, wherein the pulse is about 200 microseconds.49. The method of any one of the preceding embodiments, wherein the ultrasound is applied at a frequence of about 0.5-20 MHz.50. The method of any one of the preceding embodiments, wherein the subject is a mammalian subject.51. The method of any one of the preceding embodiments, wherein the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector.52. The method of any one of the preceding embodiments, wherein the ultrasound is directed toward a target cell.53. The method of any one of the preceding embodiments, wherein the target cell is a liver cell.54. The method of any one of the preceding embodiments, wherein the target cell is a hepatocyte.55. The method of any one of the preceding embodiments, wherein the target cell is a LSEC. 56. The method of any one of the preceding embodiments, wherein the target cell is a kidney cell.57. The method of any one of the preceding embodiments, wherein the target cell is a proximal tubular epithelial cell.58. The method of any one of the preceding embodiments, wherein the target cell is a podocyte.59. The method of any one of the preceding embodiments, wherein the target cell is a muscle cell.60. The method of any one of the preceding embodiments, in which the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy.61. The method of any one of the preceding embodiments, in which is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene wherein the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subj ect.62. The method of any one of the preceding embodiments, in which the method is a method for use of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound inDocket No. 62668-747.601treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy.63. The method of any one of the preceding embodiments, wherein the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell.64. The method of any one of the preceding embodiments, wherein the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte.65. The method of any one of the preceding embodiments, wherein the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell.66. The method of any one of the preceding embodiments, wherein the subject is a subject having a muscular dystrophy, the nucleic acid encodes dystrophin (DMD), and the target cell is a muscle cell, a cardiac cell, or a diagram cell.67. The method of any one of the preceding embodiments, wherein the subject is a human subject.68. A kit comprising the nucleic acid of any one of the preceding embodiments, and a sonoactive agent.
[0222] Among the exemplary embodiments are:1. A method of producing an aptamer-nucleic acid conjugated construct comprising a duplexed region and an aptamer, the method comprising:a. annealing a first end of a single stranded nucleic acid comprising the aptamer to a second end of the single stranded nucleic acid to form an annealed fragment;b. ligating the annealed fragment to a linear duplexed nucleic acid fragment to form the aptamer-nucleic acid conjugated construct; andc. digesting nucleic acid fragments;wherein, two or more of: the annealing, the ligating, or the digesting, occur in a same contiguous aqueous solution or occur at a same time.2. A method of producing a partially single stranded nucleic acid construct comprising a duplexed region and a single stranded region, the method comprising:a. cleaving a nucleic acid, thereby forming a linear duplexed nucleic acid fragment, wherein the nucleic acid comprises (i) an expression cassette, and (ii) less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6:1;Docket No. 62668-747.601b. annealing a first end of a single stranded nucleic acid to a second end of the single stranded nucleic acid to form an annealed fragment;c. ligating the annealed fragment to the linear duplexed nucleic acid fragment to form the partially single stranded nucleic acid construct; andd. digesting nucleic acid fragments.3. The method of embodiment 1, further comprising cleaving a nucleic acid, thereby forming a linear duplexed nucleic acid fragment comprising a nucleotide overhang, wherein the nucleic acid comprises (i) an expression cassette and (ii) less than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of at least 6: 1.4. The method of embodiment 2, wherein the linear duplexed nucleic acid fragment comprises a nucleotide overhang.5. The method of any one of embodiments 2 -4, wherein the aptamer-nucleic acid conjugated construct comprises the expression cassette, and wherein the cleaving the nucleic acid increases a yield of the aptamer nucleic acid conjugated construct resulting from performance of the method by 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 58% w / w as compared to a process which uses a standard plasmid having more than 750 nucleotides outside of the expression cassette or a sequence length ratio of the expression cassette to nucleotides outside of the expression cassette of less than 6:1.6. The method of any one of embodiments 2-4, wherein the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is at least 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1.7. The method of any one of the preceding embodiments, wherein the less than 750 nucleotides outside of the expression cassette ranges from 66 to 750 nucleotides.8. .The method of any one of embodiments 2-4, wherein the sequence length ratio of the expression cassette to nucleotides outside of the expression cassette is from 6:1 to 20:1.9. The method of any one of embodiments 2-4, wherein the nucleic acid comprises an endonuclease recognition sequence.10. The method of any one of embodiments 2-4, wherein the nucleic acid comprises a plurality of endonuclease recognition sequences.11. The method of any one of embodiments 2-4, wherein the nucleic acid comprises a first endonuclease recognition sequence and a second endonuclease recognition sequence.12. The method of embodiment 11, wherein the first endonuclease recognition sequence is positioned 5’ of the expression cassette on a sense strand, and wherein the secondDocket No. 62668-747.601endonuclease recognition sequence is positioned 3’ of the expression cassette on an antisense strand.13. The method of embodiment 12, wherein the nucleic acid comprises only the first recognition sequence and the second recognition sequence.14. The method of any one of embodiments 2-4 or 7-11, wherein the nucleic acid is circular.15. The method of any one of embodiments 2-4 or 7-11, wherein the nucleic acid is linear.16. The method of any one of embodiments 9-13, wherein the endonuclease recognition sequence comprises a type IIS endonuclease recognition sequence.17. The method of any one of embodiments 9-13, wherein the endonuclease recognition sequence is Basl.18. The method of any one of the preceding embodiments, wherein the expression cassette is at least 4000. 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 11000, 12000, 13000, 14000, 15000 or 16000 base pairs in length.19. The method of embodiment 2, wherein the single stranded region of the partially single stranded nucleic acid construct comprises an aptamer, and wherein, two or more of: the annealing, the digesting, or the ligating, occur in a same contiguous aqueous solution or occur at a same time.20. The method of embodiment 19, wherein the partially single stranded nucleic acid construct is an aptamer-nucleic acid conjugated construct.21. The method of embodiment 2, wherein the partially single stranded nucleic acid construct comprises the single stranded region at an end of the duplexed region, wherein the single stranded region closes the duplexed region.22. The method of embodiment 2, wherein the single stranded region forms a hairpin loop.23. The method of embodiment 22, wherein the hairpin loop comprises the aptamer.24. The method of any one of the preceding embodiments, wherein the aptamer comprises a nucleic acid sequence configured to bind an antigen.25. The method of any one of the preceding embodiments, wherein the aptamer comprises a nucleic acid sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides.26. The method of any one of the preceding embodiments, wherein the aptamer comprises from 25 to about 75 nucleotides.27. The method of any one of the preceding embodiments, wherein the aptamer comprises a nucleic acid sequence which forms a secondary structure.Docket No. 62668-747.60128. The method of embodiment 27, wherein one or more nucleotides in the nucleic acid sequence are paired to one or more other nucleotides in the nucleic acid sequence to form the secondary structure in the aptamer.29. The method of any one of embodiments 27-28, wherein in the aptamer nucleic acid conjugated construct, the aptamer is properly folded in the secondary structure such the secondary structure binds the antigen.30. The method of any one of the preceding embodiments, wherein the single stranded nucleic acid comprises a first end comprising a first nucleic acid sequence and a second end comprising a second nucleic acid sequence, wherein the second nucleic acid sequence is complementary to the first nucleic acid sequence.31. The method of embodiment 30, wherein the first nucleic acid sequence and the second nucleic acid sequence are each at least 10, 11, 12, 13, 14, or 15 nucleotides long.32. The method of embodiment 30, wherein the single stranded nucleic acid comprises an assembly sequence.33. The method of embodiment 32, wherein the assembly sequence comprises a nucleotide overhang.34. The method of embodiment 33, wherein the nucleotide overhang is 5’ of the first nucleic acid sequence or 3’ of the second nucleic acid sequence.35. The method of embodiment 33, wherein the nucleotide overhang comprises a sequence configured for golden gate assembly.36. The method of embodiment 33, wherein the nucleotide overhang comprises a sequence which is complementary to a sticky end left by BasI cleavage.37. The method of embodiment 33, wherein the first nucleic acid sequence and the second nucleic acid sequence each compromise non-palindromic sequences.38. The method of embodiment 30, wherein the first nucleic acid sequence and the second nucleic acid sequence each compromise non-palindromic sequences.39. The method of embodiment 30, wherein the first nucleic acid sequence and the second nucleic acid sequence do not comprise palindromic sequences.40. The method of any one of the preceding embodiments, wherein the annealing further comprises annealing a first end of a second single stranded nucleic acid comprising a second aptamer to a second end of the second single stranded nucleic acid to form a second annealed fragment.41. The method of embodiment 40, wherein the ligating the annealed fragment to the linear duplexed nucleic acid fragment further comprises ligating the second annealed fragment to a second end of the linear duplexed nucleic acid fragment.Docket No. 62668-747.60142. The method of any one of the preceding embodiments, wherein the aptamer-nucleic acid conjugated construct comprises different aptamers at each end of the construct or comprises different aptamers at a 5’ end of the construct and a 3’ end of the construct.43. The method of any one of the preceding embodiments, wherein the linear duplexed nucleic acid fragment comprises an assembly sequence.44. The method of embodiment 43, wherein the assembly sequence comprises the nucleotide overhang in the linear duplexed nucleic acid fragment.45. The method of embodiment 44, wherein the assembly sequence is positioned on a first end or a 5’ end of the linear duplexed nucleic acid fragment.46. The method of embodiment 44, wherein the assembly sequence in the linear duplexed nucleic acid fragment is complementary to an additional assembly sequence in the single stranded nucleic acid.47. The method of embodiment 43, wherein the linear duplexed nucleic acid fragment comprises a second assembly sequence.48. The method of embodiment 47, wherein the second assembly sequence comprises a second nucleotide overhang in the linear duplexed nucleic acid fragment.49. The method of embodiment 47, wherein the second assembly sequence is positioned on a second end or a 3’ end of the linear duplexed nucleic acid fragment.50. The method of embodiment 47, wherein the second assembly sequence in the linear duplexed nucleic acid fragment is complementary to a second additional assembly sequence in the second single stranded nucleic acid.51. The method of embodiment 1 or 19, wherein all of the annealing, the digesting, and the ligating occur in a same contiguous aqueous solution or occur at a same time.52. The method of embodiment 1 or 19 or 51, wherein the annealing, the digesting, or the ligating are all completed within 48 hours.53. The method of embodiment 1 or 15, further comprising adding a buffer suitable for both digestion and ligation to the solution.54. The method of embodiment 53, wherein a salt concentration of the solution is at least 20, 25, 30, 35, 37.5, 40, 45, 50, 55, 60, 65, 70, or 75 mM.55. The method of embodiment 53, wherein a salt concentration of the solution is from 20 to 75 mM.56. The method of embodiment 53, wherein a salt concentration of the solution is from 20 to60 mM.57. The method of embodiment 53, wherein a salt concentration of the solution is from 30 to 50 mM.Docket No. 62668-747.60158. The method of embodiment 53, wherein a salt concentration of the solution is at least 37.5 uM.59. The method of embodiment 53, wherein a salt concentration of the solution is about 37.5 uM.60. The method of embodiment 53, wherein the buffer comprises potassium acetate, tris-acetate, magnesium acetate, bovine serum albumin, or adenosine triphosphate, or any combination thereof.61. The method of embodiment 49, wherein the buffer comprises potassium acetate, tris-acetate, magnesium acetate, bovine serum albumin, and adenosine triphosphate.62. The method of embodiment 57, wherein the buffer comprises about 50 mM of the potassium acetate, about 20 mM of the tris-acetate, about 10 mM of the magnesium acetate, about 100 pg / mL of the bovine serum albumin, and about 1 mM of the adenosine triphosphate.63. The method of any one of the preceding embodiments, wherein the ligating comprises adding a thermotolerant ligase to a solution comprising the annealed fragment.64. The method of embodiment 59, wherein the thermotolerant ligase comprises Hi-T4 ligase.65. The method of any one of embodiments 59 or 60, wherein the thermotolerant ligase is concentrated in the solution to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 enzyme units / uL.66. The method of any one of embodiments 59 or 60, wherein the thermotolerant ligase is concentrated in the solution from about 4 to about 12 enzyme units / uL.67. The method of any one of embodiments 59 or 60, wherein the thermotolerant ligase is concentrated in the solution from about 6 to about 10 enzyme units / uL.68. The method of any one of embodiments 59 or 60, wherein the thermotolerant ligase is concentrated in the solution to about 8 enzyme units / uL.69. The method of any one of the preceding embodiments, wherein the ligating comprises incubating the solution at 37 °C.70. The method of embodiment 65, wherein the solution is incubated for at least 4 hours.71. The method of any one of the preceding embodiments, wherein the digesting comprises adding an exonuclease to the solution.72. The method of embodiment 71, wherein the digesting comprises adding a single exonuclease to the solution.73. The method of any one of embodiments 66 or 67, wherein the exonuclease is DraI.74. The method of embodiment 71, wherein the digesting comprises incubating the solution for at least 2 hours at 37 °C.Docket No. 62668-747.60175. The method of embodiment 1, further comprising purifying the aqueous solution comprising the aptamer-nucleic acid conjugated construct in a single step purification.76. The method of embodiment 71, wherein the purifying comprises binding the aptamer-nucleic acid conjugated construct to a magnetic substrate and removing the aqueous solution.77. The method of embodiment 72, wherein the purifying comprises eluting the aptamer-nucleic acid conjugated construct in a sterile aqueous solution.78. The method of any one of the preceding embodiments, wherein the aptamer-nucleic acid conjugated construct is DNA.79. The method of any one of the preceding embodiments, wherein the single stranded nucleic acid is DNA.80. The method of any one of the preceding embodiments, wherein the linear duplexed nucleic acid fragment is DNA.81. The method of embodiment 2, wherein the nucleic acid is DNA.82. The method of embodiment 14, wherein the linear nucleic acid is an amplification product comprising one or more copies of the expression cassette.83. The method of embodiment 82, wherein the amplification product is a product of rollingcircle amplification of a circular template.84. The method of embodiment 83, wherein the rolling-circle amplification is performed using a strand-displacing DNA polymerase.85. The method of embodiment 84, wherein the strand-displacing DNA polymerase is 29 (phi29) DNA polymerase.86. The method of embodiment 83, wherein the rolling-circle amplification is multiply-primed rolling-circle amplification.87. The method of embodiment 86, wherein the multiply -primed rolling-circle amplification uses random primers.88. The method of embodiment 87, wherein the random primers are random hexamer primers.89. The method of embodiment 83, wherein the rolling-circle amplification is performed using one or more sequence-specific primers.90. The method of embodiment 83, wherein the rolling-circle amplification is performed isothermally.91. The method of embodiment 90, wherein the rolling-circle amplification is performed at a temperature of about 30 °C.92. The method of embodiment 83, wherein the circular template is provided in an amount of at most 1 pg, 100 ng, 10 ng, 1 ng, 100 pg, or 10 pg, and the amplification product comprises at least 1 pg, 10 pg, 100 pg, 1 mg, 5 mg, 10 mg, or 50 mg of nucleic acid.Docket No. 62668-747.60193. The method of embodiment 82, wherein the amplification product is a concatemeric nucleic acid comprising a plurality of tandem repeats of the expression cassette.94. The method of embodiment 93, wherein the concatemeric nucleic acid is double-stranded.95. The method of embodiment 93, wherein the concatemeric nucleic acid is hyperbranched.96. The method of embodiment 82, wherein the amplification product is processed prior to ligation to generate one or more linear duplexed nucleic acid fragments comprising the expression cassette.97. The method of embodiment 96, wherein the processing comprises contacting the amplification product with one or more endonucleases.98. The method of embodiment 97, wherein the one or more endonucleases comprise a type IIS endonuclease.99. The method of embodiment 98, wherein the type IIS endonuclease is Bsal.100. The method of embodiment 97, wherein the amplification product comprises a first endonuclease recognition sequence positioned 5' of the expression cassette on a sense strand and a second endonuclease recognition sequence positioned 3' of the expression cassette on an anti-sense strand.101. The method of embodiment 100, wherein contacting the amplification product with the one or more endonucleases excises the expression cassette without retention of either the first endonuclease recognition sequence or the second endonuclease recognition sequence on the linear duplexed nucleic acid fragment.102. The method of embodiment 96, wherein the processing comprises contacting the amplification product with a protelomerase to produce one or more closed-end linear duplexed nucleic acid fragments comprising the expression cassette.103. The method of embodiment 102, wherein the amplification product comprises one or more protelomerase recognition sites flanking the expression cassette.104. The method of embodiment 83, wherein the amplification product is used in the method without an intervening propagation, fermentation, or cloning step in a living host cell.105. The method of embodiment 83, wherein the circular template does not comprise an antibiotic-resistance marker.106. The method of embodiment 83, wherein the linear nucleic acid is substantially free of bacterial host-cell DNA.107. The method of embodiment 83, wherein the rolling-circle amplification, the processing of the amplification product, and steps of any one of embodiments 2-4 or 7-11 are performed in in a same contiguous aqueous solution or occur at a same time.Docket No. 62668-747.601Definitions
[0223] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.
[0224] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.
[0225] As used herein, the term “aptamer” refers to an oligonucleotide sequence which is at least partially single stranded comprising a sequence of nucleic acids which bind a target antigen.
[0226] As used herein the term “sequence identity” refers to the percentage identity calculated as the matching residues divided by the total number of residues in the total alignment when performing a consensus alignment of two sequences, with gaps in the alignment scored as a mismatching residue.
[0227] The terms “subject,” “individual,” or “patient” are often used interchangeably herein. The subject can be a mammal. The mammal can be a human. The subject may be diagnosed or suspected of being at high risk for a disease. In some cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease.
[0228] The term “zzz vivo" is used to describe an event that takes place in a subject’s body.
[0229] The term “ex vivo" is used to describe an event that takes place outside of a subject’s body. An ex vivo assay is not performed on a subject. Rather, it is performed upon a sample separate from a subject. An example of an ex vivo assay performed on a sample is an “zzz vitro" assay.
[0230] The term “zzz vitro" is used to describe an event that takes places contained in a container for holding laboratory reagent such that it is separated from the biological source from which the material is obtained. In vitro assays can encompass cell-based assays in which living or dead cells are employed. In vitro assays can also encompass a cell-free assay in which no intact cells are employed.
[0231] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject,Docket No. 62668-747.601notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.EXAMPLES
[0232] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.Example 1: Protein SELEX Method for Screening of Nucleic Acid Aptamer
[0233] In this example, nucleic acids are screened to target recombinant proteins to produce aptamers.
[0234] Recombinant NUP 358 protein is prepared and immobilized onto a solid support, such as NHS-activated Sepharose beads or high-binding 96-well plates, ensuring proper folding and functional activity of the target protein. A randomized nucleic acid library, consisting of either single-stranded DNA (ssDNA) or RNA, is used to initiate the SELEX process. This library contains random sequence regions of 20-80 nucleotides and flanking primer-binding sites for amplification. The nucleic acid library is denatured by heating to 95°C and rapidly cooled to promote proper folding, followed by incubation with the immobilized NUP 358 in a suitable binding buffer. The buffer may include Tris-HCl, NaCl, KC1, and MgCh, with optional stabilizers for RNA aptamers.
[0235] Following incubation, unbound or weakly bound nucleic acids are removed through a series of washes using a washing buffer with gradually increasing salt concentrations to enhance specificity. The tightly bound aptamers are eluted using either a high-salt buffer or low-pH elution buffer, depending on the nature of the interaction. For RNA aptamers, elution may require gentle heating in an RNase-free environment to preserve integrity. The eluted aptamers are then amplified by PCR (for ssDNA) or reverse transcription followed by PCR (for RNA aptamers), ensuring recovery of the selected sequences for subsequent rounds.
[0236] The SELEX process is iterative, with 8-12 rounds of selection, each round involving incubation, washing, elution, and amplification. In each successive round, the washing stringency is increased to enrich the pool for high-affinity aptamers that specifically bind NUP 358. Enrichment is monitored by techniques such as fluorescence anisotropy, surface plasmon resonance (SPR), or electrophoretic mobility shift assays (EMSA), to track the increasingDocket No. 62668-747.601binding affinity of the enriched aptamer pool. To enhance the specificity of aptamers, a counter-SELEX step is introduced, wherein the library is incubated with irrelevant proteins and beads without NUP 358 to remove non-specific binders.
[0237] After the final SELEX round, the enriched pool is cloned into a suitable vector for sequencing, and bioinformatic analysis is conducted to identify unique aptamer sequences. Individual sequences are synthesized or transcribed for further characterization, including determining their dissociation constants (Ka) and binding specificity to NUP 358. High-affinity aptamers are expected to exhibit minimal cross-reactivity with other proteins. Optimization of the SELEX process may include fine-tuning washing stringency, adjusting target protein immobilization, and employing negative controls to assess non-specific background binding. The resulting aptamers are found to bind the nuclear pore complex at NUP 358.Example 2: Synthesis of closed end linear DNA constructs with single stranded aptamers
[0238] The following protocol describes formation of linear nucleic acid vectors closed at each end with single-stranded aptamers which target nucleolin, a nuclear pore protein, or immune proteins active in innate immune system activation toward double-stranded DNA in the cell.
[0239] Preliminarily, double-stranded plasmid DNA (pDNA) encoding the expression cassette of interest was chemically synthesized (e.g., SEQ ID NO: 75). Separately, single stranded DNA (ssDNA) encoding the aptamer sequence of interest (e.g., any one of SEQ ID NO: 43-54) preceded by a 5’ ITR upstream of the aptamer sequence and flanked by a 3’ ITR sequence downstream of the aptamer sequence (e.g., SEQ ID NO: 76 and 77, respectively), for example see SEQ ID NO: 78 (5’ ITR-NUP 358 Apt-3’ ITR) was chemically synthesized.
[0240] The ssDNA was resuspended in water to a concentration of about 100 uM in 20x saline sodium citrate buffer. The ssDNA was denatured by heating to 95 C for 10 min and allowed to anneal naturally at room temperature for 30 min, forming a double-stranded region by hybridization of the ITR regions and leaving the aptamer sequence as a single stranded region.
[0241] The dsDNA was linearized with Bsal digestion in water in lOx rCutSmart buffer, incubated at 37 C for 2 hours, and heat inactivated by heating to 75 C for 10 min. The linearized dsDNA was purified and concentrated to a concentration of 92 ug / uL.
[0242] Following linearization, solutions of ssDNA and dsDNA were combined, and the ssDNA was covalently bonded to the linearized dsDNA by ligation with 10X T4 ligase buffer and T4 DNA ligase at 16C, followed by heat inactivation at 75 C for 10 minute to form theDocket No. 62668-747.601dsDNA product closed at each end by single stranded DNA comprising the aptamers. The ligated product was then purified and concentrated.
[0243] Following ligation, the product was treated with endonucleases Nhel (New England Biolabs) and Pcil (New England Biolabs) to cut residual pDNA, followed by incubation in a thermal cycler for 1 hr at 37 C, addition of 1 uL of ExoIII endonuclease, incubation in a thermal cycler for another 1 hr at 37 C, and heat inactivation by heating to 75 C for 10 min. The product I then purified using DNA Clean Up and Concentrator 25 (Zymo) and eluted in water.Concentration was then determined using Qubit dsDNA BR Assay Kit. Linearization was validated by staining with nucleic acid stain on an agarose gel using gel electrophoresis.Example 3: In-Vitro Evaluation of Vectors with Nuclear Localization Elements in Transfection of iPSC-Derived Hepatocytes
[0244] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which target a nuclear pore protein; with the other side not comprising an aptamer and closed with a single stranded DNA loop (see, e.g., FIG. 12A and FIG. 12B).
[0245] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acid vectors, which were closed at one end by an aptamer and with the other side not comprising an aptamer and closed with a single stranded DNA loop. In brief, linear nucleic acid vectors having the expression cassette in double-stranded portion of the vector with closed single stranded ends comprising aptamers were chemically synthesized as described in Example 2. Each nucleic acid delivery vector utilized in the evaluation included an expression cassette having the sequence of SEQ ID NO: 75. The aptamer coupled to the expression cassette comprised the sequence of SEQ ID NO: 50. A circular miniplasmid DNA format including comprising the same expression cassette was utilized as a control, and a linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 50.
[0246] The cell line utilized in this experiment was iCell Hepatocytes 2.0 (Fujifilm Cellular Dynamics, #01434). Cells were plated on collagen Lcoated 96-well plates after thaw and were differentiated for 5 days in plating media with a daily media change. After plating for 5 days, cells were cultured in cell plating media until the day of transfection. Cells were transfected 8 days post-differentiation using 300 ng (300 uL) of the closed end linear nucleic acids vectors using 0.45 uL of Lipofectamine 3000 (Invitrogen, Cat: L3000008). Upon harvest, cells wereDocket No. 62668-747.601analyzed using Steady-Gio assay system for evaluation of fluorescence reported as relative light units (RLU) to evaluate the efficiency of the transfection.
[0247] Results are illustrated in FIGS. 8A-8B, in which it is shown that cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) at one end only and with no aptamer on the other end exhibited approximately 3.7-fold (FIG. 8B with aptamer of SEQ ID NO: 50 at the 3’ end) to 4.6-fold (FIG. 8A with aptamer of SEQ ID NO: 50 at the 5’ end) increase in fluorescence, as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element. It is also observed that that the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) at one end only and with no aptamer on the other end exhibited approximately a 2-fold increase over the linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 50.
[0248] Results of additional screenings of the closed end linear nucleic acids vectors comprising the nuclear localization element with an aptamer sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) at one end only are illustrated in FIG. 11, comparing different adaptor sequences which couple the aptamer to the cargo polynucleotide comprising the expression cassette. It is observed that adaptor sequences ST 1 (SEQ ID NO: 254), ST 3, (SEQ ID NO: 256), and ST 5 (SEQ ID NO: 258) exhibited approximately a 3-fold increase in fluorescence as compared to an adaptor sequence of SEQ ID NO: 2, and exhibited approximately a 2-fold increase in fluorescence as compared to the other adaptor sequence of SEQ ID NOS: 255, 257, 259-260.Example 4: In-Vitro Evaluation of Vectors with Nuclear Localization Elements in Transfection of iPSC-Derived Hepatocytes
[0249] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which target a nucleolin protein; with the other side not comprising an aptamer and closed with a single stranded DNA loop.
[0250] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acid vectors, which were closed at one end by an aptamer and with the other side not comprising an aptamer and closed with a single stranded DNA loop. In brief, linear nucleic acid vectors having the expression cassette in double-stranded portion of the vector with closed single stranded endsDocket No. 62668-747.601comprising aptamers were chemically synthesized as described in Example 2. Each nucleic acid delivery vector utilized in the evaluation included an expression cassette having the sequence of SEQ ID NO: 75. The aptamer coupled to the expression cassette comprised the sequence of SEQ ID NO: 46. A circular miniplasmid DNA format including comprising the same expression cassette was utilized as a control, and a linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 46.
[0251] The cell line utilized in this experiment was iCell Hepatocytes 2.0 (Fujifilm Cellular Dynamics, #01434). Cells were plated on collagen I-coated 96-well plates after thaw and were differentiated for 5 days in plating media with a daily media change. After plating for 5 days, cells were cultured in cell plating media until the day of transfection. Cells were transfected 8 days post-differentiation using 300 ng (300 uL) of the closed end linear nucleic acids vectors using 0.45 uL of Lipofectamine 3000 (Invitrogen, Cat: L3000008). Upon harvest, cells were analyzed using Steady-Gio assay system for evaluation of fluorescence reported as relative light units (RLU) to evaluate the efficiency of the transfection.
[0252] Results are illustrated in FIGS. 9A-9B, in which it is shown that cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a Nucleolin protein (SEQ ID NO: 46) at one end only and with no aptamer on the other end exhibited approximately 3.7-fold (FIG. 9A with aptamer of SEQ ID NO: 46 at the 5’ end) to 4.0-fold (FIG. 9B with aptamer of SEQ ID NO: 46 at the 3’ end) increase in fluorescence, as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element. It is also observed that that the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 46) at one end only and with no aptamer on the other end exhibited approximately a 3.5-fold increase over the linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 46.Example 5: In-Vitro Evaluation of Vectors with Innate Immune Response Avoidance Moieties in Transfection of iPSC-Derived Hepatocytes
[0253] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which comprise an innate immune response avoidance moiety; with the other side not comprising an aptamer and closed with a single stranded DNA loop.
[0254] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acidDocket No. 62668-747.601vectors, which were closed at one end by an aptamer and with the other side not comprising an aptamer and closed with a single stranded DNA loop. In brief, linear nucleic acid vectors having the expression cassette in double-stranded portion of the vector with closed single stranded ends comprising aptamers were chemically synthesized as described in Example 2. Each nucleic acid delivery vector utilized in the evaluation included an expression cassette having the sequence of SEQ ID NO: 75. The aptamer coupled to the expression cassette comprised the sequence of SEQ ID NO: 53. A circular miniplasmid DNA format including comprising the same expression cassette was utilized as a control, and a linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 53.
[0255] The cell line utilized in this experiment was iCell Hepatocytes 2.0 (Fujifilm Cellular Dynamics, #01434). Cells were plated on collagen I-coated 96-well plates after thaw and were differentiated for 5 days in plating media with a daily media change. After plating for 5 days, cells were cultured in cell plating media until the day of transfection. Cells were transfected 8 days post-differentiation using 300 ng (300 uL) of the closed end linear nucleic acids vectors using 0.45 uL of Lipofectamine 3000 (Invitrogen, Cat: L3000008). Upon harvest, cells were analyzed using Steady-Gio assay system for evaluation of fluorescence reported as relative light units (RLU) to evaluate the efficiency of the transfection.
[0256] Results are illustrated in FIGS. 10A-10B, in which it is shown that cells transfected with the closed end linear nucleic acids vectors comprising the innate immune response avoidance moiety with a sequence which is a TLR7 and TLR9 antagonist (SEQ ID NO: 53 at one end only and with no aptamer on the other end exhibited approximately 3.6-fold (FIG. 10A with aptamer of SEQ ID NO: 53 at the 3’ end) to 3.7-fold (FIG. 10B with aptamer of SEQ ID NO: 53 at the 5’ end) increase in fluorescence, as compared to the circular miniplasmid nucleic acid lacking the innate immune response avoidance moiety. It is also observed that that the closed end linear nucleic acids vectors comprising the innate immune response avoidance moiety with a sequence which is a TLR7 and TLR9 antagonist (SEQ ID NO: 53) at one end only and with no aptamer on the other end exhibited approximately a 2-fold increase over the linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 53.Example 6: In-Vitro Evaluation of Vectors with Nuclear Localization Elements in Transfection of iPSC-Derived Hepatocytes
[0257] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which target a nuclear pore protein; with the other side closedDocket No. 62668-747.601with a second single stranded aptamer which targets one of nucleolin, a nuclear pore protein, or an innate immune system avoidance moiety of extranuclear double stranded DNA in the cell.
[0258] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acid vectors, which were closed at one end by an aptamer and with the other side closed with a second single stranded aptamer. In brief, linear nucleic acid vectors having the expression cassette in double-stranded portion of the vector with closed single stranded ends comprising aptamers were chemically synthesized as described in Example 2. Each nucleic acid delivery vector utilized in the evaluation included an expression cassette having the sequence of SEQ ID NO: 75. The first aptamer coupled to the expression cassette comprised the sequence of SEQ ID NO: 50, and was tested at each of the 5’ and 3’ ends. A circular miniplasmid DNA format comprising the same expression cassette was utilized as a control.
[0259] The cell line utilized in this experiment was iCell Hepatocytes 2.0 (Fujifilm Cellular Dynamics, #01434). Cells were plated on collagen I-coated 96-well plates after thaw and were differentiated for 5 days in plating media with a daily media change. After plating for 5 days, cells were cultured in cell plating media until the day of transfection. Cells were transfected 8 days post-differentiation using 300 ng (300 uL) of the closed end linear nucleic acids vectors using 0.45 uL of Lipofectamine 3000 (Invitrogen, Cat: L3000008). Upon harvest, cells were analyzed using Steady-Gio assay system for evaluation of fluorescence reported as relative light units (RLU) to evaluate the efficiency of the transfection.
[0260] Results are illustrated in FIGS. 14A-14B, in which it is shown that: cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) with the other side closed with a second single stranded aptamer also of SEQ ID NO: 50 also configured to bind a nucleoporin protein exhibited approximately a 2.4-fold increase in fluorescence as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element; cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) with the other side closed with a second single stranded aptamer also of SEQ ID NO: 53 comprising an innate immune response moiety (TLR7 and TLR9 antagonist) exhibited approximately a 2.1-3.1 -fold increase in fluorescence as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element; and cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) with the other side closed with a second single stranded aptamer ofDocket No. 62668-747.601SEQ ID NO: 46 comprising a nuclear localization element configured to bind a nucleolin protein exhibited up to a 2.3-fold increase in fluorescence as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element.Example 7: In-Vitro Evaluation of Vectors with Nuclear Localization Elements in Transfection of iPSC-Derived Hepatocytes
[0261] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which target a nucleolin protein; with the other side closed with a second single stranded aptamer which targets one of nucleolin, a nuclear pore protein, or an innate immune system avoidance moiety of extranuclear double stranded DNA in the cell.
[0262] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acid vectors, which were closed at one end by an aptamer and with the other side not comprising an aptamer and closed with a single stranded DNA loop. In brief, linear nucleic acid vectors having the expression cassette in double-stranded portion of the vector with closed single stranded ends comprising aptamers were chemically synthesized as described in Example 2. Each nucleic acid delivery vector utilized in the evaluation included an expression cassette having the sequence of SEQ ID NO: 75. The aptamer coupled to the expression cassette comprised the sequence of SEQ ID NO: 46. A circular miniplasmid DNA format including comprising the same expression cassette was utilized as a control, and a linear nucleic acid vectors closed at each end with an aptamer having the sequence of SEQ ID NO: 46.
[0263] The cell line utilized in this experiment was iCell Hepatocytes 2.0 (Fujifilm Cellular Dynamics, #01434). Cells were plated on collagen I-coated 96-well plates after thaw and were differentiated for 5 days in plating media with a daily media change. After plating for 5 days, cells were cultured in cell plating media until the day of transfection. Cells were transfected 8 days post-differentiation using 300 ng (300 uL) of the closed end linear nucleic acids vectors using 0.45 uL of Lipofectamine 3000 (Invitrogen, Cat: L3000008). Upon harvest, cells were analyzed using Steady-Gio assay system for evaluation of fluorescence reported as relative light units (RLU) to evaluate the efficiency of the transfection.
[0264] Results are illustrated in FIGS. 13A-13B, in which it is shown that: cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a Nucleolin protein (SEQ ID NO: 46) at one end with a second single stranded aptamer also comprising the sequence configured to bind a Nucleolin proteinDocket No. 62668-747.601(SEQ ID NO: 46) at the second end exhibited approximately similar levels of expression as the circular miniplasmid nucleic acid control lacking the nuclear localization elements; cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a Nucleolin protein (SEQ ID NO: 46) at one end with a second single stranded aptamer of SEQ ID NO: 53 comprising an innate immune response moiety (TLR7 and TLR9 antagonist) exhibited approximately a 1.3-1.8-fold increase in fluorescence as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element and the innate immune response avoidance moiety; and cells transfected with the closed end linear nucleic acids vectors comprising the nuclear localization element with a sequence configured to bind a Nucleolin protein (SEQ ID NO: 46) at one end with a second single stranded aptamer comprising a sequence configured to bind a nucleoporin protein (SEQ ID NO: 50) exhibited up to a 2.3-fold increase in fluorescence as compared to the circular miniplasmid nucleic acid lacking the nuclear localization element.Example 8: In-Vitro Evaluation of Vectors with Innate Immune Response Avoidance Moieties in Transfection of iPSC-Derived Hepatocytes
[0265] The following experiment evaluates expression of a fluorescent reporter transgene following transfection of iPSC-derived hepatocytes with linear nucleic acid vectors closed at one with single stranded aptamers which comprise an innate immune system avoidance moiety; with the other side closed with a second single stranded aptamer which targets one of nucleolin, a nuclear pore protein, or an innate immune system avoidance moiety of extranuclear double stranded DNA in the cell.
[0266] A cargo polynucleotide comprising a fluorescent reporter transgene (tdTomato) under the influence of a CAG promoter was utilized as the expression cassette in all vectors. The expression cassette was positioned in the center double-stranded region of the linear nucleic acid vectors, which were closed at on...
Claims
Docket No. 62668-747.601CLAIMSWhat is claimed is:
1. A nucleic acid composition comprising: a 5’ end and a 3’ end with a cargo polynucleotide positioned between the 5’ end and the 3’ end, an aptamer comprising a nuclear localization element or an innate immune response avoidance moiety at either the 5’ end or the 3’ end, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end.
2. The nucleic acid composition of claim 1, wherein the aptamer comprises the nuclear localization element.
3. The nucleic acid composition of any one of the preceding claims, wherein the aptamer comprises a sequence of SEQ ID NO: 50.
4. The nucleic acid composition of any one of the preceding claims, wherein the aptamer comprises a sequence of SEQ ID NO: 46.
5. The nucleic acid composition of any one of the preceding claims, wherein the nucleic acid composition increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the nuclear localization element.
6. The nucleic acid composition of claim 1, wherein the aptamer comprises the innate immune response avoidance moiety.
7. The nucleic acid composition of any one of claims 1 or 6, wherein the aptamer comprises a sequence of SEQ ID NO: 53.
8. The nucleic acid composition of any one of claims 1 or 6-7, wherein the nucleic acid composition increases expression of a transgene encoded by the cargo polynucleotide by at least 1.5, 2, 2.5, 3, 3.5, or 4 fold as compared to a nucleic acid composition comprising the cargo polynucleotide but lacking the immune response avoidance moiety.
9. The nucleic acid composition of any one of the preceding claims, wherein the aptamer is at the 5’ end and there is no aptamer at the 3’ end.
10. The nucleic acid composition of any one of the preceding claims, wherein the aptamer is at the 3’ end and there is no aptamer at the 5’ end.
11. The nucleic acid composition of any one of the preceding claims, wherein there is only one aptamer in the nucleic acid composition.
12. The nucleic acid composition of any one of the preceding claims, wherein the single stranded end not comprising an aptamer comprises a sequence of any one of SEQ ID NOS: 254-281.Docket No. 62668-747.60113. A nucleic acid composition comprising a 5’ end and a 3’ end with an cargo polynucleotide positioned between the 5’ end and the 3’ end, a single aptamer having a sequence of SEQ ID NO: 50 at either the 5’ end or the 3’ end which is coupled to the cargo polynucleotide with an adaptor sequence of any one of SEQ ID NOS: 254, 256, or 258, and a single stranded end not comprising an aptamer at the 3’ end or the 5’ end opposite from the aptamer at either the 5’ end or the 3’ end having a sequence of any one of SEQ ID NOS: 254-281.
14. The nucleic acid composition of claim 13, wherein the adaptor sequence comprises a 5’ and a 3’ end, and the single aptamer having a sequence of SEQ ID NO: 50 is positioned between the 5’ and the 3’ end of the adaptor sequence.
15. The nucleic acid composition of any one of the preceding claims, wherein the cargo polynucleotide comprises an expression cassette.
16. The nucleic acid composition of any one of the preceding claims, wherein the expression cassette comprises a therapeutic transgene.
17. The nucleic acid composition of any one of the preceding claims, wherein the therapeutic transgene comprises FVIII, FIX, DMD, COL4A5, PKD1, PKD2, or ATP7B.
18. The nucleic acid composition of any one of the preceding claims, wherein the expression cassette comprises a promoter sequence.
19. The nucleic acid composition of any one of the preceding claims, wherein the expression cassette is at least partially double stranded.
20. The nucleic acid composition of any one of the preceding claims, wherein the promoter sequence is double stranded.
21. The nucleic acid composition of any one of the preceding claims, wherein the aptamer is coupled to an adaptor sequence.
22. The nucleic acid composition of any one of the preceding claims, wherein the adaptor sequence comprises a sequence of any one of SEQ ID NOS: 101-128, or 254-281.
23. A method of expressing a therapeutic transgene in a subject comprising administering to the subject the nucleic acid composition of any one of the preceding claims.
24. Use of the nucleic acid composition of any one of the preceding claims in a method of treating a genetic disorder in a subject in need thereof comprising administering to the subject the nucleic acid composition of any one of the preceding claims.
25. The method of any one of the preceding claims, further comprising administering to the subject a sonoactive agent.
26. The method of any one of the preceding claims, wherein the sonoactive agent comprises a microbubble.Docket No. 62668-747.60127. The method of any one of the preceding claims, further comprising administering ultrasound energy to the subject.
28. The method of any one of the preceding claims, wherein applying ultrasonic energy to the cell of the subject comprises applying the ultrasound energy at a first mechanical index (MI) that is less than or equal to 0.4 (e.g., 0 < MI < 0.4).
29. The method of any one of the preceding claims, further comprising applying ultrasonic acoustic energy to the cell of the subject at a second MI that is greater than the first MI.
30. The method of any one of the preceding claims, wherein the first MI is about 0.07.
31. The method of any one of the preceding claims, wherein the second MI is at least 1.5.
32. The method of any one of the preceding claims, wherein the second MI is at least 2.0.
33. The method of any one of the preceding claims, wherein the second MI is at least 2.9.
34. The method of any one of the preceding claims, wherein applying ultrasonic energy to the cell at the second MI comprises applying the ultrasonic acoustic energy in a pulse.
35. The method of any one of the preceding claims, wherein the pulse is less than 2 s.
36. The method of any one of the preceding claims, wherein the pulse is up to 500 microseconds.
37. The method of any one of the preceding claims, wherein the pulse is 1 microsecond to 500 microseconds.
38. The method of any one of the preceding claims, wherein the pulse is about 100-300 microseconds.
39. The method of any one of the preceding claims, wherein the pulse is about 200 microseconds.
40. The method of any one of the preceding claims, wherein the ultrasound is applied at a frequence of about 0.5-20 MHz.
41. The method of any one of the preceding claims, wherein the subject is a mammalian subject.
42. The method of any one of the preceding claims, wherein the nucleic acid(s) is not comprised by or encapsulated within a viral capsid or a viral vector.
43. The method of any one of the preceding claims, wherein the ultrasound is directed toward a target cell.
44. The method of any one of the preceding claims, wherein the target cell is a liver cell.
45. The method of any one of the preceding claims, wherein the target cell is a hepatocyte.
46. The method of any one of the preceding claims, wherein the target cell is a LSEC.
47. The method of any one of the preceding claims, wherein the target cell is a kidney cell.
48. The method of any one of the preceding claims, wherein the target cell is a proximal tubular epithelial cell.Docket No. 62668-747.60149. The method of any one of the preceding claims, wherein the target cell is a podocyte.
50. The method of any one of the preceding claims, wherein the target cell is a muscle cell.
51. The method of any one of the preceding claims, in which the method is a method to treat a subject in need of a gene therapy or a protein replacement therapy.
52. The method of any one of the preceding claims, in which is a method of treating a mammalian subject having a genetic disorder with a nucleic acid encoding a therapeutic transgene wherein the cargo polynucleotide comprises an expression cassette encoding the therapeutic transgene, wherein the therapeutic transgene is configured for expression in the target cell of the subj ect.
53. The method of any one of the preceding claims, in which the method is a method for use of the nucleic acid, the sonoactive agent or the microbubble, and the ultrasound in treatment of a subject having a genetic disorder requiring a gene therapy or a protein replacement therapy.
54. The method of any one of the preceding claims, wherein the subject is a subject having Hemophilia A or FVIII deficiency, the nucleic acid encodes FVIII, and the target cell is a liver cell.
55. The method of any one of the preceding claims, wherein the subject is a subject having Alport’s Syndrome or COL4A5 deficiency, and the nucleic acid encodes alpha5(IV) chain of collagen IV, and the target cell is a podocyte.
56. The method of any one of the preceding claims, wherein the subject is a subject having PKD1 or polycystin-1 deficiency, and the nucleic acid encodes polycystin-1, and the target cell is a kidney cell.
57. The method of any one of the preceding claims, wherein the subject is a subject having a muscular dystrophy, the nucleic acid encodes dystrophin (DMD), and the target cell is a muscle cell, a cardiac cell, or a diagram cell.
58. The method of any one of the preceding claims, wherein the subject is a human subject.
59. A kit comprising the nucleic acid composition of any one of the preceding claims, and a sonoactive agent.
